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Summary
Phage display, a powerful polypeptide display technology, affords the rapid 
identification of peptides and proteins that interact w ith a target of interest 
The aims of the project were the phage display identification of peptides 
that interact w ith a druggable target in a brain disorder (glioblastoma 
multiforme) and the identification of peptides that serve as targeting 
vectors for brain delivery. Validation studies were undertaken to qualify 
the use of a cyclic-7mer peptide phage library against targets including 
streptavidin and paracetamol chosen as examples of a large complex and 
small simple molecule, respectively. W ith the aim of identifying peptide 
phages that bind to the luminal surface of brain microvasculature, a 
primary in-vitro porcine model o f the blood-brain barrier (BBB) comprising 
primary brain capillary endothelial cells was established and characterised. 
An in-vivo phage display was undertaken in the rat w ith the aim of 
identifying peptide sequences that mediated translocation across the BBB 
into brain grey matter. A 7-mer cyclic peptide was identified w ith sequence 
AC-SYTSSTM-CGGGS that enhanced the uptake of phages into brain grey 
matter by 4-fold compared to control w ild-type phages. This peptide may 
serve as a novel targeting vector for the delivery of a therapeutic cargo to 
the brain. Caveolin-1 was identified as a potential new therapeutic target 
in in-vitro models of grade IV astrocytomas (glioblastoma multiforme), w ith 
siRNA knockdown of caveolin-1 associated w ith reduced glioma cell 
proliferation and invasiveness. W ith the caveolin-1 scaffolding domain (aa 
81-101 in the caveolin-1 protein) as a target, an in-vitro peptide phage 
selection was undertaken and identified a series of peptides that bind the 
scaffolding domain w ith high affinity. These peptides w ill serve as a 
template for the development of low molecular weight peptidomimetics 
that inhibit caveolin-1 function. In conclusion, the studies in this thesis have 
demonstrated the u tility  of phage display in experimental therapeutics of 
brain disorders.
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Chapter 1
Chapter 1 Phage display and experimental brain
therapeutics
Chapter 1
1.1 CNS disorders
W ith an ageing population disorders o f the brain and central nervous 
system (CNS) are increasingly prevalent)!, 2]; estimates suggest that one in 
every three individuals w ill suffer some brain disorder during the ir life [3 ]. 
Disorders o f the CNS vary greatly in th e ir epidemiology and aetiology but 
include CNS tumours, neuroAIDS, amyloidoses (Alzheimer's; prion disease), 
neurodegenerative diseases (Parkinson's; Huntingdon's; drug or alcohol 
abuse) and mood disorders (anxiety; depression; bipolar disease). Despite 
the increasing prevalence o f CNS disorders, the rate at which new 
therapeutic entities fo r the ir treatm ent reach the m arket is significantly 
slower than for peripheral disorders[4]. This has been as a consequence o f 
a poor understanding o f many diseases o f the brain and the blood-brain 
barrier (BBB), which restricts significant diffusional access to the brain. 
Classically, CNS drug discovery programs have concentrated either on the 
rational design o f small lipophilic molecules that would be predicted on the 
basis o f structure to result in a therapeutic response or the high- 
throughput functional screening o f vast chemical libraries. In recent years 
however the molecular dissection o f various central disorders has resulted 
in a shift in focus towards therapeutic biomacromolecules such as peptides, 
proteins, antibodies and nucleic m aterial. For example various clinical tria ls 
are underway investigating am yloid-p immunotherapy w ith  IgG for the 
treatment o f Alzheimer's disease[5]. However access to the brain of these 
biologies is even more problematic than fo r small molecules because o f the 
lim iting nature o f the BBB.
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Phage display is a powerful combinatorial technology fo r the display o f 
polypeptides on the surfaces o f bacteriophages. Phage display libraries 
that are comprised o f many billions o f phages each displaying a unique 
polypeptide, show gr^at-utiljty fo r the discovery o f peptides and antibodies 
that target vasculature to increase residency tim e at a tissue and as 
scaffolds ror dug discoydry. The research that follows in subsequent 
chapters o f this diesis has been driven by an interest in u tiliz ing phage 
display technology as a component in experimental therapeutics aimed at 
brain disorders. Specifically, to  discover peptides that may promote 
macromolecule traversal across the BBB o r to address issues surrounding 
the discovery o f novel peptide brain therapeutics, particu larly for gliomas 
(grade iv astrocytomas) w ith in  which a target protein, caveolin-1, has been 
identified for modulation.
l i  Astrocytomas
Tumours o f the central nervous system essentially fa ll into two categories, 
primary and secondary. Secondaries that originate from  a prim ary tumour 
growing w ith in the periphery are the most common CNS tum our type and 
are generally treated via surgical resection and chemotherapy directed 
against the prim ary tum our itself.
Primary brain tumours are subdivided in to  neuroepithelial tumours that 
arise from astrocytes or oligodendrocytes, the so-called glial tumours, or 
tumours arising from meningeal, germ o r lym phatic tissue[6, 7]. Glial
3
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tumours are the most abundant primary tumour type in the brain o f which 
astrocytomas are the most common w ith estimates suggesting ~ 75% of all 
neuroepithelial tumours are astrocytomas. Histologically, gliomas can be 
distinguished as astrocytic, oligodendroglial or a heterogeneous mixture 
known as oligoastrocytomas. The grading of astrocytomas follows 
histological staging and is based on a four-tiered scheme established by the 
World Health 0rganisation[8-10] in 1993 that essentially reflects severity 
of disease from a benign to highly aggressive phenotype (see Table 1.1).
Table 1.1 World Health Organization classification of astrocytomas
WHO Classification Common nomenclature
Grade 1 Pilocytic astrocytoma
Grade 2 Diffuse or low-grade astrocytoma
Grade 3 Anaplastic (malignant) astrocytoma
Grade 4 Glioblastoma multiforme
The staging is associated w ith a number of histological features that include 
nuclear atypia, mitotic activity, angiogenic capacity and pseudopalisading 
necrosis, a feature specific to gliomas that is a particularly poor prognostic 
factor[7, 11]. Gliomas graded as 3 or 4 are exceptionally aggressive with 
median survival rates of 2-3 years and 9-12 months respectively[12]. 
Despite radical surgical resection combined w ith radio- and chemo­
therapies 5-year survival rates for grade IV gliomas are reported to be 3% 
at best The majority o f gliomas arise in the frontal lobe[13] w ith computed 
tomography (CT) generally revealing distortion of lateral and third brain 
ventricles w ith significant displacement of both middle and anterior 
cerebral arteries. Factors that may indicate poor prognosis include 
advanced age, neurological deficits at presentation and partial surgical
4
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resection due to the diffuse yet extensive (centimetres) in filtra tion  of 
astrocytoma cells into healthy brain parenchyma that surrounds the 
tumour site. It remains a complex challenge to affect complete surgical 
resection w ithout introducing severe neurological deficits. Surgical 
resection combined w ith  radiotherapy and concurrent treatm ent w ith  the 
chemotherapeutic agent temozolomide, an oral alkylating agent that 
methylates DNA, modestly extends life  in grade 4 astrocytomas by 2-3 
months compared to resection w ith  radiotherapy alone, and is now the 
preferred treatment regimen in grade 4 astrocytomas[14]. The 
implantation o f biodegradable polym er wafers impregnated w ith  alkylating 
agents such as carmustine (Gliadel™) d irectly into the surgical cavity 
created when a tumour is excised has also proven relatively effective 
extending life  by around 2 m onths[15], however significant m igration of 
glial tumour cells often extends beyond the application area o f wafers. It 
remains patently clear that there is a pressing need to design new 
treatment modalities and delivery systems to target high-grade 
astrocytomas since 6-month disease free progression has stalled at 31% in 
grade 3 tumours and < 15% in grade 4 tum ours[16].
Gliomas share a number o f features w ith  non-brain cancers including 
invasion, angiogenesis, self-directed proliferation, evasion o f apoptosis and 
avoidance o f immune surveillance[17]. W hilst astrocytomas show 
significant heterogeneity, there appear to  be a number o f genetic anomalies 
that are common to grade 3 and 4 tumours. Grade 3 tumours show marked
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anomalies in the retinoblastoma-associated cell-cycle regulatory pathways 
particularly mutations and deletions in the cyclin-dependent kinase 
inh ib ito r pl6INK4A/CDKN2A and in the retinoblastoma susceptibility locus 
1 (pRBl), as well as overexpression o f cyclin- dependent kinase 4 (CDK4) 
and human double minute 2 (HDM2)[17, 18]. Chromosome 10, which 
houses tumour-suppressor phosphatase and tensin homolog (PTEN), is 
commonly deleted when grade 3 astrocytomas transform  to grade 4[19]. In 
addition overexpression in a number o f signal transduction pathways leads 
to uncontrolled cellular proliferation, survival and invasion. These 
pathways are generally associated w ith  tyrosine kinases under the control 
o f growth factors such as epidermal grow th factor (EGF), platelet derived 
growth factor (PDGF), vascular endothelial growth factor (VEGF), 
hepatocyte growth factor/scatter factor (HGF/SF), caveolin and insulin-like 
growth factor (IGF)[19].
1.3 The Blood-Brain barrier
The blood-brain barrier serves to  protect the central nervous system from 
potentially harmful endogenous and xenobiotic molecules[7, 20]. As a 
corollary it  also shields the brain from  therapeutic agents that may be 
effective in treating a wide variety o f CNS disorders[7]. W hilst anatomically 
the BBB is comprised o f endothelial cells tha t line brain microvasculature, 
the intimate association o f astrocytes, pericytes and neuronal cells w ith  the 
endothelia significantly modifies its functionality. It is clear that a highly 
restrictive paracellular pathway at the BBB significantly lim its brain
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infiltration to all but those drugs w ith physicochemical properties that 
afford the ready penetration of lipophilic cell membranes or those drugs 
that exploit endogenous active transport pathways that include solute 
carriers or endocytic pathways. W hilst it  is apparent that the density of 
endocytic vesicles at the BBB ranks amongst the lowest reported for 
different endothelial cell types[21], endocytosis at the BBB is a critical 
pathway that mediates the uptake of nutrients essential for normal brain 
function and provides significant communicative links to the periphery. A 
number of strategies to exploit these pathways have already been explored 
using a diverse set of delivery vectors that includes hormones[22, 23], 
cytokines[24], cell penetrating peptides[25-27], transferrin and transferrin 
receptor antibodies (reviewed in [20, 28, 29]], nanoparticles[30-32], toxins 
and products of micro-organisms[20]. W hilst the field is s till in its infancy 
with, to date, no delivery vector reaching the market, impressive results are 
beginning to accumulate and there is much excitement that these strategies 
w ill eventually provide a generic platform for the delivery of significant 
concentrations of chemotherapeutics as well as other CNS active drugs to 
their site of action in the brain.
1.4 Caveolae and caveolin
Caveolae, the predominant vesicle type at the BBB[33], were 
morphologically identified in the early 1950s by transmission electron 
microscopy[34, 35] and were firs t described as 'little  caves' -  vesicular 
invaginations of the plasmalemma 50 -  100 nm in diameter. It was later
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recognised that caveolae also exist as highly-organised microdomains on 
the plasmalemma that are morphologically indistinguishable from 'normar 
membrane[36]. Early references to these domains classified them as a 
subset of lip id rafts but this definition has been rescinded in recent years 
w ith evidence that certain probes localize to caveolae microdomains but 
not to lipid rafts[36, 37]. The relationship between the different forms of 
caveolae is not clearly understood and even w ith in the same cell type 
caveolae may be morphologically diverse. W hilst caveolae are found on the 
surface of a wide range of cells they are particularly enriched on capillary 
endothelia, fibroblasts, adipocytes type I pneumocytes and muscle cells of 
all divisions i.e. cardio-, skeletal- and smooth- muscle cells. Caveolin-1 (22 
KDa), the first product of the caveolin gene fam ily to be identified[38,39], is 
the major structural and functional element o f caveolae. Although caveolin- 
1 is the signature biochemical marker w ith in caveolae, the domains are 
sim ilarly enriched in cholesterol, sphingomyelin and glycosphingolipids 
giving rise to detergent resistant areas o f the plasmalemma. Further, a rich 
variety of cell surface receptors localise to caveolae domains and may 
initiate endocytic processes upon binding of their cognate ligand(s).
Caveolae and caveolin maintain a diverse set o f functions that are still being 
uncovered but they clearly play a significant role in vesicular transport, 
homeostasis of cholesterol, compartmentalisation of signal transduction 
events and modulation of tumour growth, invasion and aggressiveness (for 
detailed reviews see [40-43]).
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1.5 Polypeptide display systems
Display platforms that express recombinant polypeptides on their surface 
are an invaluable tool for the exploration of protein-protein interactions. To 
date at least five display platforms have been described: phage-, cell-, 
mRNA-, Ribosome- and DNA- display (Figure 1.1). These technologies 
share a common principle: a direct linkage between genotype and 
phenotype that affords identification of the displayed polypeptide by 
genomic sequencing (for a detailed review of these technologies see [44]). 
Of the five technologies described, it is probably phage display that has 
seen the most widespread application.
Phage Display
Recombinant DNA 
encoding displayed 
peptide or protein
mRNA
Linker
Displayed Peptide ^  
or Protein
Display Platform Q  
DNA
Ribosome Display
mRNA Display
DNA Display
Cell Display
Figure 1.1 Polypeptide display technologies. Polypeptides encoded by recombinant genetic 
information can be expressed on a variety of biological scaffolds.
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L5.1 Phage Display
Phage display is a powerful combinatorial screening technology for the 
study of protein-protein, protein-peptide or protein-nucleic acid 
interactions. The filamentous bacteriophage readily accepts relatively 
sizeable insertions of additional genetic material into the genome that 
results in the display of foreign proteins or peptides as fusions w ith 
bacteriophage coat proteins. Phage libraries that contain a repertoire of 
many billions of clones each displaying a unique protein or peptide can be 
subjected to an affinity selection process against a target o f interest Those 
phage dones that display a protein that strongly interacts w ith the target 
can be recovered and amplified for further rounds o f selection before the 
direct link between genotype and phenotype is exploited to identify the 
protein or peptide displayed. The in itia l invention o f phage display was 
described in 1985 by George Smith o f the University o f Missouri in the 
seminal manuscript "Filamentous fusion phage: novel expression vectors 
that display cloned antigens on the virion surface"[45]. Little could George 
Smith have envisaged the power and application o f phage display as a 
combinatorial screening technique for the exploration of protein-protein 
interactions or to probe and characterize a diverse set o f biological and 
inert surfaces.
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1.6 Phage Biology
1.6.1 Phage Structure
The filamentous phages f l,  fd and M13 are part of the Inoviridae family o f 
bacteriophages, belonging to the Inovirus genus and are characterized by 
semi-flexible filamentous virions w ith  helical symmetry. Filamentous 
phages belong to the Ff class of organisms that infect Escherichia coli that 
harbour the F plasmid and whose surface therefore are decorated w ith 
multiple copies o f the F-pilus. The genomes o f M13, f l  and fd have been 
sequenced in their entirety and share approximately 98% homology[46-48] 
and unlike other members of the Ff phage class do not k ill the host 
oiganism during their replicative life-cycle but slow the rate of 
multiplication by 25 -  50% [49,50]. The physical dimensions of filamentous 
phages put them on the nano scale (6.5nm x 930nm) w ith a molecular 
weight of approximately 16.3 MDa and they are composed of as much as 
87% protein by mass. Essentially the filamentous phages are comprised of 
a covalently closed circle o f single stranded DNA some 6400-nucleotides in 
length housed in a protein capsid cylinder (see Figure 1.2).
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Figure 1.2 Schematic representation of the Ff bacteriophage virion. Schematic shows the 
location of the capsid proteins (Top) and the orientation of the genes encoding coat and 
other proteins around the single stranded DNA (Bottom).
The capsid, composed of five coat proteins, has numerous functions 
including protection of the genetic information as well as a role in virion 
replication which proceeds under the control of both phage capsid and host
bacteria components (see Table 1.2)
Table 1.2 Filamentous phage genes and protein products.
Gene Amino acid 
residues
MWt Function Location Used for 
display
II 410 46,137 DNA replication Cytoplasm -
X 111 12,672 DNA replication Cytoplasm -
V 87 9,682 Binding ssDNA Cytoplasm -
VIII 50 5,235 Major capsid protein Phage filament Yes
III 406 42,522 Minor capsid protein Phage terminus Yes
VI 112 12,342 Minor capsid protein Phage terminus Yes
VII 33 3,599 Minor capsid protein Phage terminus Yes
IX 32 3,650 Minor capsid protein Phage terminus Yes
1 348 39,502 Assembly Inner membrane -
IV 405 43,476 Assembly Inner membrane -
XI 108 12,424 Assembly Outer membrane -
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The capsid is composed of approximately 2700 copies of the 50-amino acid 
major coat protein pVUI which are oriented at a 20° angle from the lateral 
axis o f the virion, overlapping to form an uninterrupted a-helix[51] w ith 
only the last five amino-terminal residues (46-50) exposed at the surface 
resulting in significant resistance o f pVIII to protease digestion[52]. 
Residues 10-13 o f the carboxy-terminus form the inner wall o f the protein 
cylinder w ith four positively charged lysine residues w ith in this region 
interacting w ith the negatively charged sugar-phosphate backbone of the 
ssDNA[53, 54]. pVIII monomers are held together through interactions 
between the residues that connect the amino and carboxy terminals of 
pVIII and form a stable inner core.
At one terminus of the phage are approximately 5 molecules each of pVII 
and pIX, two of the smallest ribosomally translated proteins thought to 
exist Both their structure and arrangement at the blunt end o f the phage 
remain unclear although efforts to model these proteins are underway [55, 
56]. At the opposite end of the virion are approximately five copies each of 
p ill and pVI that account for around 2% of the phage length (10-16 nm). 
Whilst the structure and arrangement o f pVI remains elusive p ill has been 
extensively characterized. In electron micrographs of the phage particle, 
p ill is seen to emanate at the 'pointy' end of the virion and is exposed on 
the surface as small 'knots' [57].
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The coat protein p ill is the one most commonly utilised for display 
purposes and is comprised of three domains designated CT, N1 and N2 
linked to each other by glycine rich spacers[58]. The 68-residue N1 domain 
is essential for bacterial infection, directing the phage ssDNA into the 
bacterial cytoplasm and for the insertion o f coat proteins into the bacterial 
membrane ready for subsequent phage assembly. The N2 domain (130 
residues) is responsible for binding to the bacterial F-pilus and thus 
initiates the infection process via formation o f disulphide bridges between 
the phage and the bacterial cell[59, 60]. The surface exposure o f these two 
domains makes them susceptible to protease digestion that renders the 
virion non-infectious[57, 61]. The carboxyl terminus CT (150 residues) 
which resides w ithin the viral particle anchors pi 11 and helps mediate 
assembly termination and release o f phage virions from the bacterial cell.
L62 Phage Genome
Filamentous phage are particularly well suited for the display of foreign 
proteins since their genome tolerates relatively significant insertions of 
genetic material into non-essential regions, coat proteins can be modified 
without loss of infectivity, phage virions are stable to a wide range of 
environmental conditions including proteases[62], non-aqueous media[63], 
temperature and pH[45, 64] and since the ir propagation does not k ill the 
bacterial host,phage can be produced in large quantities ( ~ lx l0 12 virions 
per ml). The -  6400 nucleotide phage genome contains nine genes 
encoding eleven proteins and a major non-coding region termed the
14
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intergenic region (Ig) which is the site o f origin for the synthesis o f (+) and 
(-) complementary strands o f phage DNA. The Ig region also contains a 
packaging signal (PS) that is essentially a seeding point around which the 
capsid is assembled.
The genes are arranged around the circular ssDNA according to their 
function in the phage life-cycle: proteins translated from genes 11, X and V 
direct replication o f the phage genome, genes VII, IX, VIII, III and VI encode 
the capsid proteins whilst genes I, XI and IV encode proteins that are 
involved w ith the phage assembly process in the bacterial cell membrane. 
Transcription, which proceeds counter clockwise using the (-) strand of the 
dsDNA intermediary o f viral DNA replication begins at gene II. Differences 
in both promoter and ribosome binding strength and accessibility divide 
the genome into two transcription regions, the infrequently transcribed 
(genes III -  IV) and the frequently transcribed (genes II -  VIII). A weak 
termination signal (Rho-dependent) preceding gene I is transcription 
lim iting whilst overlapping transcripts from multiple promoters and 
multiple RNA processing events increase the abundance of RNAs for genes 
dosest to the term inator thus resulting in high levels o f pV and pVIII, 
proteins required in the greatest abundance. W hilst there are few regions 
of the genome that do not encode a protein, antibiotic resistance cassettes 
can be inserted into the Ig region or between gene VIII and III but care must 
be taken not to disturb promoter or term inators as there is a precise
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balance that must be maintained to allow production of phage virions 
without killing the bacterial host
1.7 Phage lifecycle
1.7.1 Infection
All filamentous phage utilize small hair like appendages on bacteria called 
p ili as receptors for infection and w hilst phage can infect cells that lack p ili, 
the process is highly inefficient w ith estimates suggesting infection is 4-5 
orders of magnitude less efficient than pilus mediated infection[65]. 
Infection is initiated when the N2 domain o f p ill binds the tip  of the 
pilus[59, 60]. The low copy number o f p ili per bacterial cell (up to 12 per 
cell[66]) means infection proceeds more efficiently w ith high m ultip licity of 
infection and when there is high bacterial cell density. After the in itia l 
binding step, the pilus mechanically retracts[67, 68] drawing the p ill 
terminus o f the phage (pointy end) into the bacterial periplasm. It remains 
to^elucidated whether the retraction is a response to phage binding or is 
part of the inherent retraction-assembly cycling of bacterial p ili. Binding of 
N2 to the pilus appears to displace N1 from its normal interaction w ith N2 
where it subsequentiy interacts w ith domain 3 of the bacterial protein TolA 
that extends into the periplasm from the bacterial cytoplasm [69, 70]. The 
precise molecular mechanism o f the subsequent stages o f infection remain 
to be fully elucidated however it  is clear that there is some form of 
depolymerisation of the phage proteins pVIII, pVII and pIX, directed by Tol 
Q, R and A which are essential for phage infection[65, 69], followed by
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translocation of the viral ssDNA into the cytoplasm. The exact role of Tol Q 
and R is unclear although it has been suggested that they interact to form 
some type of pore or channel through which the DNA translocates and this 
may be aided by the CT region of pill.
A schematic of the DNA replication, protein synthesis pathways and protein 
location within the infected E. coli cell can be seen in Figure 1.3 and is 
described in following sectio
Outer
Capsid & 
assembly  
proteins
Bacterial
en7\/me<?
m embrane  
& murein layer
Figure 1.3 Schematic of the phage DNA repliperCfon, protein synthes isan^pro tein location of 
the Ff filamentous bacteriophage following bacterial (E^colijnfection). /
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1.7.2 Replication
After the phage (+) strand translocates into the bacterial cytoplasm, 
bacterial RNA and DNA polymerases mediate the production o f the (-) 
strand. A bacterial topoisomerse II converts the dsDNA to a negatively 
chaiged, covalently closed supercoil designated the Replicative Form (RF) 
the (-) strand o f which serves as a template for mRNA transcription which 
is then translated into the various phage proteins, pi I cuts the (+) strand of 
the RF in the intergenic region yielding a prim er that is elongated by 
bacteria] DNA polymerase using the (-) strand as template. The original (+) 
strand is displaced as rolling-circle replication proceeds and is rejoined to 
form a circular ssDNA by pH. The (+) strand is then re-converted to the 
supercoiled RF by RNA and DNA polymerases and topoisomerase II as 
previously described. RF production continues thus until a critical 
threshold of pV is reached above which pV dimers form and bind (+) strand 
DNA physically preventing conversion to RF. Replication subsequently 
favours synthesis o f the (+) strand. The interaction of pV-dimers w ith 
ssDNA collapses the circular strand into an 800 x 8 nm rod-like structure 
comprised of ~800 pV dimers and a single ssDNA molecule[71-74] which is 
the substrate for assembly o f phage virions. The ssDNA is not entirely 
endosed by the pV dimers w ith both term inal hairpins le ft uncoated, 
presumably because pV do not bind dsDNA such that the packaging signal, 
around which phage assembly occurs, is exposed [75].
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1.73 Assembly
Those phage proteins not engaged in the cytoplasmic replication o f the 
phage genome are synthesized and inserted into the cytoplasmic or outer 
membrane o f the bacterial host[56]. Filamentous phage assembly is 
essentially a secretory process, assembly occurs w ith in the cytoplasmic 
membrane and phages are extruded from the bacterial cell as they are 
assembled. Both p ill and pVIII are synthesised w ith an amino terminal 
signal peptide attached that directs insertion into the cytoplasmic 
membrane. The signal peptide is cleaved leaving the proteins to span the 
cytoplasmic membrane w ith the ir carboxy-terminals in the cytoplasm and 
amino-terminals in the periplasm. The remaining capsid proteins (pVI, pVII 
and pIX) are synthesized w ithout signal peptides and the mechanism of 
membrane insertion and protein orientation is uncertain. W hilst pVI is 
hydrophobic and theoretically has three membrane spanning regions, pVII 
and pIX probably only have a single membrane spanning region [76]. 
Assembly only proceeds when the five capsid and three assembly proteins 
are present, there is a proton motive force, ATP and a bacterial 
Thioredoxin[77,78]. The process is divided into five stages:
1. Preinitiation: characterized by the formation of an assembly site that 
is visible in electron micrographs as a close apposition o f the 
cytoplasmic and outer membranes that resembles bacterial 
adhesion zones[79]. These are thought to be mediated by the
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interaction of pIV oligomers in the outer membrane channel w ith pi 
and pXI on the cytoplasmic membrane to form a closed pore.
2. Initiation: in this step, pVII and pIX along w ith the firs t collection of 
pVIII oligomers interact w ith the PS to form the blunt end of the 
phage particle directed by the assembly helper protein pi. Although 
the exact details and order o f association w ith PS remains unclear, it 
does appear that this in itia l assembly results in a conformational 
adjustment to pi allowing it  to interact w ith the periplasmic 
terminus of pIV causing the channel to open and accept the 
developing phage assembly [80, 81]. The insertion o f the phage into 
the open pore is essential in preventing 'bacterial bleed' which 
would lead to cell death. Mutations in pVII and pIX have been noted 
which results in the formation of an open pore that allows entry of 
foreign material into the cell and escape of bacterial elements from 
the cell which together results in growth inhibition[79].
3. Elongation: successive replacement of pV dimers w ith pVIII results 
in phage elongation and translocation across the cytoplasmic and 
outer membranes. Two interactions occur during this process: the 
cationic carboxy-terminals o f pVIII interact w ith the sugar- 
phosphate backbone of the DNA and the central regions o f pVIII 
interact w ith each other to ‘seal' in the DNA.
4. Pretermination: in this penultimate step the membrane embedded 
pIll-pVl complex is incorporated onto the term inal end of the 
developing virion[82]. In the absence o f p ill, the developing phage
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particle remains anchored to the cell membrane giving opportunity 
for packaging o f extra copies o f the phage genome to yield 
polyphage which detach when pi 11 becomes available [83].
5. Termination: release o f the phage is mediated through a 
conformational change in the 150 residue CT domain o f p ill and 
more specifically a 121 residue subdomain starting at the carboxy- 
terminus is responsible for release o f stable virions. A shorter 93- 
residue sequence affords release of the phage particle but results in 
a virion that is unstable to detergents.
18 Coat proteins used for display
Since the interaction o f capsid proteins during assembly largely involves 
the hydrophobic regions that span the membrane, theoretically any protein 
or peptide attached to the periplasmic terminus o f the capsid protein 
stands a reasonable chance o f being displayed. Of course this is true only if  
it  can be translocated across the cytoplasmic membrane and it  does not 
hinder any of the processes during assembly. The firs t example was 
demonstrated by George Smith who fused EcoRI fragments to the ami no­
terminus of the p ill capsid protein[45]. These phages could be selected 
from a pool of phages in which they were the m inority clones by affin ity- 
purification against an EcoRI antibody adsorbed to culture plastics. The 
EcoRI displaying phages remained infective and could be amplified in E. 
coli. Iterative rounds of selection or panning as it  has been termed 
significantly enriched for the EcoRI displaying phage. W hilst all o f the five
21
Chapter 1
capsid proteins have been used to display peptides or proteins their 
relative success and u tility  is variable. Display on the m inor coat proteins 
pVIII and plX[84] as well as pVI has been reported[85] but in the main 
successful display has prim arily been achieved via fusions w ith pi 11 and 
pVIII.
l£ . l  p ill and pVIII display
Historically, p ill has been the most w idely utilised capsid protein for 
display. Whilst display is lim ited to five copies o f the peptide or protein per 
virion, large inserts do not appear to interfere w ith the assembly process 
although the larger the displayed protein the less infectious the phage 
virion becomes[45]. Generally, the genetic material encoding the peptide or 
protein is inserted in the phage genome between the signal sequence and 
the start of the N1 domain, although foreign proteins have been inserted 
between N1 and N2 and between N2 and CT[86]. Insertion at these 
alternate sites generally leads to a significant reduction in infectivity due to 
steric hindrance o f the interaction o f N1 and N2 w ith the pilus. Display 
between N1 and N2 is however particularly advantageous when protease 
resistant peptides are required since cleavage of the displayed peptide w ill 
render the phage particle non-infectious[86,87].
The inherently greater number o f pVIII proteins on the virion surface offers 
the opportunity to display many more units o f foreign protein per phage 
particle. Insertion of small DNA sequences encoding 6-8 residues between
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the pVIII signal peptide and the amino term inal coding region leads to 
display on virtually all copies of pVIII (~2700) [88-90]. However larger 
inserts are not well tolerated presumably because the resulting phage 
assembly w ill not f it through the pIV channel or pVIII is not efficiently 
translocated to the bacterial membrane[56], in such cases a 'phagemicT 
system is required[91, 92].
The classification o f phage vectors (see Table 1.3), as described by George 
Smith[93], is essentially based on the coat protein used for display, whether 
the protein is displayed on all copies o f the capsid protein and whether the 
recombinant protein is encoded by the phage genome or plasmid 
(phagemid).
Table 13 Qassification of phage display systems (adapted from [94]).
Vector type Coat protein A ll or some copies of 
coat protein display
Phage or Phagemid
type 3 p ill All Phage
type 8 pVIII All Phage
type 33 p ill Some Phage
type 88 pVIII Some Phage
type 3+3 pin Some Phagemid
Type 8+8 .£V*»........ Some Phagemid
The expression characteristics o f the displayed polypeptide is largely 
determined by the parental phage used in the library for example a w ild- 
type phenotype (M13KE) whose genome is intact save for the coat protein 
gene which is altered for display, a neutered phage that is propagated as a 
plasmid under antibiotic selection (f88-4) and a true phagemid (pComb3) 
that only carries the encoded polypeptide, the gene for the coat protein 
used for display and a phage origin of replication.
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L9 Wild-type phage vector M13KE
The studies conducted in this thesis have utilized Type 3 display w ith the 
M13KE vector. In many ways this is the simplest phage display vector since 
the function of the w ild-type parent phage is largely maintained. The 
genetic information encoding the protein to be displayed is inserted into 
the region of the genome that encodes the carboxy terminus o f the coat 
protein's leader sequence and the amino terminus o f the mature capsid 
protein. This leads to display at the amino term inal o f the capsid protein. 
Whilst this vector can be used to produce type 8 vectors, as previously 
described displayed peptides w ill by necessity be very short (6-8 residues). 
M13KE can be utilized to display large proteins such as scFV and Fab 
fusions but are almost exclusively used to produce p ill libraries displaying 
peptides up to 30 amino-acids in length[95]. Larger proteins probably 
interfere w ith insertion of p ill into the membrane for assembly, reduce 
infectivity through steric hindrance o f the p lll-p ilus interaction and are 
more susceptible to both protease degradation and misfolding.
M13KE, derived from M 13m pl9[96,97], contains a lacZ gene that produces 
blue plaques on plates containing 5-Bromo-4-chloro-3-indolyl-p-D- 
galactoside (X-gal) and isopropyl-p-D-thiogalactopyranoside (IPTG). Kpnl 
and Eagl restrictions sites in gene III make it  easy to splice the recombinant 
peptide gene into the vector. M13KE clones amplify to quite significant 
titers of 1013-1014 virions.mh1 w ithout antibiotic selection and generate RF 
DNA in sufficient quantities in liquid culture to afford DNA sequencing of
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the genome to allow identification of the displayed peptides. Unfortunately, 
libraries derived from M13KE are invariably contaminated w ith 
vanishingly small quantities of the w ild-type parent phage (no Kpnl or EagI 
restriction site; clear plaques on IPTG/X-gal plates) which, in the absence of 
a well defined target interaction, may overcome the library population w ith 
successive selection rounds due to an advantageous infectivity since p ill is 
not occupied w ith displayed peptide. That said, M13KE has excellent 
infectivity w ith nearly 100% o f the phage selected in any given round 
amplified in bacterial culture assuming they are infected at the correct 
m ultiplicity of infection. This is particularly critical in early rounds of 
panning where a given clone is represented w ith a low frequency in the 
library population. For example the commercially available New England 
Biolabs Ph.D.™-C7C library contains 1.28 x 109 unique clones and a panning 
study utilizes 2 x 1011 phage virions such that each clone is present at a 
frequency of ~ 160. Clearly if  the recovery of a given clone is only 1% in the 
first round of panning this represents a single copy of the clone -  using 
M13KE phage ensures this single copy w ill be amplified.
1.10 Applications of phage display
The studies conducted in this thesis that involve phage display are based on 
the New England Biolabs Ph.D.™ peptide libraries and therefore the 
remainder of this introduction w ill discuss the applications and lim itations 
of peptide libraries and more specifically Type 3 vectors i.e. a peptide
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expressed on each of the five copies of pi 11, in the identification of peptides 
that interact with a given target
1.10.1 Applications o f phage display in disease therapeutics
The aim of many phage display selection projects is to derive a peptide that 
interacts with a draggable target to affect a therapeutic response. One 
advantage of phage libraries is that they can be used to investigate several 
orders of magnitude more entities than a chemical library that is limited to 
a few thousand clones. Unfortunately, affinity selection strategies in phage 
display are generally not designed to select for clones that elicit a biological 
response as a result of a binding interaction. More generally it is simply the 
binding event itself that is the intended outcome. As a result further 
selection is often required to identify those clones within the binding 
population that meet some user defined requirement such as activity as an 
agonist[98-100] or antagonist[101-103]. Bonetto and co-workers[104] for 
example isolated a series of 31 peptides that bound melanocortin-1 
receptor and subsequently assessed their capacity to stimulate the 
receptor. Among the 31 peptides investigated, they found two peptides 
were weak agonists (ECso 1 1 -1 6  pM), two peptides were strong agonist 
(ECso 14 -  25 nM) and one peptide was a partial antagonist (IC50 36 pM).
Whilst to date no phage derived product has reached market, there are a 
number of clinical trials currently being undertaken using peptides derived 
from phage display: DX-88 (Ecallantide) from Dyax Corp is a highly specific
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and potent inhibitor o f kallikrein (Ki -  20 -  40 pM)[105-107]. Kallikrein is a 
key molecule in the regulation of inflammatoiy and blood clotting 
processes and plays a role in a number o f autoimmune and inflammatory 
conditions. Dyax have successfully completed phase 3 tria ls o f DX-88 in the 
treatment o f hereditary angiodema (HAE) and phase I / l l  tria ls for the 
prevention of blood loss in on-pump coronary artery bypass graft (CABG) 
surgery; Compstatin (Potentia Pharmaceutics Inc.) [108, 109], a cyclic 
13mer peptide originally identified from phage display, is a selective and 
potent inhibitor (Kd ~ 0.13 pM) o f C3 protein in the complement cascade 
and w ill shortly enter clinical tria ls for the treatment o f age-related macular 
degeneration. The development o f Compstatin benefited from a 
multidisciplinary optimisation of the binding affin ity o f the original peptide 
to C3 through chemical, biophysical, and computational approaches; CIBG- 
300 (Center of Genetic Engineering and Biotechnology, Havana), is an 
inhibitor of Protein kinase CK2 phosphorylation. Overexpression o f CK2 
has been shown to be both oncogenic and tumorigenic. Early phase clinical 
trials o f CIGB-300 have shown 75% o f volunteers w ith microinvasive or 
preinvasive cervical cancers experience a significant reduction in lesion 
volume and 19% of the volunteers exhibited complete histological 
regression [110].
Despite these promising reports, the role o f peptides as drugs in their own 
right is still in its infancy prim arily because delivery and pharmacological 
issues such as poor oral stability and rapid degradation generally lim it their
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use. An exciting solution to these issues is to identify peptides that interact 
with a target and then design low molecular weight peptidomimetics from 
these lead peptides through in-silico molecular modelling and molecular 
dynamics. Hao and co -w o rke rs [lll] have identified cyclic 7mer peptides to 
Cysteine-rich intestinal protein 1 (CRIP1), a biomarker for the early 
detection of breast, cervical and pancreatic cancers, that bind with modest 
affinities (kd — 30-60 pM). The lead candidate peptide was molecularly 
modelled and docked w ith CR1P1. Using the resultant data, the peptide was 
re-engineered in~silico to improve the docking. The resultant amino-acid 
sequence was synthesized and its binding affinity characterized. The Kd was 
found to be — 2.6 pM, a 10-fold greater affinity than the initial lead peptide. 
Extending these in-silico modelling simulations may afford the rational 
design of low molecular weight peptidomimetics based on the initial 
peptide.
1.10.2 Applications of phage display in drug delivery
Phage display is routinely employed to identify polypeptides that bind to 
cell surface receptors and proteins for the purpose of enhancing drug 
delivery to a particular tissue type. This is feasible because vascular beds in 
normal and pathological conditions are highly specialised landscapes that 
can be mapped using phage display technologies[112-115]. Whilst the 
selected polypeptides may not be entirely specific for a particular organ or 
tissue type they may prove useful in delivering therapeutic concentrations 
of a drug or a gene to its site of action. A variety of phage display selection
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techniques can be used to identify targeting or homing polypeptides. If the 
identity o f a surface receptor or epitope o f interest is known and it  can be 
purified or recombinantly expressed then it  can be attached to a support 
and selected against in-vitro. The receptor is either immobilised on a solid 
support or exposed to phage library in a soluble form w ith subsequent 
capture via an affin ity tag. Many examples of these techniques can be found 
in the literature against a staggering diversity o f targets too numerous to 
mention here but are covered in detail in a number o f excellent review 
articles [44,116-120].
More recently selections have been made in-vitro on normal and malignant 
cell cultures. This strategy has the advantage that prior knowledge of the 
identity o f a receptor on the cell surface need not be known. Subtractive 
selection strategies where library is exposed firs t to normal cells or 
malignant cells not associated w ith the prim aiy tumour before exposure to 
primary malignant cells aids the identification of polypeptides specific for 
the tumour cell of interest Hong and Clayman[121] used a 12-mer peptide 
library to screen in-vitro human head and neck squamous cell cancers 
(HHNSCC) and identified a peptide sequence that internalizes into 
HHNSCCs but not human prostate carcinoma, astrocytoma or human colon 
carcinoma cell lines; the peptide translated to the in-vivo environment w ith 
fluorescent labelled peptide observed to accumulate in tum our tissue 
implanted in mice. Similarly identified peptides have been reported for 
tumours associated w ith the liver[122,123], colon[124], prostate[125] and
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stomach[126]. It is of course not just malignancies that can be targeted in 
this way, normal cell cultures are amenable to selection processes as well 
and significant efforts have been invested in isolating peptides that may 
cross biological barriers. Unfortunately, cellular internalisation of 
macromolecules is not a simple issue and intracellular delivery remains a 
complex challenge.
Many researchers forego in-vitro selections and inject a phage libraiy 
directly into animal models. In common with selections against in-vitro cell 
cultures in-vivo phage display does not require a pre-existing knowledge of 
a receptor to be targeted but affords an unbiased and internally controlled 
selection process that identifies phage-displayed peptides that home to a 
particular tissue. Essentially, a phage library is injected into the animal and 
allowed to circulate for sufficient time to ensure adequate exposure of 
vascular beds to phages. A saline perfusion is often used to remove phages 
remaining in the circulation before the tissue of interest is extracted and 
the phages within it recovered. Peptides have been identified in this way 
that home to a range of normal and diseased tissues including heart[127], 
kidney [114], lung[128], skin[129], pancreas[130], gastro-intestinal
tract[131-134], uterus[135], adrenal gland[135], prostate[136], 
breast[137] and adipose tissue[138]. Researchers have sought to extend 
the utility of in-vivo phage display derived peptides to monitor disease 
progression. A recent report[139] used phage display identified peptides to 
monitor the progression of a pancreatic cancer model from a benign to a
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metastatic stage. RIPl-Tag2 is a transgenic model o f islet cell carcinoma 
and the research group hypothesised that the vasculature in pre-malignant 
lesions differs significantly from an established tumour. By undertaking 
phage selection processes at each stage o f tumour progression the group 
were able to isolate stage specific peptides that differentiated between the 
vasculature of pre-malignant angiogenic islets and established tumour. 
Further, a number o f the peptides identified selectively homed to 
pancreatic tumours but not tumours growing under the skin.
It may prove possible to use phage libraries to isolate patient specific 
peptides either by using excised pathological tissue as target or by 
intravenous administration o f peptide phage libraries directly into the 
patient Some pioneering work has already been conducted in this 
field[113] where a cancer patient on life-support but w ith no brain stem 
activity was injected w ith a 7-mer cyclic phage library and after 15 minutes 
circulation time bone marrow, white adipose, skeletal muscle, prostate and 
skin tissue was biopsied. A number o f identical tripeptide motifs were 
found to accumulate in all tissues analysed but some tripeptide motifs were 
found to home to a single tissue. These data reflect current knowledge that 
certain vascular markers are ubiquitously expressed w hilst others are 
tissue-specific
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U 0 3  Phage therapy
So far this introduction has been concerned w ith utilizing phage virions 
solely as vectors for the selection o f polypeptides that interact w ith target 
However, it  would be imprudent to ignore the potential uses of phage as 
therapeutics in their own rig h t Phage therapy entered the public 
consciousness in 1925 w ith the publication o f the Pullitzer prize winning 
novel Arrowsmith by Sinclair Lewis[140]. The book culminates w ith the 
discoveiy of a phage that kills bacteria responsible for the pathogenesis of 
bubonic plague.
The origins o f phage therapy probably date to the late 19th century w ith the 
observation of a heat labile, filterable antibacterial that killed Vibrio 
cholerae in the Jumna and Ganges rivers[141]; two years later, the same 
effect was observed for Bacillus subtilis. The exact identity o f this 
antibacterial remained elusive however until 1915 when Frederick Twort 
observed a glassification o f micrococci on standard agar culture plates and 
suggested this was the result o f some form o f acute infectious disease[142]. 
Felix d#Herelle[143] coined the term plaque to describe this glassification 
or as we now interpret it  a clearing of a bacterial lawn that indicates 
bacterial infection w ith phages. D'Herelles observation that patients who 
recover more rapidly from dysentery and typhoid have higher faecal phage 
titers paved the way for the commercialization o f bacteriophage 
preparations through the Societe Francaise de Teintures Inoffensives pour
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Cheveux (The French Society for Safe Hair Colouring or L'Oreal as it  is 
known today) [144].
Whilst other companies including Eli L illy  became involved in the 
commercialization o f phage products, the advent o f modern antibacterial 
therapy in the 1930s all but bankrupted the science of phage therapy 
although the Eliava Institute of Bacteriophage, Microbiology and Virology in 
Tblisi, Georgia continued and continues to invest in the development of 
phage therapies[145]. Antibiotic resistance has led to a resurgent interest 
in research and development o f phage therapeutics and at least eight 
commercial enterprises are involved in the development o f clinically 
relevant phage medicines. Most phage, have a specific affin ity for only a 
small group o f bacteria predicated by the interaction of phage components 
(such as p ill on M13) w ith bacterial surface receptors. Upon interaction, 
the viral DNA is translocated into the bacterial cell for transcription where 
lytic or lysogenic replication may occur. Lytic phages replicate and 
assemble and then 'burst* from the host cell resulting in cell death. This is 
the result o f hydrophobic pore formation by holins that allow access of 
lysins and endolysins to the petidoglycans in the bacterial membrane[146, 
147]. In the lysogenic lifecycle, bacteriophage DNA becomes integrated in 
the host bacterium's genome. This newly generated material termed a 
prophage is replicated during cell division. The lysogenic lifecycle is shifted 
to a lytic one when exposed to some external trigger, such as UV radiation.
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Lytic phage are in many ways an ideal antibacterial agent - they are target 
specific and the > 1 x 108 species o f phage probably means there is a phage 
therapeutic for every bacterial species, they k ill bacteria rapidly and 
amplify at the site o f infection and are relatively inexpensive to produce. 
Further, the FDA recognize that humans ingest vast quantities o f phages on 
a daily basis and tacitly accept that they are safe for oral 
administration[148]. It is perhaps topical administration however that has 
seen the most interest w ith the application o f cocktails of phage to chronic 
wounds either as simple suspensions or incorporated into some form of 
dressing system such as a biodegradable polymer infused w ith phage and 
antibiotics [149]. The systemic administration of phage therapeutics is 
complicated by an inadequate knowledge of the pharmacokinetic and 
pharmacodynamic properties o f most phage species w ith many studies 
indicating that the tim ing of administration is critical for infection 
control[150, 151]. Attaching phage display derived peptides that target 
particular organs to a therapeutic phage through recombinant techniques 
may afford site-specific delivery o f the phages and negates some o f the 
pharmacokinetic issues associated w ith phage therapy. Recent reports 
suggest that phages, which are naturally immuno-stimulatory[152, 153], 
may also be useful as vaccine delivery vehicles either by vaccinating w ith 
phages displaying the antigen[118,154] or by utilizing phages to deliver a 
DNA expression cassette integrated into the phage genome[152,155-157].
i
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1.11 Scope of thesis
The increasing prevalence o f CNS and brain disorders has intensified the 
requirements for novel therapeutic and targeting entities. Peptides are 
increasingly finding u tility  as novel therapeutics to treat a wide range of 
diseases and disorders and have also shown promise in enhancing 
macromolecular drug transport across biological barriers. Phage display 
libraries afford the rapid identification o f peptides that interact w ith a 
target of interest and may find significant u tility  in addressing issues 
surrounding drug discovery and drug delivery. Therefore, the research that 
follows in this thesis is driven by an objective to explore the relevance of 
phage display identified peptides as experimental therapeutics in brain 
disorders.
The objective in Chapter 2 was in-house validation o f a commercially 
available cyclic 7mer peptide phage display library. The library was 
validated against two molecules, streptavidin and paracetamol. 
Streptavidin is a large macromolecule routinely used to ensure the integrity 
o f a phage lib ra iy  and as such the amino acid sequences of peptides that 
bind streptavidin have been widely reported. Paracetamol (4-AAP) is a low 
molecular weight species w ith two closely related structural isomers. 
Paracetamol is a simple model but represents a d ifficu lt target since it  is 
comprised of few functional groups for peptide interaction. Nevertheless it 
provides a system in which to examine the capacity o f phage display to 
isolate peptides that distinguish between very small structural variations.
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Chapter 3 details the establishment and characterization of a BBB model 
comprised o f prim ary porcine brain microvascular capillary endothelial 
cells. The phenotypic characteristics o f the model were compared to 
primary rat and a variety o f immortalized BBB cell lines as well as 
published in-vivo data. The established model along w ith two immortalized 
BBB cell lines from mouse and rat origins were exposed to phage library in 
an effort to identify peptides that would bind to brain microvasculature to 
increase the residency time at the BBB in-vivo.
Chapter 4 expands upon the phage display work in chapter 3, seeking to 
identify peptides that mediate, in a sequence specific manner, the in-vivo 
traversal o f phages across the BBB. Rats were injected w ith phage library 
and, after a brief circulation time to allow displayed peptides to direct 
phages into the brain, the brains were excised, white matter and capillaries 
depleted and the phages in the brain parenchyma recovered and examined. 
The capacity o f identified peptides to mediate traversal across the BBB was 
explored by co-injecting rats w ith peptide phages and insertless phages and 
determining subsequent tissue distribution profiles. Finally a
physiologically based pharmacokinetic model was designed to 
contextualize the in-vivo data.
The objective of chapter 5 was to examine the role of caveolin-1 in the 
induction of an aggressive phenotype w ith in in-vitro  models of 
glioblastoma multiforme (grade iv  astrocytoma); overexpression of 
caveolin-1 has been observed to positively correlate w ith an aggressive
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phenotype in a variety o f cancers. The expression levels o f caveolin-1 and a 
series of downstream signalling markers were examined in four human 
glioblastoma multiforme cell lines. Subsequently, the effects o f siRNA 
knockdown of caveolin-1 and inhibition o f key molecules (mTOR and ERK) 
in the caveolin-1 signalling pathway, on invasion and proliferation were 
determined.
Given that overexpression o f caveolin-1 in glioblastoma multiforme 
appears to drive an aggressive phenotype and that the actions o f caveolin-1 
are primarily mediated through a caveolin scaffolding domain (CSD) w ith in 
caveolin-1, in chapter 6, peptides were identified via phage display that 
bind CSD. The binding o f identified peptides to CSD was further 
characterized by enzyme linked immunosorbant assay.
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2.1 Introduction
2.1.1 General principles of phage display panning studies
The objective o f any phage display selection process is to reduce the in itia l 
phage library (109 unique clones represented by 100 -  200 copies o f each 
done) to a small population o f phages that have an increased 'suitability* 
for a user defined requirement such as a binding interaction, a targeting 
moiety, agonism or antagonism o f a biological or chemical event e tc [l]. 
After the in itia l selection, the phages are amplified in a bacterial host such 
that each clone in the population is now represented by many m illions of 
copies. These amplified phage clones can then be subjected to iterative 
rounds of selection to further enrich the pool for those phage clones that 
are the 'fittest* for the chosen criterion. A generalised panning experiment 
is detailed in Figure 2.1.
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4) Eluted phages are 
a m p l i f i e d  in t h e  
bacterial host (E. coli).
1) Peptide library phages 
are exposed to target
r
\  5) Amplified phages serve 
as input into the next 
iterative panning round.
3) Bound phages are 
eluted.
2) Non-binding phages are 
washed away with multiple 
detergent washes.
6) After 4 rounds of 
panning phages in the 
final elution are gene 
sequenced to identify 
the displayed peptide.
Figure 2.1 Schematic of a generic phage display panning strategy.
Any phage selection process is essentially governed by two factors: yield 
and stringency[l]. Yield is the number of phages within the population that 
interact with the target and 'survive' the selection process. This is 
determined by stringency, the property that discriminates clones that 
interact with target with high affinity from the rest of the population, which
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may nevertheless show moderate affin ity for target In the firs t round of 
selection yield is im portant w ith the need to avoid discarding clones 
through overly stringent selection conditions and thus losing clones that 
interact w ith ta rget[l, 2]. In later rounds o f selection increasing stringency 
helps to remove from the population those phages that only moderately 
interact w ith the target There is an upper lim it to stringency that is defined 
by a background level o f phage 'contamination' that w ill survive a selection 
process even when there is no interaction w ith target W ith successive 
selection rounds a point is approached where all the clones in the 
population interact w ith the target w ith roughly the same affin ity  and 
further rounds of panning result in a shift in selection pressure towards 
factors such as expression levels o f the displayed peptide or infectivity of 
the virion, both of which may result in relatively weaker candidates being 
selected. This is exemplified in type 3 libraries where the displayed peptide 
may sterically hinder interaction o f pi 11 w ith the bacterial pilus such that it 
w ill be amplified at a reduced rate. Such clones w ill therefore be 
represented as a lower proportion o f the binding population even when the 
displayed peptide has greater affin ity for target than other clones in the 
population.
2.1.2 Affinity selection
Phage display libraries can be screened or 'panned' against a diverse range 
of molecules and surfaces including peptides, proteins, nucleic acid 
material[3, 4], cells[5-7], tissues[8, 9], whole organisms[10-13] and low
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molecular weight entities[14, 15]. Irrespective of target, by far the most 
common selection pressure utilised in the screening o f library against 
target is the affin ity o f a given polypeptide displayed on the phage clone for 
a target molecule. A generalised schematic o f a phage panning procedure 
can be seen in Figure 2.1. Essentially the target is exposed to the phage 
library for a period o f time to allow interaction between the displayed 
peptide and target Those phage clones w ith an a ffin ity for the target 
(usually a tiny proportion o f the parent library) are captured on the surface 
of the target and those that do not bind or have lim ited affin ity for the 
target are washed away. The bound phage are recovered into solution using 
an elution strategy that may include non-specific disruption of phage-target 
bonds (e.g. low pH washes) [16] or a specific elution w ith either excess free 
target or w ith a cognate ligand (s) for the target[17-20]. In each case, the 
eluate contains a sub-population o f phage clones from the original library 
that have an increased affin ity for the target The eluted phages, which 
remain infective, are subsequently amplified in the host bacterium to afford 
iterative rounds of panning to further enrich for the highest affin ity 
binders. After 3-4 rounds o f selection, the phage clones in the final eluate 
are propagated on a clonal basis before the relevant coding region in the 
viral DNA is sequenced to determine the peptide displayed.
2.13 Target presentation
The majority of phage display panning experiments are designed against 
targets immobilised to a solid support such as derivatised or activated
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polystyrene surfaces, activated dextrans, epoxide beads, paramagnetic 
beads, nitrocellulose membranes, derivatised biosensor chips or permeable 
beaded agarose gels. A variety o f techniques have been employed to affect 
this immobilisation including cross-linking of -NH2, -SH or -CHO to 
modified or activated surfaces, non-covalent adsorption to a hydrophobic 
surface, attachment through a molecular tag such as biotin, GST or His(6) 
which bind their cognate binding partner and capture o f IgG-Fc fusions to 
anti-Fc antibody (Table 2.1).
Table 2.1 Example immobilization matrices used for target presentation in phage binding 
selections.
Capture M atrix Immobilization mechanism Issues
Maxisorp (Nunc) Non-specific adsorbance Matrix binders
Covalink (Costar) Cross-linking of -SH, -CHO or Matrix binders, limited
-NH 2 to activated surface capacity
Oxirane acrylic beads Cross-linking of-N H 2 or -SH Matrix binders
(Sigma) to epoxide
Biosensor chip (Biacore, Cross-linking of -SH, -CHO or Matrix binders, limited
QCM) -NH 2 to modified dextran capacity
Avidin coated plates/beads Capture of biotinylated target Peptidergic biotin
(Promega, Nunc) via avidin-biotin interaction binders
Ni2* pr antibody (His)6 interaction with Ni2+ or Ni2* or antibody
plates/beads (Qiagen) antibody binders; (His)6 binders
Panning methodologies against immobilised target are generally classified 
as one- or two- step selection procedures. In one-step selections the phage 
library is directly exposed to immobilized target w hilst in two-step 
selections the target, fused to an affin ity tag, is in itia lly  exposed to the 
library in a solution or suspension phase, then in a second step, the phage- 
target-tag complex is reacted w ith a surface decorated w ith a molecule that 
captures the complex via the attached affin ity tag. Two-step selection
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generally results in considerably lower yields but favours monovalent 
interactions and selections based on binding affin ity and kinetics rather 
than avidity where m ultiple peptide copies interact w ith  target[21-24].
2.13.1 Elution
After washing away non-binding and weakly binding phage clones w ith a 
detergent buffer, the binding phage must be recovered for amplification. 
Non-specific elution strategies seek to weaken phage-target interactions, 
exploiting, w ithout loss o f infectivity, the robustness o f the phage particle to 
a wide-range of conditions including extremes o f pH, temperature and 
exposure to proteases[l]. Alternatively, the binding phage clones may be 
competitively eluted w ith excess free target or specifically eluted w ith a 
cognate ligand[17-20], the latter is particularly effective when the target is 
presented w ithin a crude m ixture o f related or unrelated 'contaminants' 
since the ligand w ill displace only those phages that bind the target 
However, careful consideration of binding kinetics must be given when 
using competitive ligand elution since it  is a two-stage process requiring 
first the spontaneous dissociation o f the phage clone from target followed 
by occupation w ithin the target by the competitive ligand. Clearly, each 
process w ill have its own kon/kofr w ith typically a reduction in koff for the 
phage clone an indicator o f increased affin ity for target I f  the incubation 
period w ith the competitive ligand is too short, those phage clones w ith 
highest affin ity w ill not be eluted. Conversely, a long incubation time w ill
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not discriminate between high and low affinities since essentially all the 
binding clones w ill be displaced.
Whilst it  would seem logical that directly adding bacterial host cells to the 
phage-target-support complex would be the optimal recovery strategy, it  is 
apparent that only 1-10% o f the clones recovered by elution are recovered 
by direct bacterial in fection[l]. As the iterative panning rounds are 
completed, the progress o f affin ity selection can be quantitatively 
monitored w ith techniques such as enzyme-linked immunosorbant assay, 
surface plasmon resonance[25] or quartz crystal microbalances.
2.1*4 Technology validation
In preparation for panning studies against targets involved in the 
pathobiogenesis o f glioma and for the discovery o f peptides that cross the 
BBB to deliver novel therapies into the brain, a series of phage display 
studies were designed to validate the phage library and phage selection 
strategies. Two targets were utilised for this prelim inary validation 
exercise, streptavidin a 53 KDa tetrameric protein and 4-acetamidophenol 
(4-AAP; paracetamol) a low molecular weight species. Some consideration 
w ill now be giving to the selection o f these targets and issues o f panning 
against them.
2.1.4.1 Streptavidin
Streptavidin is a ~ 53 KDa tetrameric protein purified from the bacterium 
Streptomyces avidinii. The incredible high affin ity of the vitam in biotin
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(244 Da) for streptavidin (Kd ~ 10-14 M)[26] has intrigued researchers for 
many years and the interaction has found application in a diverse range of 
biomedical and biotechnological fields[27]. Through technologies such as 
phage display, streptavidin has also proven particularly amenable to the 
discovery o f peptide ligands that interact w ith  the biotin binding 
pocket[28-30]. The ready crystallisation o f apostreptavidin (streptavidin 
without biotin bound) and complexes o f streptavidin w ith biotin or 
streptavidin w ith novel peptide ligands[30], has made streptavidin an ideal 
model for the exploration o f the structural determinants of high affin ity 
peptide-ligand pairs. The availability o f a diverse range of streptavidin 
derivatised supports coupled w ith the knowledge of linear and cyclic 
peptide sequences that bind streptavidin[28, 31] makes the molecule an 
ideal starting point to examine new libraries and to test selection strategies 
before panning against the desired target
2.1AJ1 4-AAP
Peptides that bind low molecular weight organic species would have 
significant application in such areas as therapeutics, biosensing and 
neutralisation and sensing applications in the environmental and chemical 
sciences. However, the scientific literature only has a few accounts of 
phage-peptide interactions w ith non-proteinaceous low molecular weight 
targets[32-34]. The slow progress in identifying peptides that bind low 
molecular weight species either from phage display or other combinatorial 
peptide technologies is largely associated w ith complex issues of
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immobilising the low molecular weight entity w ithout chemically 
occupying one of the lim ited recognition groups on the molecule itself. To 
overcome these issues, it  was hypothesised that insoluble complexes of a 
molecule could be panned against and then manipulated w ith the insoluble 
complexes washed and, together w ith  binding phages, captured by 
centrifugation techniques. The advantage o f this approach should be that 
the surface o f the molecule is entirely exposed w ith no functional groups 
occupied or lost through attachment to a surface, affin ity tag or carrier 
protein. The disadvantage is that peptide-phage may not bind the molecule 
once in solution.
The molecule 4-acetamidophenol (molecular weight 151.17 Da) was 
chosen as the low molecular weight target because it  is a relatively simple 
molecule w ith two structural isomers (Figure 2.2) 2- and 3- 
acetamidophenol (2-AAP; 3-AAP) that d iffe r only in the orientation o f the 
hydroxyl group around the benzene ring.
N-<4-h><troxyphetiyl)acetamide N-(2-hydroxypbenyl)acetamide N-(3-hydroxyphenyI)acetainide
2-acetamidophenol 3 -acelamidophenol
ftuacetamoi
Figure 22 Structure of 4-acetamidophenol and its isomers 2-acetamidophenol and 3- 
acetamidophenoL
As secondary objectives to panning against 4-AAP, isolating a peptide that 
can discriminate 4-AAP from 2-AAP and 3-AAP would serve as proof of
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principle for a new panning strategy against insoluble complexes. Further, 
such a peptide may be o f practical value since 4-AAP, the most commonly 
administered analgesic in the UK, accounts for more than 70,000 cases of 
overdose annually and 15% of all drug related poisoning deaths[35]. A 
peptide that binds 4-AAP may therefore find u tility  for diagnostic sensing 
or as a therapeutic antidote in its own rig h t
2.13 Objectives
In this section o f the thesis a series o f discrete phage display panning 
strategies were employed to identify cyclic peptide(s) that bind to 
streptavidin and to the low molecular weight organic species 4-AAP. In 
streptavidin panning studies, streptavidin was immobilised on both a solid 
plastic support and on paramagnetic beads. Functionality o f identified 
peptides was investigated using ELISA.
In the case of 4-AAP, occupancy o f one of the lim ited functional groups on 
the molecule, through attachment to a solid support, was avoided by 
panning against insoluble complexes o f 4-AAP. To further enrich for high 
affinity 4-AAP binders, a deletion step to remove peptide phage that bound 
the isomers 2-AAP and 3-AAP was also included. The functionality of 
identified peptide phage particles that bind 4-AAP was examined w ith 
respect to altering the diffusion capacity o f 4-AAP and w ith respect to 
attenuating the cellular toxicity o f 4-AAP in an in-vitro hepatocyte cell 
model.
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The chapter is divided into two sections, one for streptavidin w ith specific 
materials and methods, results and discussion and one for 4-AAP w ith 
specific materials and methods, results and discussion. A section detailing 
general phage methods precedes the specific sections.
12 Materials & Methods -  Phage Display
2.2.1 Materials
Sodium chloride (NaCl); magnesium chloride (MgCb); I PTC; X-gal; nuclease 
free water; propan-2-ol; sodium bicarbonate (NaHCOs); and ethanol were 
obtained from Fisher Scientific (Loughborough, UK). Tween 20 was 
obtained from Amersham (L ittle  Chalfont, UK). Agarose was obtained from 
Bioline (London, UK). Big dye v3.1 and 5x sequencing buffer were obtained 
from Applied Biosystems (Warrington, UK). Luria-Bertani (LB) broth; LB 
agar; bovine serum albumin (BSA); Trizma (Tris-HCl); tetracycline; 
dimethyl formamide; sodium azide (NaN3); glycine-HCl and PEG-8000 were 
obtained from Sigma-Aldrich (Dorset, UK). SuperBlock™ blocking buffer 
(guaranteed biotin free) was obtained from Pierce (Northumberland, UK).
222 Phage library
The Ph.D.™-C7C cyclised 7-mer disulphide constrained peptide-phage 
library (New England Biolabs, Hitchin, UK) was used for all panning 
experiments. This library represents 1.2 x 109 unique genotypes encoding 
random cyclised peptides fused to the p ill coat protein o f the filamentous 
phage M13. The general m otif o f the displayed peptide is N'AC-XXXXXXX-
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CGGGSC where X7 represents a unique 7-mer peptide, the two cysteine 
residues cyclise the peptide and GGGS is a short amino acid spacer that 
links the peptide to the N terminus o f the phage pi 11 coat protein.
123 Phage display media and solutions
• LB Medium: 10 g Bacto-Tiyptone, 5 g yeast extract, 5 g NaCl, ddH20 
to 1 L
• IPTG/X-gal: 1.25 g IPTG, lg  X-gal in 25 ml dimethyl formamide.
• LB/IPTG/Xgal Plates: LB medium + 15 g-L1 agar. Autoclave, cool to 
~ 60°C and add 1 ml IPTG/X-gal. Aseptically dispense into 90 mm 
petri dishes (12 ml per dish). Store plates at 4°C in the dark.
• Agarose Top: 10 g Bacto-Tryptone, 5 g yeast extract, 5 g NaCl, 1 g 
MgCh.6H20, 7 g agarose. Autoclave, dispense into 50 ml aliquots. 
Store solid at room temperature, melt in microwave as needed.
• Tetracycline Stock: 20 mg-ml1 in ethanol.
• Blocking buffer: 0.1 M NaHCOa (pH 8.6), 5 mg.ml*1 BSA, 0.02% 
NaN3.
• TBS: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl.
• TBS-T: TBS + 0.1% v /v  Tween or TBS + 0.5% v /v  Tween.
• Glycine elution buffer: 0.2 M Glycine-HCl (pH 2.2), 0.1% w /v  BSA.
• PEG/NaCl: 20% w /v  polyethylene glycol-8000,2.5 M NaCl.
• Iodide Buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 4 M Nal.
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224 Maintenance of the bacterial host used for phage propagation
The male specific coliphage M13 readily propagates in the ER2738 (F; 
Tet*) strain of £  coli which is supplied by New England Biolabs w ith the 
Ph.D.™C7C library. The F plasmid w ith in ER2738 houses a mini-transposon 
that confers tetracycline resistance affording the selection of £  coli colonies 
that express the F-pilus when cultured using selective medium. In all phage 
studies detailed in this thesis M13 were propagated w ith in cultures 
inoculated from tetracycline doped LB agar plates streaked w ith glycerol 
stocks o f ER2738. Plates were streaked at the beginning o f the week, 
inverted and incubated at 37°C overnight and then stored at 4°C wrapped 
in parafilm; plates were discarded after 7 days.
2X5 Phage amplification and purification
Fourteen hours before phage propagation, a single colony of ER2738 was 
picked from ER2738 streak plates and deposited in 10 ml o f LB broth and 
incubated at 37°C for 14 hrs. A 2 ml aliquot o f the culture was then added to 
18 ml of LB broth in a 250 ml Erlenmeyer flask and the phage to be 
propagated was added to this culture. The flask was sealed w ith aluminium 
foil and incubated for 4.5 hours at 37°C w ith gentle orbital shaking (150 
rpm). The amplified culture was transferred to a 50 ml centrifuge tube and 
centrifuged at 7500g (15 mins; 4°C). The supernatant was collected in a 
fresh 50 ml centrifuge tube and re-centrifuged. The upper 90% (18 ml) of 
this second supernatant was aspirated and transferred to a fresh 50 ml 
centrifuge tube containing 3ml PEG/NaCl; this solution was incubated for 1
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hr at 4°C after which a precipitate was observed. The solution was then 
centrifuged at 7500 g (15 mins; 4°C) and the supernatant discarded. The 
tube was briefly re-centrifuged (1 min) and residual supernatant aspirated. 
The phage pellet was suspended in 1 ml TBS and the phage re-precipitated 
through addition of 200 pi o f PEG/NaCl (1 hour; 4°C). The precipitate was 
pelleted by centrifugation (14,000 g; 10 mins; 4°C) and the supernatant 
discarded; after a 1 min re-centrifugation, residual supernatant was 
discarded. Finally, the phage pellet was suspended in 200 pi o f TBS 
containing 0.02% NaN3 and stored at 4°C for up to 1 month after which any 
unused material was transferred to 50% glycerol stock and stored at -80°C 
for up to 2 years.
2X6 Phage plaque formation assay
Phages in amplified stocks and panning elutions were quantified using 
bacterial titration. Phages were serially diluted (1:10) in LB broth (108 -  
1011 for amplified stocks; 101 -  104 for eluates) before 10 pi was 
transferred to 190 pi o f ER2738 (ODeoo -  0.5) and incubated at room 
temperature for 5 mins. A 3 ml aliquot o f molten agarose top was dispensed 
into a 15ml centrifuge tube (one tube for each serial dilution) and the phage 
culture added. After gentle mixing, the molten agarose top was carefully 
poured onto pre-warmed LB-agar plate containing IPTG/X-gal; plates were 
inverted and incubated overnight at 37°C and then inspected for phage 
numbers. Library phage are derived from M13mp9 and carry the LacZa 
gene producing blue colonies in the presence of IPTG/X-gal, insertless
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phages, used in some studies detailed in the thesis, appear as clear plaques 
on IPTG/X-gal plates.
2^.7 Gene sequencing
The linkage of genotype w ith phenotype in phage display was exploited to 
identify the amino-acid sequence o f the displayed peptide. Essentially, 
phages were amplified on a clonal basis, DNA extracted and subjected to 
PCR amplification followed by automated dye-labelled dideoxynucleotide 
sequencing to determine the DNA sequence encoding the displayed 
peptide.
2.2.7.1 Phage plaque amplification and DNA extraction
Using a sterile 1 ml pipette tip, individual plaques o f phages were picked 
from phage tite r plates bearing < 100 colonies. Each harvested plaque was 
deposited into 3ml o f a culture o f ER2738 (OD600 ~ 0.5); all phages w ithin
a singlejsolated fwell separated) plaque have the same genome an 
display the samepeptide^After cultures were incubated for 4.5 hours (37°C,
150 rpm orbital shaking), 1 ml o f supernatant was dispensed into a 
microcentrifuge tube. The £  coli were pelleted (14,000g, 10 mins, 4°C) and 
the supernatant aspirated and added to a fresh microcentrifuge tube 
containing 200 pi o f PEG/NaCl. Phages were precipitated for 10 minutes at 
room temperature and then pelleted by centrifugation (14,000g, 10 mins, 
4®C). The supernatant was discarded and the phage pellet suspended in 100 
pi iodide buffer and 250 pi o f ethanol. A 10 min incubation at room
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temperature precipitates phage ssDNA leaving the phage protein coat in 
solution. The DNA was pelleted by centrifugation (14,000 g, 10 mins, 4°C) 
and then briefly washed in 180 pi o f 70% ethanol. Finally the DNA was 
suspended in 30 pi o f molecular grade H2O.
24.7.2 PCR
A 5 pi aliquot o f DNA obtained in 2.2.7.1 was added to a PCR tube 
containing 0.30 pi Big Dye v3.1 (dye-labelled dideoxynucleotides), 2 pi 5x 
sequencing buffer, 1.6 pi prim er (1 pm ol.pl1; sequence 
5'CCCTCATAGTTAGCGTAACG3') and 1.1 pi ddH20. Dye-labelled 
dideoxynucleotides were incorporated and amplified using a PCR cycle 
reaction comprising denaturation at 96°C for 30 sec, annealing at 50 °C for 
15 sec, extension at 60°C for 4 mins repeated for a total o f 31 cycles. Upon 
completion of reaction, PCR product was precipitated w ith 90 pi o f 70% 
isopropanol (15 mins; room temperature) and then pelleted by 
centrifugation (14,000g; 4°C; 30 mins). The pellet was washed 2x w ith 180 
pi of 70% isopropanol and then dried briefly under vacuum. The DNA pellet 
was sequenced on an ABI Prism 3100 Genetic Analyzer (Medical Genetics 
department, Cardiff University or Biosciences department, Cardiff 
University) and chromatograms were processed using 4Peaks (A. 
Griekspoor and Tom Groothuis, mekentosj.com). A BLAST search of the 
SWISSPROT database (http://w ww.ncbi.nlm .nih.gov/blast/) was 
performed to identify homologies between displayed peptides and known
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peptide sequences. Peptide sequence alignment was performed using 
Qustal W using default settings (www.ebi.ac.uk/clustalw).
228 Statistical analysis
Statistical analysis was performed using Graphpad Prism (Graphpad 
Software; California, USA). Results were expressed as mean ± standard 
deviation (SD) unless otherwise stated. Statistical significance between 
multiple groups was assessed using a two-way ANOVA followed by a post 
hoc Bonferroni test Single group differences were determined using a one­
way ANOVA followed by Dunnett's post hoc. P < 0.05 was considered 
significant
23 Streptavidin Panning
23.1 Materials & Methods
23.1.1 Materials
Nunc Immobilizer™- streptavidin plates (Cat No 436014) were obtained 
from Fisher Scientific (Loughborough, UK). Streptavidin paramagnetic 
particles (SA-PMPs) were obtained from Promega (Southampton, UK).
23.13 Panning studies
To validate the use o f the phage library in our laboratory a series of 
panning studies were conducted against streptavidin. The literature has 
reported peptides isolated from phage display libraries that bind 
streptavidin[28] and a consensus m otif appears to be the tripeptide m otif 
HPQ. Two strategies were employed to select peptides:
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• Strategy 1: Ph.D.™-C7C library exposed to streptavidin covalently 
attached to a 96 well plate.
• Strategy 2: Ph.D.™-C7C library exposed to paramagnetic beads 
coated in Streptavidin.
This was to determine whether selections against the same target 
presented in different ways yielded the same or sim ilar peptides.
Strategy 1: Non-specific binding sites were blocked by incubating 
streptavidin coated wells w ith SuperBlock™ for 1 hour. After aspirating 
blocking buffer and washing 6x w ith TBS-T (0.5%) the streptavidin target 
was exposed to 2 x 1011 pfus o f Ph.D.7*i-C7C. Following a 1 hr incubation at 
room temperature on an orbital shaker (150 rpm), non-binding phages 
were aspirated and discarded. The streptavidin was washed lOx w ith TBS- 
T (0.5%) to remove those phages that bind w ith lim ited affinity. Phages 
binding w ith higher affin ity were eluted using 3x glycine elution buffer 
washes. The elutions were either pooled (i.e. all three glycine elutions 
combined) or only the th ird  glycine elution was collected. In both cases the 
phages in the elution were amplified, purified and titered as previously 
described to serve as input into the next iterative panning round. A total of 
three panning rounds were completed for each of the two experiments 
after which a selection o f colonies from the final panning round were gene 
sequenced.
Strategy 2:10 mg of SA-PMPs were dispensed into a microcentrifuge tube 
and were washed 3x w ith 1 ml o f TBS (pelleted using a neodymium rare
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earth magnet between washes). The SA-PMPs were then suspended in 100 
pi o f TBS containing 2 x 1011 pfus o f PhDC7C™ library. After a 1 hr 
incubation (room temperature: 18 -  24°C; gentle rocking: 50 rpm) the SA- 
PMPs were pelleted using a rare earth magnet and the supernatant 
aspirated and discarded. The SA-PMPs were washed lOx w ith TBS-T (0.5%) 
before being exposed to 3x 5 minute glycine elutions (200 pL) during which 
the SA-PMPs were sonicated. The glycine elutions were neutralized, pooled 
and amplified to serve as input into the next iterative panning round. A 
total o f three panning rounds were completed after which a selection of 
colonies were randomly selected from the th ird  glycine elution from round 
three and gene sequenced.
23.1.3 ELISA analysis of a streptavidin binding phage done 
A phage based ELISA was developed to quantitatively assess the interaction 
o f a streptavidin binding phage clone w ith  a streptavidin coated surface. A 
100 pi aliquot o f TBS containing 1 x 1010 pfus o f either streptavidin binding 
phages or insertless phages was added to streptavidin coated wells of a 96 
well microtiter plate; some wells had been exposed to a 10- or 100- fold 
excess of biotin for 15 minutes prio r to addition o f phages. After 1 hr the 
supernatant was aspirated and the wells washed 6x w ith TBS-T (0.5%). To 
each well was added 200 pi o f a 1:5000 dilution o f HRP-anti-M13 mAb in 
TBS-T (0.5%). After 1 hour, the wells were washed 3x w ith ddlhO and then 
exposed to lOOpl o f HRP substrate (o-phenylenediamine (OPD) in TBS).
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After 15 minutes the OPD was quenched w ith 50 pi of 2.5 M H2SO4 and the 
optical absorbance at 492 nm recorded.
23J1 Results
2SJ2.1 Analysis of phage recovery and peptide sequences in streptavidin 
phage studies
Streptavidin was immobilised on two different supports for panning 
experiments, a plastic 96 well m icrotiter plate (Strategy 1) and on 
paramagnetic particles (Strategy 2). Figure 2.3 shows the recovery of 
library phages from strategies 1 and 2 respectively. In both strategies a 
significant enrichment for binding phages was observed with progressive 
rounds of panning In contrast, in strategy 1, in studies where library 
phages were substituted for insertless phages, the number of insertless 
phages recovered did not increase in progressive rounds. In strategy 1, two 
experiments were undertaken where either the three glycine elutions were 
pooled and amplified for input in the subsequent panning round, or glycine 
elution 3 alone was amplified to serve as input in the subsequent panning 
round. The results indicate that recovery is marginally greater when 
amplifying glycine elution 3 (round 3) alone but the number of phages 
recovered in each experiment is w ithin the same order of magnitude and 
therefore the difference has limited practical significance.
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Figure 2.3 Phage recovered in glycine elutions from streptavidin coated plastic support (A) or 
from SA-PMPs (B). Increasing recovery of library peptide phage but not insertless phages is 
observed with progressive panning rounds in (A) indicating enrichment of streptavidin 
binding species in the library population.
The HPQ motif previously reported as a high affinity binder to strepatavidin 
was identified in all panning studies and the majority [87%) of the colonies 
sequenced (see Table 2.2). Of note, there was significant commonality 
between sequences identified in strategies 1 and 2 with all clones 
displaying the generic peptide motif AC-GX1X2X3HPX4-CGGGS where Xi = 
T/S/W, X2 = H /F/Y /W , X3 = L /I/W /F  AND X4 = Q /M /L.
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Table 22  Sequences of displayed peptides identified in panning studies against streptavidin.
Sample name Sequence
Strategyl
SA coated plastic support -  pooled elutions
Glycine elution 3 [pooled sample) AC-GTHLHPP-CGGGS
Golony 1 AC-GTFIHPQ-CGGGS
Colony 2 AC-GTFIHPQ-CGGGS
Colony 3 AC-GSYWHPQ-CGGGS
SA coated plastic support -  elution 3
Glycine elution 3 [pooled sample) AC-GTFIHPL-CGGGS
Colony 1 AC-GTFIHPQ-CGGGS
Colony 2 AC-GTFIHPM-CGGGS
Colony 3 AC-GSYWHPM-CGGGS
Strategy 2
SA-PMPs
Colony 1 AC-GSYWHPQ-CGGGS
Colony 2 AC-GSYWHPQ-CGGGS
Colony 3 AC-GTYFHPQ-CGGGS
Colony 4 AC-GSYWHPQ-CGGGS
Colony 5 AC-GSYWHPQ-CGGGS
Colony 6 AC-GNWIHPQ-CGGGS
Colony 7 AC-GSYWHPQ-CGGGS
Colony 8 AC-GSYWHPQ-CGGGS
2 3 2 .2  ELISA analysis of a streptavidin binding peptide phage
Confirmation of the binding o f peptide phage to strepatavidin was 
undertaken using ELISA. Phages displaying peptide AC-GSYWHPQ-CGGGS, 
identified in both strategies 1 and 2, or insertless phages were exposed to a 
strepatvidin coated plate in the presence or absence of biotin. Figure 2.4 
shows that the binding of AC-GSYWHPQ-CGGGS phages to streptavidin is 
significantly greater than insertless phages 85 fold greater) and that this 
binding can be prevented by blocking streptavidin sites w ith excess biotin. 
In contrast biotin does not affect the binding of insertless phages to 
streptavidin.
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Figure 2.4 ELISA confirmation of the binding of a phage clone displaying peptide sequence 
AC-GSYWHPQ-CGGGS to streptavidin. For the same phage input, the absorbance produced 
with AC-GSYWHPQ-CGGGS virions (a direct measure of the number of phage binding)  is ~ 85 
fold greater than insertless phage. Blocking AC-GSYWHPQ-CGGGS binding sites with biotin, 
either in 10- or 100-fold excess, significantly reduces the level of Pep-strep-1 binding by 4.5- 
and 7.1-fold respectively; in contrast biotin had no effect on the binding of insertlesss phages 
to streptavidin. Inset: data for AC-GSYWHPQ-CGGGS presented on a linear scale highlights 
the reduction in binding when binding sites on streptavidin are blocked with biotin. Data are 
mean ± SD (n=3J. * represents a statistically significant difference( P < 0.05) compared to 
streptavidin alone; f  represents a statistically significant difference (  P < 0.05) between 
insertless phage and AC-GSYWHPQ-CGGGS binding to streptavidin alone; ns represents no 
statistically significant difference (  P> 0.05) compared to streptavidin alone.
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2A  4-AAP Panning
14.1 Materials & Methods 
2A.1.1 Materials
4-acetamidophenol; 2-acetamidophenol and 3-acetamidophenol were 
obtained from Sigma-Aldrich (Dorset, UK). Acetonitrile (HPLC grade) and 
Nudeopore track-etched polycarbonate filters (pore size 0.1pm; 13mm 
diameter) were obtained from Fisher Scientific (Loughborough, UK).
14.12 Panning studies
The Ph.D.ra-C7C library was used for all panning experiments against 4-AAP 
and its structural isomers 2-AAP and 3-AAP. A schematic o f the panning 
experiments can be seen in Figure 2.5, w ith  all panning conducted against 
suspensions o f insoluble complexes of 4-AAP, 3-AAP or 2-AAP.
The panning was divided into: (i) “ Isolation strategy 1“ involving four 
rounds o f panning against 4-AAP (rounds 1-4): undertaken w ith the 
objective of isolating a pool o f peptide phage library members that bind 
with high affinity to 4-AAP. (ii) (rounds 5-6) “ Isolation strategy 2“ involving 
an additional two rounds o f panning: undertaken to delete from the 4-AAP 
binding pool those phage also binding to the structural isomers 2-AAP and
3-AAP. The in itia l input to round 5 comprised phages from the final (3rd) 
glycine elution step of panning round 4 from “ Isolation strategy 1“. A t the 
end of each round in “ Isolation strategy 2“ a further panning against 4-AAP 
as target was undertaken to augment the 4-AAP selection.
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Figure 2.5 Schematic of phage panning experiments. In “Isolation strategy 1" the aim was to 
isolate a pool of clones enriched with peptide phage that bind 4-AAP. The Ph.D.™-C7C library 
was exposed to insoluble complexes of 4-AAP. The third glycine elution was collected and the 
phage amplified in E. coli and a further 3 rounds of panning completed (4 rounds in total). 
Some peptide phages collected in Round 4 were sequenced. The remainder were used as input 
for “Isolation strategy 2“. In “Isolation strategy 2 “ peptide phages that bound the isomers 2- 
AAP and 3-AAP were deleted from the 4-AAP binding pool by two additional rounds of 
exposure to insoluble complexes of 2-AAP and 3-AAP. Peptide-phage that did not bind 2-AAP 
or 3-AAP were collected and then exposed to 4-AAP to augment the 4-AAP binding population 
(Rounds 5-6).
For “Isolation strategy 1" 4-AAP was suspended at 500 mg.ml*1 in 4 ml TBS 
and incubated for 1 hr at 37°C with 2 x 1011 plaque forming units (pfu) of 
the Ph.D.™-C7C phage library. After incubation the 4-AAP was pelleted by 
centrifugation (10,500g; 10 mins) and the non-binding phages in the 
supernatant discarded. The 4-AAP pellet was then washed 6x with TBS-T 
(0.5%) with the 4-AAP pelleted and supernatant discarded between each
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/ Owash. The 4-AAP binding phages were than eluted w ith 3x 5 min 200 pi 
glycine buffer elutions w ith the 4-AAP pelleted between each elution. The 
third glycine elution, containing the highest affin ity binders, was collected, 
amplified and purified serving as input for the next iterative round of 
panning. After four such rounds o f panning w ith in ''Isolation strategy 1" an 
aliquot o f the 4th round binders (3rd glycine elution) were gene sequenced. 
The remainder o f the phage (3rd glycine elution) was amplified and served 
as the input into "Isolation strategy 2".
In "Isolation strategy 2" a total o f 2 x 1011 pfus o f phage from round 4 were 
exposed to a suspension o f 2-AAP (500 mg.ml*1; total volume 4ml) for 1 hr 
at 37°C after which the isomer was pelleted and the supernatant, 
containing 2-AAP non-binding peptide-phage, transferred to a suspension 
of 3-AAP (500 mg.ml*1; total volume 4ml) for 1 hr at 37°C. The 3-AAP was 
subsequently pelleted and the supernatant, now containing phages that do 
not bind either 2-AAP or 3-AAP, were transferred to a suspension o f 4-AAP 
(500 mg-ml*1; total volume 4ml) for 1 hr at 37°C. Following this, the 4-AAP 
was pelleted, the pellet washed 6x w ith  TBS-T (0.5%) and 3x low pH 
glycine elutions completed w ith the th ird  glycine elution collected and 
amplified. A second panning round against 2-AAP, 3-AAP and 4-AAP was 
repeated before gene sequencing to identify 4-AAP binding peptide 
sequences.
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£4.1.3 4-AAP permeability studies
The effect o f a peptide phage isolated in the panning procedure upon the 
diffusion of 4-AAP across a semi-permeable membrane was examined; this 
was used as one functional endpoint to assess peptide phage binding to 4- 
AAP. Permeability studies were conducted in 1 ml Franz cell diffusion 
apparatus w ith the donor and receiver chambers separated by a semi- 
permeable membrane (Nucleopore track-etched polycarbonate filters, 100 
nm pore size). Phages were found to be incapable of penetrating this 
membrane to any great extent - after 4 hrs less than 1 x 10-6 % o f the phage 
pfu loaded in the donor chamber (1 x 1011 pfus) was able to penetrate to 
the receiver chamber.
The study was initiated by adding 200 pi o f a 4-AAP solution (100 pM in 
TBS) into a Franz cell donor chamber either alone or w ith a binding peptide 
phage PARA-061 that had been isolated in the 4-AAP phage panning 
procedure (strategy 1 and 2); 4-AAP was pre-exposed to phages for 30 
mins prior to loading. As a control, the effect upon 4-AAP diffusion of a non­
binding peptide phage clone, NB-062 (AC-HKSSPHQ-CGGGS; from panning 
washings) was examined. The phage virions were incubated in a 1:1 
stoichiometric ratio w ith 4-AAP molecules. Since each phage can display up 
to five copies of the peptide, this equates to a maximum of 5 peptide copies 
per 4-AAP molecule. At predetermined time points following the start o f the 
permeability experiment 200 pi samples o f the receiver chamber were 
collected and 4-AAP quantified by HPLC-UV. Receiver chamber sample
76
Chapter 2
volume was replenished w ith an equal volume of TBS. The cumulative 
membrane transport o f 4-AAP as a function o f time was determined and the 
apparent permeability coefficients (p) calculated using equation 2.1. 
dM
- - j-m  p x A x C o  Equation 2.1
Where dM /dt represents the rate o f change in cumulative mass of 4-AAP 
transferred from donor -  receiver, A represents the area of the Nucleopore 
membrane (0.95 cm2) and Co is the original concentration o f 4-AAP in the 
donor chamber (100 pM).
24X4 HPLC quantification of 4-AAP
To determine 4-AAP and 3-AAP concentrations, HPLC-UV was undertaken 
using a HP1050 HPLC system w ith a Varian Pursuit XRs analytical (5pm) 
C18 (150 mm x 4.6 mm) column. Elution was performed w ith a mobile 
phase of 50:50 acetonitrile:H20 at a flow  rate o f lm l.m in*1; the injection 
volume was 50 pi. The concentration o f compounds was determined by UV 
detection (wavelength 550nm) against linear (r2 > 0.99) calibration curves. 
The lim it o f detection for each compound was ~ 2 pM. Calibration 
standards in the range 2-100 pM were prepared for each compound and 
run on each day of analysis. The relative standard deviation for w ith in day 
and between day precision was less than 10%. The accuracy was 
determined by subtracting the measured concentration from its nominal 
value; the mean relative error (M.R.E.) o f the difference from theoretical 
was less than 10%.
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2.4.1.5 In-vitro hepatotoxicity assays
As a second assessment o f the functionality o f the selected 4-AAP binding 
peptide phage clone PARA-061, an examination was made o f the in-vitro 
modulation o f 4-AAP induced hepatotoxicity. Preliminary in-vitro  toxicity 
studies were undertaken to determine the most efficient method of 
monitoring 4-AAP toxicity and its attenuation in the hepatocarcinoma cell 
line Hep3B. Appendix 1 details the growth characterisation of the Hep3B 
cell line and investigations into the time and concentration dependent 
hepatotoxicity of 4-AAP and its attenuation w ith the sulphydryl group 
donor N-acetylcysteine (NAC) w ith in Hep3B cells. These studies included 
micrographic monitoring of confluent monolayers of Hep3B, MTT (3-(4,5- 
dimethyethiazol-2-yl)-2,5-diphenyltetrazolium bromide) assessment of 
mitochondrial dehydrogenase activity, measurement of lactate 
dehydrogenase (LDH) leakage from the cell and determination of 
intracellular levels o f reactive oxygen species. A ll measures o f toxicity 
showed 4-AAP to be hepatotoxic in a time and concentration dependent 
manner.
MTT, a colorimetric assay w idely used to assess cell v iab ility and 
proliferation, distinguishes viable cells from non-viable through the 
reduced activity of mitochondria in non-viable cells. Mitochondrial activity 
is monitored through the reduction o f the water-soluble yellow tetrazolium 
salt MTT to an insoluble blue formazan sa lt The method used was based on
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that first detailed by Mosmann et al [36] and later by Plumb et al[37] but 
with modifications.
Hep3B cells were seeded in a 96 well plate at a density of 3xl04 cells.cnr2 
until 80% confluent The cells were exposed to varying concentrations of 4- 
AAP (5, 20 or 40 mM) or 3-AAP (1, 5, 10, 20 or 50 mM) ± the sulphydryl 
group donor N-acteylcysteine (NAC; 10 mM) for 5, 24 or 48 hours. At the 
indicated time intervals, media was aspirated from each well and replaced 
with 200 pi of fresh media. A 50 pi aliquot of MTT stock (2 mg-ml1 MTT in 
culture medium) was immediately added to each well. The plate was 
wrapped in aluminium foil and incubated for 4 hours at 37°C. The media 
was then aspirated and 200 pi of DMSO added to each well to permeabilise 
the cell membrane and release the intracellular formazan dye. Immediate 
addition of 25 pi of Sorensen's glycine buffer (0.1M glycine; 0.1M NaCl; pH 
10.5) fully solubilised the formazan dye. The absorbance was immediately 
measured spectrophotometrically at 570 nm using an Anthos htll m icrotiter 
reader. Background absorbance of DMSO controls was subtracted from 
sample absorbance. Cells exposed to culture medium alone were used as 
reference for 100% viability and to which all experimental variables were 
compared.
MTT was used to assess the phage modulation of in-vitro hepatotoxicity and 
was chosen over other measurements of hepatotoxicity (LDH leakage, 
generation of reactive oxygen species and intracellular levels of
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glutathione) because the culture format in the MTT study means that 
phages can be incubated in a physiologically relevant stoichiometric ratio 
with 4-AAP. MTT assays were undertaken follow ing a five hour incubation 
of Hep3B cells w ith 40 mM 4-AAP in the presence or absence of the 4-AAP 
binding peptide phage clone PARA-061, the non-binding peptide phage 
done NB-062 or NAC (10 mM). The phage virions were incubated in a 
1:100 stoichiometric ratio w ith 4-AAP molecules i.e. 1 peptide for every 20 
4-AAP molecules; the phage numbers used reflects the maximum phage 
pfus that can be obtained w ith amplification.
1AJL Results 
2A2.1 Analysis of phage recovery and peptide sequences in 4-AAP studies
The details o f the panning scheme to select peptide phages that bind 4-AAP 
are outlined in Figure 2.5. The strategy enabled the selection of peptides 
that specifically bound 4-AAP but not its isomers 2-AAP and 3-AAP. Prior to 
panning studies, the solubility o f 4-AAP and its isomers in the TBS panning 
buffer was determined using HPLC-UV, the results o f which confirmed that 
500 mg of the respective isomer in 4ml TBS resulted in adequate formation 
of insoluble complexes (data not shown).
Analysis of phage tite r in iso la tion  strategy V  rounds 1-3 showed that the 
percentage of phage input recovered in the 3rd glycine elution progressively 
decreased (Figure 2.6). However, at panning round 4 the phage recovered 
in die 3rd glycine elution showed a small relative increase of 20% compared
80
Chapter 2
to glycine wash 3 in round 3 (5000 pfus recovered cf 4000 pfus) suggesting 
enrichment o f a 4-AAP binding population. A sequential isolation strategy 
was then adopted (iso la tion  strategy 2") to augment selection o f 4-AAP 
binding phage through the deletion o f peptide-phage clones that also bound 
the isomers 2-AAP and 3-AAP. In the in itia l round of panning in "Isolation 
strategy 2* (round 5 of the overall scheme) w ith an input o f lx lO 11 pfus 
from round 4 only 100 phage clones were recovered in the th ird  glycine 
elution. This dramatic reduction in recovery in round 5 is not unexpected 
since the isomers only d iffer in the orientation o f the hydroxyl and amide 
groups on the benzene ring and one would not anticipate many peptide 
sequences could distinguish this orientation. However, w ith an input of 
lx lO 11 pfus into round 6, an enrichment in the population of 4-AAP specific 
binders was evidenced by a 10-fold increase in recovered peptide-phage 
clones in glycine elution 3 (Figure 2.6).
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Figure 2.6 Phage recovered in panning isolations. (A) Phage recovered in glycine elutions 1-3 
reduces for rounds 1-3 and then increases in round 4 indicating enrichment of 4-AAP binding 
phage. Deletion of 2-AAP and 3-AAP binding phage in round 5 dramatically reduces phage 
recovery. In round 6 enrichment of a 4-AAP binding population is evidenced by increased 
recovery in glycine elutions 2 and 3. (B) Phage recovered in glycine elution 3 in all panning 
rounds. These elutions were amplified to serve as input in the subsequent panning round.
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Expressing the number of phage recovered in each glycine elution in 
rounds 5 and 6 as a percentage o f the total clones recovered in the 
respective round (Table 2.3) shows enrichment for high affin ity clones, 
since in addition to an increase in the total number o f phage recovered in 
round 6, there is a significant increase in the percentage of total clones 
recovered in glycine elutions 2 & 3 i.e. in round 5 the majority o f clones 
were recovered in glycine elution 1 (~  86%) w hilst in round 6 the majority 
were recovered in glycine elutions 2 & 3 (~  56% and 33.9% respectively).
Table 23 Phages recovered in rounds 5 & 6. Round 6 shows a two-fold increase in the total 
number of phage recovered compared to round 5. In round 5 the majority of phages 
recovered were in glycine elution 1. Conversely in round 6 an enrichment for high affinity 
binders was observed in glycine elutions 2 & 3.
Total pfus % pfus recovered % pfus recovered % pfus recovered
recovered in Glycine 1 in Glycine 2 in Glycine 3
Round 5 1400 85.7 7.1 7.1
Round 6 3100 9.7 56.45 33.9
After sequencing clones from round 4 (“ Isolation strategy 1*) and round 6 
("Isolation strategy 2"), the sequence N'AC-NPNNLSH-CGGGSC', designated
PARA-061, was identified in both strategies suggestive of its presence in 
high copy number (Table 2.4). This sequence was taken forward for 
functional evaluation. W hilst ClustalW analysis
(http://www.ebi.ac.uk/clustalw/) o f clones from both isolation strategies 
did not highlight any common motifs, analysis o f their prim ary amino acid 
sequences (Table 2.5) revealed the peptides to largely comprise 
hydrophilic amino acid residues (47%) w ith asparagine, threonine, serine 
and glutamine the most frequent
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Table 2.4 Amino acid sequences of 4-AAP binding peptide-phage clones analysed on 
completion of Isolation strategies 1 and 2.
Peptide sequences of phage clones 
binding to 4-AAP with unknown 
isomer binding status___________
Peptide sequences of phage clones 
binding to 4-AAP with 2-AAP and 3-AAP 
isomer binding phage clones deleted
Isolation strategy 1, round 4
(Sample of five peptide phages 
selected from phage plaques)
Isolation strategy 2, round 6
(Sample of twenty-one peptide phages 
randomly selected fr-pnfphage plaques)
AC-NPNNLSH-CGGGS (PARA-061) 
AC-WHTHTD-C 
AC-TTASGAR-C 
AC-TDLLPRH-CGGGS 
AC-PTAPLHN-CGGGS
AC-NPNNLSH 
AC-RAPSQTV 
AC-DGNSRTQ 
AC-TTLTKTF 
AC-TLRSATA 
AC-SHLHSPL 
AC-ENTQKNS 
AC-SQGRLGQ 
AC-DRNGSNA 
AC-SQHSSRS 
AC-LNSHLQT 
AC-RTTSOAL 
AC-TSOWRLH 
AC-MNQGMRA 
AC-KQQMEPA 
AC-VLHKGFQ 
AC- SPWQHKN 
AC-THSLTIQ 
AC-ADKQTTL 
AC-HHGDSAV 
AC-WQPWIRH
■CGGG* (PARA-061)
CGGGS^--------------
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
CGGGS
k /
Detailed analysis o f the physicochemical properties of the round 6 peptides 
(Table 2.5) shows they can essentially be separated into two distinct 
groups -  those w ith a pi between 6.7 and 8 48%) and those w ith a pi of
either 10.1 or 11 (~  43%) indicating that the panning strategy employed 
has led to the isolation o f peptides w ith a bimodal pattern of 
physicochemical properties.
1
j
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Table 2.S Physicochemical properties of 4-AAP binding phage clones sequenced from round 6. 
Ml the peptides sequenced are essentially hydrophilic and with the exception of peptide 
sequence MHCDSAV, the sequences fa ll into two distinct physicochemical groupings, those 
with isoelectric point (pi) of 6.7 -  8 and those with isoelectric points of 10.1 -11.
Sequence Net Charge 
atpH7.0
Pi Average
hydrophllidty
Percentage
hydrophilic
residues
AC -NHGDSAV- CGGS -0.9 4.9 -0.1 29%
AC-ADKQTTL-CGGS 0 6.7 0.4 43%
AC-DGNSRTQ-CGGS 0 6.8 0.9 71%
AC-DRNGSNA-CGGS 0 6.8 0.9 71%
AC-RTTSOAL-CGGS 0 6.8 0.5 43%
AC-ENTQKNS-CGGS 0 6.9 0.9 86%
AC-KQQNEPA-CGGS 0 6.9 0.7 57%
AC-TSOURLH-CGGS 0.1 7.8 0 43%
AC-NPNNLSH-CGGS 0.1 7.8 -0.2 57%
AC-LMSHLQT-CGGS 0.1 7.8 -0.5 43%
AC-THSLTIQ-CGGS 0.1 7.8 -0.6 29%
AC-SHLHSPL-CGGS 0.2 8 -0.6 29%
AC-TTLTICTF -CGGS 1 10.1 -0.4 14%
AC-VLHK6FQ-CGGS 1.1 10.1 -0.4 29%
AC-SPMQHKN-CGGS 1.1 10.1 0 57%
AC-RAPSQTV-CGGS 1 11 0.2 14%
AC-TLRSATA-CGGS 1 11 0 29%
AC-SQGRLGQ-CGGS 1 11 0.3 57%
AC-SQHSSRS-CGGS 1.1 11 0.6 86%
AC-MNQGMRA-CGGS 1 11 -0.3 43%
AC-NQPNIRH-CGGS 1.1 11 0.2 57%
MEAN 0.43 8.63 0.12 47%
A search of the SWISSPROT database w ith the BLAST search engine to 
identify short nearly exact matches to known proteins and peptides did not 
reveal any homologies o f note. This is probably to be expected since a 
literature search did not reveal any natural peptide or protein motifs 
known to bind 4-AAP.
2AJ2J1 4-AAP permeability studies
To assess die capacity o f the phage peptide clone PARA-061 to bind 4-AAP, 
die permeability of 4-AAP across an inert semi-permeable membrane (0.1 
pm pore diameter) was determined follow ing pre-incubation of the 4-AAP
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with the PARA-061 clone. The 4-AAP in solution was pre-exposed to PARA- 
061 (stoichiometric ratio o f one phage particle per 4-AAP molecule) for 30 
mins after which the PARA-061/4-AAP solution was loaded into the donor 
chambers of Franz cell diffusion apparatus. The permeability o f 4-AAP 
under these conditions was compared to the permeability of an equimolar 
dose of 4-AAP alone, and the permeability o f an equimolar dose o f 4-AAP 
pre-exposed to, and co-loaded w ith, phage clone NB-062. The diffusion of 4- 
AAP was not rate-lim ited by the Nucleopore membrane (0.1 pm pore size) 
as evidenced by a sim ilar 4-AAP permeability across Nucleopore 
membranes w ith a 3 pm pore diameter (data not shown). Figure 2.7 shows 
that the control phage NB-062 had no effect (p > 0.05) on 4-AAP 
permeability w ith 4-AAP permeability co-efficients of 77.05 ± 4.49 and 
76.87 ± 4.56 xlO*6 cims*1 when incubated respectively w ith and w ithout NB- 
062. However, when 4-AAP was exposed to the 4-AAP peptide-phage clone 
PARA-061, the permeability coefficient was significantly redpced-fp-<^05) 
to 59.54 ± 3.38 xlO*6 cm-s1 representing an approximate 20% reduction 
compared to both 4-AAP alone and to 4-AAP exposed to
86
Chapter 2
C/5
EoCO
O
c
05
O
£
05Oo
JD
03
05
E
k_
05
CL
77.05 ± 4.4976.87 ±4.56
Figure 2.7 Permeability of 4-AAP through a nucleopore membrane (lOOnm pore size] placed 
between the donor and receiver chambers of a Franz cell. Permeability experiments showed 
that PARA-061, but not peptide-phage clone NB-062, significantly (p < 0.05] reduced 4-AAP 
permeability. * Signifies statistically significant difference (p <0.05] compared to any of the 
other treatments. DATA are mean t  SEM for three separate experiments, (n = 8 for each 
experiment].
2.4.2.3 In-vitro hepatotoxicity assays
Figure 2.8 highlights the time and concentration dependent toxicity of 4- 
AAP on Hep3B cells as determined by MTT assay.
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Figure 2.8 Mitochondrial dehydrogenase activity of Hep3B cells exposed to 4-AAP. Results 
expressed as percentage of controls where controls are either no treatment or cells exposed 
to NAC (10 mM) alone. Hep3B cells exposed to 4-AAP showed a time and concentration 
dependent toxicity. A 5 hr exposure to 40 mM 4-AAP led to a significant (p < 0.05) 24% 
reduction in cell viability that was prevented by co-incubation with NAC. DATA are mean ± 
SD (n=4). * Signifies statistically significant difference (p <0.05) compared to no treatment 
cells.f Signifies statistically significant difference (p <0.05) compared to cells exposed to NAC 
alone.
After five hours exposure to a 40 mM concentration of 4-AAP, a significant 
(p < 0.05) 24 ± 2.1% reduction in cell viability was observed. The loss in 
viability could be prevented by co-incubation with 10 mM NAC. Exposure to 
lower concentrations of 4-AAP (5 and 20 mM) for 5 hours did not cause any 
significant (p > 0.05) loss in cell viability. In cells exposed to 4-AAP for 24
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hours cell v iability significantly (p < 0.05) decreased w ith concentrations of 
4-AAP at 5, 20 and 40 mM resulting in a loss o f cell v iability by 13 ± 3.0%, 
27 ± 1.0% and 87 ± 1.1% respectively. The same trend was observed at 48 
hours exposure w ith respectively, 19 ± 1.0%, 56 ± 1.0% and 90 ± 1.3% loss 
in viability compared to control. The loss in cell v iab ility following exposure 
to 4-AAP for 24 and 48 hrs could not be prevented by co-incubation w ith 
NAC
In order to analyse whether PARA-061 is specific for 4-AAP, an in-vitro 
functional assessment o f its interaction w ith 3-AAP was undertaken and 
this was achieved through measurement o f Hep3B cell viability on 
exposure to 3-AAP w ith the MTT assay. Prelim inary studies (Figure 2.9) 
showed that 3-AAP is toxic to Hep3B cells in a concentration- and time- 
dependent manner. However, co-incubating hepatocytes exposed to 3-AAP 
with NAC for 5 hours abrogated toxicity at all 3-AAP concentrations 
investigated. After 24 hour exposure, 3-AAP induced toxicity was greater 
than toxicity at 5 hours and could not be prevented by co-incubation w ith 
NAC at any concentration investigated.
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Figure 2.9 Mitochondrial dehydrogenase activity in Hep3B cells exposed to 3-AAP with results 
expressed as mean absorbance at 570 nm as percentage control where control is either no 
treatment or exposure to NAC (10 mM) alone. 3-AAP is toxic to Hep3B cells in a time and 
concentration dependent manner. A 5 hr exposure to 10, 20 or 40 mM 3-AAP led to a 
significant (p <0.05) reduction in cell viability that was prevented by co-incubation with NAC. 
Exposures for 24 hours also resulted in loss in cell viability but this loss could not be 
prevented by co-incubation with NAC. DATA are mean ± SD (n=4). * Signifies statistically 
significant difference (p <0.05) compared to no treatment cells. * Signifies statistically 
significant difference (p <0.05) compared to cells exposed to NAC alone.
2.4.2.4 Phage modulation of in-vitro hepatotoxicity
The functionality of the 4-AAP peptide-phage binding clone PARA-061 was 
assessed by examining its in-vitro effectiveness in preventing hepatocyte 
toxicity following exposure of Hep3B to toxic concentrations of 4-AAP. The 
MTT study results detailed above indicated exposure to 40 mM 4-AAP for 5 
hours was optimal to test the effectiveness of the PARA-061 clone in
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minimising loss o f hepatocyte viability. Co-incubation of phage clone PARA- 
061 w ith 4-AAP, in a 1:100 ratio (that is potentially 1 displayed peptide to 
20 4-AAP molecules), prevented loss in hepatocyte viability to the same 
extent as cells treated w ith the sulphydryl group donor NAC and 4AAP 
(Figure 2.10A). The non-binding phage clone NB-062 when co-incubated 
w ith 4-AAP (40 mM) for 5 hrs did not prevent loss in cell viability (Figure 
2.10A).
In Hep3B cells exposed to 3-AAP (40mM for 5 hours), NAC abrogated 
toxicity but PARA-061 did not indicating PARA-061 to be selective for 4- 
AAP (Figure 2.10B). Control studies showed that exposure of hepatocytes 
to lx lO 11 phages did not result in toxicity (Figure 2.10C).
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Figure 2.10 Mitochondrial dehydrogenase activity of Hep3B cells exposed to 4-AAP or 3-AAP 
with results expressed as mean absorbance at 570nm as percentage control where control is 
either no treatment or exposure to N-acetylcysteine (NAC) alone. (A) In Hep3B cells exposed 
to 4-AAP (40 mM for 5 h) and co-incubated with peptide-phage PARA-061, 4-AAP induced 
hepatotoxicity was prevented. In contrast, co-incubation with phage clone NB-062 did not 
prevent 4-AAP induced hepatotoxicity. Data are mean ± SEM for three separate experiments 
where n = 6-8 for each experiment * Signifies statistically significant difference (p < 0.05) 
compared to no treatment control cells and binding phage clone PARA-061. (B) In Hep3B 
cells exposed to 3-AAP (40 mM for 5 h) and co-incubated with peptide-phage PARA-061, 
hepatotoxicity could not be prevented in contrast to cells co-incubated with NAC. Data are 
mean ± SD (n=4). * Signifies statistically significant difference (p <0.05) compared to no 
treatment control cells. (C) Exposure ofHep3B cells to phage clones PARA-061 or NB-062 did 
not result in any loss in cell viability. Results are presented as mean ± SD (n = 4).
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2.5 Discussion
Successfully identifying peptide motifs that bind to a target o f interest using 
phage display requires careful study design to select appropriate 
conditions that ultim ately w ill discriminate high affin ity binding peptides 
from the rest o f the phage pool. It is clear that a 'one-size fits a ir 
experimental procedure does not exist and factors such as target 
presentation, washing protocols, elution stringency must be diligently 
considered. In many ways streptavidin is an exception to this rule since it 
appears to be amenable to a range o f panning methodologies that w ill yield 
peptides containing the HPQ m otif w idely reported in the lite rature [28,31] 
to bind w ith high affin ity w ith in the biotin binding pocket It is interesting 
that cyclic peptides have been shown to bind streptavidin w ith significantly 
greater affin ity than the ir linear counterpart For example at pH 7.3 cyclic 
CAECHPQFCIEGRKN' (Kd = 0.023 pM) binds streptavidin w ith -  7000 fold 
greater affin ity than linear CAEFSHPQNTCIEGRKN' (Kd = 160 pM)[30]. This 
is not as a consequence o f interaction o f the cysteine residues w ith 
streptavidin, although they are surface exposed, rather it  reflects a decrease 
in entropy o f unbound cyclic versus unbound linear peptide.
The ready success in identifying peptides that bind to macromolecules such 
as streptavidin is in sharp contrast to the difficulties in selecting against 
low molecular weight species. It is clear that peptides and proteins can 
form strong interactions w ith small molecules such as those formed during 
the in-vivo generation of antibodies against haptens - low molecular weight
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molecules conjugated to carrier proteins such as albumin. W hilst antibody 
phage display has been used to identify antibodies to haptens [32, 34, 38- 
41], to date no peptide isolation has been reported. The prim ary obstacle in 
these selections is presenting the target to the peptide phage particles 
w ithout occupying one of the lim ited functional groups w ith in the molecule 
through immobilisation strategies or introducing a significant chemical 
functionality such as linker groups or affin ity tags that peptide phage may 
bind to preferentially. Insoluble complexes of low molecular weight 
molecules w hilst having a heterogeneous and indeed non-defined surface 
should nevertheless display the various functional groups o f the parent 
molecule and therefore represent a target against which phage display 
selection can be undertaken. The studies have shown that our in-laboratory 
phage display protocols can effectively identify peptides that bind large 
complex biomacromolecules and small molecules w ith lim ited functional 
groups.
Whilst the primary aim o f these studies was validation, there were some 
interesting consequences of note particularly w ith respect to 4-AAP. 
Specifically, the peptide identified against 4-AAP may find use in the 
diagnosis or treatment o f 4-AAP induced hepatotoxicity. 4-AAP is 
metabolised by the hepatic cytochrome P450 system and specifically 
isoenzyme CYP2E1(10). In therapeutic doses o f 4-AAP — 4% is converted 
through CYP2E1 to a toxic intermediary W-acetyl-p-benzoquinone imine 
(NAPQI) which is sequestered through the oxidation o f reduced
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glutathione. In overdose, stores of reduced glutathione are quickly depleted 
and NAPQI accumulates forming adducts to cellular macromolecules by 
covalent binding through cysteine groups which disrupts protein 
conformation and function. The clinical antidote o f choice is the sulfydryl 
group donor N-acetylcysteine (NAC). The administration of NAC is often 
reserved until laboratory based diagnostic tests confirm overdose, 
prim arily because some 3-6% o f patients suffer severe anaphylactic 
reactions on intravenous administration. Standard laboratoiy based 
determinations of 4-AAP concentration in patient blood samples can take 
many hours and w ith the window o f opportunity for successful treatment 
w ith NAC a maximum of 24 hours after ingestion, delays in sample 
processing or in patients presenting many hours after overdose may result 
in an ineffective reversal o f poisoning. Point o f care tests[42] would have 
significant advantage in the rapid diagnosis o f 4-AAP overdose using pin 
prick volumes o f blood on a sensing platform, in much the same way as 
glucose levels are monitored in diabetes. Very early stage development o f a
4-AAP biosensor based on the peptide identified in these studies are 
underway using molecularly imprinted polymers (MIPs)[43]. A peptide- 
MIP sensing platform  is not w ithout precedent, Itoda and co-workers[44] 
identified a peptide against glucose oxidase using phage display and 
produced a simple polymeric system w ith the peptide conjugated to the 
polymer; an increase in the binding affin ity o f the peptide in the conjugate 
for glucose oxidase was observed compared to peptide alone[44].
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It is interesting to hypothesise the use of a phage based medicine for the 
treatment o f 4-AAP overdose. As w ill be shown in Chapter 5, following 
intravenous administration M13 phage prim arily accumulate in the 
liver[45, 46], the site o f 4-AAP toxicity, and would therefore act as a 
rudimentary delivery vector for a therapeutic moiety which in this case 
could be a peptide that binds 4-AAP. The modest amelioration of cell 
toxicity demonstrated by the peptide sequence identified in the studies in 
section 2.4.2.4 may be improved by re-engineering the phage to display the 
peptide on the pVIII phage protein thus exposing ~  200 -  300 copies on the 
phage surface compared to 5 in the lib rary used. W hilst the intravenous 
administration of phages in man may not receive approval until sometime 
in the future, phage based medicines delivered orally are tacitly accepted as 
safe by the FDA[47] w ith few apparent adverse reactions and this should go 
some way to accelerating studies in man.
The studies in this chapter have demonstrated that w ith the correct 
strategy phage display technologies can be utilized to identify peptides that 
bind large complex biomacromolecules and small, simple molecules w ith 
lim ited functional groups. W hilst the strategy o f using insoluble complexes 
as die panning target may or may not prove appropriate for a wide range of 
similar molecules, peptides that are functional w ith respect to such 
molecules and that can be identified by display approaches is an original 
finding [14]. Peptides generated in this way w ill serve as recognition motifs
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within the next generation of hybrid polymeric molecular sensors or as 
therapeutics in their own rig h t
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Chapter 3 Establishment of an in-vitro primary porcine 
blood-brain model for the phage display identification 
of peptides that bind brain microvasculature
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3.1 Introduction
3.1.1 The Blood-Brain Barrier
The delivery o f therapeutic macromolecules into the central nervous 
system and particularly into the brain remains a significant challenge for 
the Pharmaceutical Sciences. This is as a consequence of the cellular 
interplay between capillary endothelial cells, astrocytes, pericytes and 
neurones in the cerebral microvasculature that results in a complex and 
restrictive three-dimensional architecture termed the blood-brain barrier 
(BBB)[l-3]. The BBB essentially serves to isolate the brain in a discrete and 
highly-regulated compartment that is protected both physically and 
biochemically from the fluctuating milieu o f the systemic circulation. Non­
fenestrated endothelial cells continuously lining the brain microvasculature 
coupled w ith the expression of intercellular tight junctions (zonulae 
occludentes) and a relative paucity of endothelial vesicles prevents 
significant solute entry into the brain w ith even small lipophilic molecules 
that readily partition across lip id  membranes often excluded by active 
efflux transport mechanisms or by metabolic enzymes.
3.1.2 Brain microenvironment
The role o f the brain microenvironment in the development o f a fully 
differentiated BBB cannot be overstated. Elegant transplantation studies in 
the early 1980s[4] revealed that implants o f avascular tissue fragments 
from 3-day-old quail brain into the coelomic cavity o f chick embryos were 
infiltrated by vasculature arising from the gut and yet developed a
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functional BBB phenotype. Conversely, blood vessels infiltrating avascular 
embryonic quail somites implanted into brain ventricles of the chick lost 
their barrier properties despite the brain origin of the endothelial cells 
invading. In another series of transplantation studies [5, 6], mouse brain 
tissue transplanted onto the embryonic chorioallantoic membrane of the 
chick egg becomes vascularised by chick blood vessels that, although 
normally leaky, begin to express BBB markers. Together these studies 
imply that properties of the brain tissue itself must direct the development 
and maintenance of brain microvasculature. Histological studies[7] have 
revealed close association of brain capillary endothelia with a number of 
cell types and cell processes that include perivascular endfeet of astrocytic 
glia, pericytes, microglia and neuronal projections that in combination 
induce the fully differentiated BBB phenotype (Figure 3.1).
Basal Lamina
Pericyte
Junction
Capillary
Astrocyte Foot Process
Tight
Capillary Endothelial Cell
Lumen
Figure 3.1 Schematic representation of the cellular architecture at the blood-brain barrier. 
Although the primary anatomical barrier is the continuous lining of brain microvasculature 
with non-fenestrated endothelial cells, it is the complex and dynamic interaction of 
endothelial cells with astrocytes, pericytes and neurons that provide the fully differentiated 
and competent BBB neurovascular unit (adapted from [8]).
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3.13 Astrocytes
Astrocytes, the foot processes o f which form a network o f fine lamellae that 
envelop more than 99% o f the abluminal surface o f brain microvascular 
endothelia[9], have long been recognised to play a key role in the 
differentiation of the BBB. W hilst astrocytes do not in themselves 
constitute a cellular barrier as evidenced by the passage o f horseradish 
peroxidase between astrocytic cell junctions[10], they significantly enhance 
the restrictive paracellular barrier o f BBB endothelium. In studies that 
complement those o f Stewart and Wiley, Janzer and R^ff [11] demonstrated 
primary rat astrocytic tissue when implanted in thp^fnterior chamber of the
eye in adult syngeneic rats becomes.'Vascularised by leaky vessels
/
originating from the iris that ^develop a restrictive phenotype upon 
in filtra tion o f the astrocyte»4&ore recently in-vitro studies have shown that 
culturing prim aiy brain microvascular endothelial cells in apposition to 
primary astrocytes or astroglioma cell lines results in restoration of an 
endothelial phenotype that more closely resembles the in-vivo BBB. This is 
evidenced by increases in transendothelial electrical resistance (TEER) and 
decreases in permeability to classical paracellular probes such as sucrose 
and mannitol [12-15]. It is interesting to note that in the developing 
embryo CNS capillaries only begin to display barrier properties after 
astrocyte differentiation[16]. Clear lines of evidence now exist that 
astrocytes regulate many BBB features including the regulation o f tight 
junctions[17-20], the up-regulation and polarized localization of 
transporters that include the m ulti-drug resistance transporter P-
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glycoprotein (P-gp)[21], the principal brain glucose transporter GLUT-1 
and the system-L and system-A amino acid transporters as well as a 
number o f key metabolic enzyme systems[22, 23]. Such effects are partially 
explained by the release o f soluble astrocytic paracrine factors, the precise 
identity o f which remains elusive but is thought to include transforming 
growth factor-0 (TGF0)[24], glial derived neurotrophic factor (GDNF)[25, 
26], basic fibroblast growth factor (bFGF)[20], IL-6 and hydrocortisone[27]. 
Further efforts to understand the effects o f astrocytes on the development 
of a fully differentiated BBB phenotype are ongoing w ith particular 
emphasis on co-culture models o f prim ary brain endothelia w ith astrocytes 
and brain endothelia cultured in astrocyte conditioned media (ACM). It is 
dear however that BBB induction by glial cells is both complex and highly 
regulated and significant communication between endothelium and glial 
cells is essential.
3.1.4 Pericytes
The pericyte is a specialized smooth muscle cell at the BBB located on the 
abluminal microvascular surface and separated from the endothelia and 
astrocytic foot processes by a basal lamina readily penetrated by pericytic 
projections. W hilst the prim ary role o f pericytes appears to be provision of 
vasodynamic capacity and structural integrity they play a key role in new 
vessel formation during brain development and also appear to contribute 
towards auto-regulation of blood flow  distribution[28, 29]. Pericytes, like 
astrocytes, do not constitute an intrinsic permeability barrier but express a
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significant range o f metabolizing enzymes that include gamma glutamyl 
transpeptidases[30], glutamylaminopeptidases[31], aminopeptidases A and 
N[32] and glutamic acid decarboxylase[33] which indicates a role as an 
enzymatic barrier particularly w ith respect to peptides. In addition, 
pericytes may also be the most potent in itia to r o f CNS immunity via 
antibody dependant phagocytosis[34]. Evidence is beginning to emerge 
that pericytes play a lim ited role in influencing BBB paracellular 
permeability w ith in-vitro models o f brain endothelial cells cultured w ith 
pericytes demonstrating an up-regulation o f the tight junctional protein 
occludin[35] and a decrease in permeability to the paracellular marker 
sodium fluorescein[36].
3.1.5 BBB Models
One of the aims o f this thesis is the phage display identification o f peptides 
that increase brain uptake o f a therapeutic cargo. There are two ways in 
which this may be accomplished: (i) identification of peptides that 
essentially adhere to brain microvasculature to increase the residency time 
of a therapeutic cargo at the BBB, or (ii) identification o f peptides that 
stimulate an endocytotic or transcytotic event to carry the cargo across the 
BBB. This chapter is concerned w ith the identification o f peptides that 
adhere to vasculature as in (i) and a phenotypically representative in-vitro 
model o f the BBB would afford selection of such peptides. This model needs 
to accurately represent polarized transport systems and metabolic and 
signaling pathways that are evident in-vivo. It is also important for the
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phage display studies that the model accurately reflects the significant 
paracellular restrictiveness at the BBB, not because of an interest in 
transendothelial solute screening, but because the studies in this chapter 
w ill seek to identify phages that bind surface element(s) on the luminal 
membrane and not the basal membrane; the latter would be inaccessible in- 
vivo due to the presence of highly-restrictive tight junctions.
Whilst a range of immortalized BBB cells lines are available both 
commercially and from academia (Table 3.1), in general their value would 
be limited in phage studies by intercellular junctions that are leaky and a 
poorly differentiated phenotype compared to their in-vivo counterpart 
particularly w ith respect to their receptor and transporter profile.
Table 3.1 Immortalized brain capillary endothelial cell lines reported in the literature from 
academic and commercial laboratories (updated and adapted from [37]).
Spades Cell line Nature of transformation Ref
Human SV-HCEC SV40 T antigen [38]
HBEC-51 SV40 T antigen [39]
BB19 SV40 T antigen [40]
NKIM-6 pLXSN16E6E7 [41]
HCMEC/D3 SV40 T antigen [42]
Mouse MBEC SV40 T antigen [43]
S5C Adenovirus El A gene [44]
TM-BBB4 SV40 T antigen [45]
b.End3 Polyoma virus middle T-antigen [46]
b.End5 Polyoma virus middle T-antigen [46]
Rat RBE4 Adenovirus El A gene [47]
GPNT SV40 T antigen [48]
CR3 SV40 T antigen [49]
GP8.3 SV40 T antigen [50]
RBEC1 SV40 T antigen [51]
RCE-T1 Rous sarcoma virus [52]
Bovine t-BBEC-117 SV40 T antigen [20]
SV-BEC SV40 T antigen [53]
BBEC-SV SV40 T antigen [54]
Porcine PBMEC/C1-2 SV40 T antigen [55]
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Primary BBB models, which are more challenging to isolate and maintain, 
are more closely related to the in-vivo phenotype. Whilst brain 
microvascular endothelial models isolated from bovine brains are the most 
fully characterised[56, 57], apprehension over bovine spongiform 
encephalopathy (BSE) has resulted in changes to the law regarding 
handling of neural tissue from bovine sources that has dissuaded many 
researchers from its use. Efforts have been underway to isolate primary 
brain endothelia from other animal species including rat[58] and guinea 
pigs[59] with some success but generally the yield of cells (~ l-2  million per 
brain) is insufficient to allow for large scale, high throughput permeability 
experiments. More recently primary human BBB models have been 
investigated but have so far proven leaky in comparison to other primary 
systems[60,61]. Further, primary human cell models w ill face difficulties in 
obtaining a reliable and ethical supply of fresh human brain tissue.
3.1.6 Requirements of an in-vitro cell model of the BBB
Whilst in-silico and experimentally determined drug physicochemical 
properties have been used to give a gross indication of the interaction of 
vectors and therapeutics w ith the BBB [62-73], they frequently do not 
correlate with in-vivo therapeutic effects. Essentially this is because such 
predictors are based exclusively on the potential of the candidate molecule 
to undergo passive diffusion processes which, in its simplest form, is 
related to molecular size and lipophilicity and does not account for 
metabolic systems or transporters (both influx and efflux) present within
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the microvasculature. Whilst in-vitro BBB models may not fully represent 
the in-vivo phenotype they provide a system to mechanistically explore 
various aspects of BBB drug transport, fundamental biological and 
pathological processes and metabolic systems in addition to screening for 
transendothelial solute diffusion. As first described by Gumbleton and 
Audus[37], in-vitro BBB models should meet a number of criteria:
I. The model should display a restrictive paracellular pathway. The in- 
vivo blood-brain barrier is highly effective in lim iting transendothelial 
transport of solutes and any in-vitro model must have a restrictive 
paracellular pathway if  it is to discriminate between candidate molecules 
displaying low, moderate or high BBB permeability with sufficient 
sensitivity. Moreover the relative permeability of high brain extraction 
molecules, such as the benzodiazepines, compared to low brain extraction 
molecules, such as sucrose and mannitol, indicates the discriminative 
power of the model in terms of paracellular and transcellular diffusion 
routes. BBB models that do not display suitable paracellular restrictiveness 
for transendothelial solute screening, for example immortalized BBB cell 
lines, may still provide useful data on kinetic uptake of molecules into brain 
endothelial cells and may afford dissection of endocytic pathways within 
them.
II. The model should have a cellular architecture that is comparable with 
the in-vivo BBB. Gross morphology including cell dimensions, volume and 
surface area of cell-cell interaction must retain parity with in-vivo
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architecture. Further, expression and activity of metabolic enzymes and 
complexity of tight junctional elements must also be maintained.
HI. The model should retain Junctional expression o f key BBB 
transporters. The emerging role of efflux transporters in the expulsion of a 
diverse range of xenobiotics from brain endothelia as well as the 
importance of nutrient transporters that maintain brain homeostasis 
predicate a representative expression and distribution of such transporters 
in any in-vitro BBB model. Whilst the specificity of a molecule for a given 
transporter can be determined in cell models distinct from BBB endothelia, 
for example polarized transfer across the MDR1 transfected MDCK 
cells[74], it is critical to establish the quantitative relationship between in- 
vitro and in-vivo transporter function and this is more closely served by a 
representative in-vitro BBB phenotype.
IV. The model should be easy to isolate and maintain in culture To 
facilitate high-throughput studies the model should ideally be isolated in 
large unit volume and retain phenotypic stability with a high number of 
population doublings. The failure of continuous cell lines to demonstrate a 
representative BBB phenotype necessitates a strategy to preserve the 
isolated primary cell line for long periods of time without loss in function to 
facilitate investigations over extended periods of time.
3.1.7 Objectives
This current work was focused on developing a consistent and effective 
isolation protocol for the culture of primaiy porcine brain microvascular
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capillary endothelial cells (PBMVECs) to afford the phage display selection 
of peptides that bind the luminal membrane of brain microvasculature. 
PBMVECs were isolated from the whole brain of pigs by a procedure that 
essentially involved enzymatic digestions to produce a crude suspension of 
grey matter and microvessels. The microvessels were then separated by 
density centrifugation and subsequently enzymatically digested to yield 
capillary endothelial cells. Assessment of restrictive barrier properties 
including permeability to paracellular and transcellular probes validated 
the model; the inductive influence of astrocytes and astrocytic co-factors 
was also explored. Whilst the isolation protocol was loosely based on the 
methods described by Frank et al[75], significant modifications to the 
isolation and culture procedures were undertaken in these studies. Finally, 
a series of panning experiments against PBMVECs and the immortalised 
BBB cells lines b.End3 and RBE4 were conducted in an effort to identify 
peptides that bind brain microvascular endothelia.
3.2 Materials
3.2.1 Cell culture
Dulbecco's modified Eagle's medium (DMEM) containing 25 mM HEPES; 
DMEM-.F12; M199; Trypsin-EDTA; sodium pyruvate; heat inactivated fetal 
bovine serum (FBS); heat inactivated fetal horse serum (FHS); Penicillin G 
(100 unit per ml); Streptomycin (lOOpg per ml) and L-glutamine 200mM 
(xlOO) were obtained from Invitrogen, (Paisley, UK). Non-essential amino 
acids; hydrocortisone and 2-mercaptoethanol were obtained from Sigma-
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Aldrich Chemical Co., (Foole, UK). All cell culture plastics and Transwell™ 
inserts were obtained from Coming Costar, (High Wycombe, UK).
3^2 Isolation materials
Dispase Type II; collagenase-dispase (Vibrio alginolyticus/Bacillus 
pofymyxa) and rat tail collagen type 1 were obtained from Roche, (East 
Sussex, UK). Percoll (1.219 g/m l density) was obtained from Pharmacia, 
(Buckinghamshire, UK).
3^3 cAMP Modulators
CPT-cAMP (8-(4-chlorophenylthio)-adenosine 3', 5'-cyclic monophosphate) 
was obtained from Sigma-Aldrich Chemical Co., (Poole, UK). Ro20-1724, a 
phosphodiesterase inhibitor, was obtained from Calbiochem, (Nottingham, 
UK).
3.2.4 Uptake and transport studies
[6,6(n)-3H]sucrose and [2-14C]diazepam were obtained from Amersham 
Life Science, (Little Chalfont, UK). OptiPhase HiSafe3™ liquid scintillation 
fluid was obtained from Fisher Scientific Chemicals, (Loughborough, UK). 
Rhodamine-123 (2-[6-Amino-3-imino-3H-xanthen-9-yl]-benzoic acid 
methyl ester) and Verapamil hydrochloride were obtained from Sigma- 
Aldrich Chemical Co., (Poole, UK).
32.5 Electron microscopy
Neutrally-buffered 2% osmium tetroxide in veronal acetate buffer and 
Araldite (CY212) resin were obtained from TAAB Laboratories Equipment
113
Chapter 3
Ltd., (Aldermaston, UK).
3^.6 Western analyses
DC protein assay k it was obtained from Bio-Rad, (Hertfordshire, UK). 
Rabbit polyclonal caveolin-1 antibody was obtained from BD Transduction 
Laboratories, (Oxford, UK). Swine anti-rabbit HRP-conjugated IgG reporter 
antibody and rabbit anti-mouse HRP-conjugated IgG reporter antibody 
were obtained from Dako, (Cambridge, UK). Rainbow™ molecular weight 
marker and Hyperfilm ECL™ were obtained from Amersham Life Science 
(Little Chalfont, UK). Super Signal Ultra™ was obtained from Pierce, 
(Chester, UK).
%2J RT-PCR
Ultraspec™ DEPC treated water was obtained from Biogenesis (Poole, UK). 
Random hexamer primers (pdN6) was obtained from Amersham Life 
Science (Little Chalfont, UK). Dithiotheritol (DTT); first strand RT buffer 
(x5); moloney murine leukaemia virus reverse-transcription (MMLV-rt); 
deoxynucleotide triphosphate monomers (dNTPs) and forward and reverse 
primers were obtained from Invitrogen, (Paisley, UK). RNAsin was obtained 
from Promega, (Southampton, UK). PCR reaction buffer (xlO); MgCfr and 
Taq polymerase were obtained from Qiagen Ltd (Crawley, UK). 100 bp DNA 
molecular weight marker ladder was obtained from ABGene, (Surry, UK). 
Ethidium bromide was obtained from Sigma-Aldrich Chemical Co., (Poole, 
UK).
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33 Methods
33.1 Cell lines
The rat C6 glioma cell line (passages 18-23) was seeded at lx lO 4 cells.cnr2 
and maintained in culture medium comprising M199 supplemented with 
10% heat inactivated FBS, and the antibiotics penicillin G (100 units/ml) 
and streptomycin sulfate (100 pg/ml). The mouse brain microvascular cell 
line b.End3 (passages 27-33) was seeded at a density of 0.5 x 104 cells.cnr2 
and maintained in culture medium comprising DM EM supplemented with 
10% heat inactivated FBS, and the antibiotics penicillin G (100 units/ml) 
and streptomycin sulfate (100 pg/ml), 1% w /v non-essential amino acids, 
glutamine (2 mM), 2-mercaptoethanol (5 pM) and sodium pyruvate (1 
mM). The rat brain microvascular cell line RBE4 was seeded at a density of 
lx lO 4 cells.cnr2 and maintained in culture medium comprising Ham's F10 
and aMEM (1:1, v /v) supplemented w ith 10% FBS, 1 ng.ml1 basic 
fibroblast growth factor (bFGF), 300 mg-ml*1 Geneticin and 1 ng-ml1 
glutamine. The human epidermal squamous carcinoma cell line A431 
(passage 27) and the Monkey African Green kidney cell line MA104 
(passages 16-23) were seeded at densities of 4 x 104 cells.cnr2 and 3 x 104 
cells.cm~2 respectively and were maintained in culture medium comprising 
DMEM supplemented w ith 10% heat inactivated FBS, and the antibiotics 
penicillin G (100 units/m l) and streptomycin sulfate (100 pg/ml), 1% w /v 
non-essential amino acids and glutamine (2 mM). All cultures were 
maintained at 37°C in a humidified atmosphere (5% C02/95% air) and 
culture medium replenished eveiy 48 hours.
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53*2 PBMVEC and RBMVEC isolation and culture mediums
• Preparation medium: M199, 100 pg.mH Penicillin, 100 pg.mH 
streptomycin.
• Culture medium: 90% M199, 10% fetal horse serum, 100 pg.mH 
Penicillin, 100 pg.ml*1 streptomycin.
• Freezing medium: 70% M199,20% horse serum, 10% DMSO.
• Switch medium: DMEM:Hams-F12 (1:1 v/v), 100 pg.mH Penicillin, 
100 pg.ml-1 streptomycin, 550 nM hydrocortisone.
• *BBB isolation buffer': 1.3 M NaCl; 50 mM KC1; 16 mM 
Na2HP0 4 .2 H20 ; 10 mM NaH2P04.2H20; 130 mM HEPES; 55mM 
Glucose.
• Continuous percoll gradient (p = 1.032g/m l): 30% percoll (p = 
1.129g/ml), 10% M199,10% *BBB isolation buffer', 50% PBS.
• Discontinuous percoll gradient: see Table 3.2.
Table 32 Recipe for light and heavy' components of discontinuous percoll gradient The 
light component is gently layered onto the heavy* component to give a sharp interface 
between the two components.
lig h t Percoll* 'Heavy Percoll*
Percoll 2.72 ml 6.49 ml
Horse serum 50 pi 50 til
ddHK) 6.28 ml (with phenol red) 2.51 ml
'BBB isolation buffer* 1 ml 1 ml
Final Volume 10 ml 10 ml
333 Porcine brain capillary endothelial cell isolation procedure
The isolation protocol developed in Cardiff is largely based upon the 
methods described in the pioneering work of Franke[75] but with 
significant modifications:
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1. The intact heads from pigs aged less than 5 months old were 
obtained from an abattoir immediately following termination (< 10 
mins after death) and transported to the laboratory within 30 mins.
2. The brains from four heads were surgically removed by making a 
vertical incision in the skin from the forehead to the nose to expose 
the skull, which was subsequendy opened with a surgical cutter 
(MSxe 636II, C&E Fein Gmbh & Co. KG, Stuttgart, Germany) to reveal 
the brain. The brains were carefully removed by hand, whilst 
wearing sterile gloves, and submerged in sterile ice cold (4-8°C) FBS 
for 5 mins.
3. The meninges and large surface vessels were carefully removed 
from the brain using a sterile scalpel and forceps and were 
discarded.
4. The accessory organs (cerebellum, brain stem, hypothalamus etc) 
and white matter i.e. leaky tissue were carefully dissected away 
from the cortical grey matter and discarded.
5. The grey matter was then minced to a fine paste (~ 1 mm3 pieces) 
using a stainless steel rolling multi-blade cutter.
6. The paste was transferred to a sterile container and suspended to 
200 ml in preparation medium containing dispase type II at a final 
concentration of 0.5% w/v.
7. The resultant suspension was incubated for 2 hours at 37°C with 
gentle shaking (125 rpm) on a Mini Orbital Shaker S05 (Bibby 
Sterilin Ltd., Staffordshire, UK). The end point of the enzymatic
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digestion was visually identified by dipping a sterile glass rod into 
the suspension withdrawing the rod and identifying red 
microvessels attached to the glass. The digestion was terminated by 
putting the suspension on ice for 5 mins.
8. The suspension was divided equally between two centrifuge bottles 
each containing 150 ml 30% percoll stock solution (p = 1.032g.ml1) 
and centrifuged for 10 mins (6000g, 4°C) using a swing-out Avanti J- 
25 centrifuge (Beckman Coulter Inc., California, USA).
9. The floating layer containing cell debris, fats, myelin etc, was 
carefully aspirated and discarded and the remaining suspension was 
centrifuged at 1700g for 10 min at 4°C. At this stage observation of 
the bottom of the flask revealed vibrant red streaks of microvessels.
10. The supernatant was carefully aspirated and the microvessel pellet 
suspended to a final volume of 20 ml w ith pre-warmed (37°C) 
culture medium containing lm g-m l1 (0.1% w /v) collagenase- 
dispase II from Vibrio alginolyticus/Bacillus polymyxa. The 
suspension was incubated for 45 -  75 mins at 37°C with gentle 
orbital shaking (125 rpm). After 45 mins, the suspension was 
observed microscopically every 10 minutes until clusters of 
microvascular cells were observed. Over-digestion occurs when the 
clusters break up and result in a population of single cells that when 
cultured do not form monolayers.
11. To remove any remaining undigested vessels, the digestion was 
filtered through 180 pm nylon mesh.
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12. The cell clusters were pelleted by centrifugation (185g, 4°C) for 10 
mins and the supernatant discarded.
13. The pellet was suspended in 20 ml of culture medium and a final 
purification was completed by carefully layering the suspension on a 
discontinuous percoll gradient, prepared from 10 ml of a light 
percoll suspension (p = 1.03 g-m l1) layered on 10 ml of a heavy 
percoll suspension (p = 1.07 g.mb1), and centrifuging for 10 mins 
(1300& 4°q.
14. The capillary endothelia fraction, appearing as a band at the sharp 
interface of the percoll gradients (p ~ 1.05 g/m l), was carefully 
needle aspirated in a volume of approximately 2ml taking care to 
avoid shear stresses. A pellet at the bottom of the heavy percoll was 
observed to contain erythrocytes and a ‘floating* layer contained 
other debris.
15. The aspirated fraction was washed in 20ml of culture medium and 
after removing a small aliquot for cell counting (~ 100 pi) was 
centrifuged for 10 minutes (1300g, room temperature).
16. A typical isolation from four brains yielded ~ 100 million 
endothelia] cells. The cells were either used immediately after 
isolation or were frozen. Frozen vials of cells, containing 5-6 million 
cells, were prepared by suspending the cells in freezing medium and 
cooled to -80°C over 2 hours and then transferred to a ciyofreezer (- 
130°C).
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3.3.4 RBMVEC isolation
The isolation of primary rat brain microvascular endotheilal cells 
(RBMVECs) largely paralleled the isolation of PBMVECs but with 
modifications:
1. Terminally anaesthetised rats (male SD; 350 -  450 g) were 
decapitated and the brains carefully removed by making a vertical 
incision in the skin from the forehead to the nose to expose the skull. 
A scissors was then used to crack open the skull before blunt forceps 
were used to carefully remove the brain.
2. The meninges and large surface vessels were carefully removed 
from the brain using a sterile scalpel and forceps and were 
discarded.
3. The accessory organs (cerebellum, brain stem, hypothalamus etc) 
and white matter i.e. leaky tissue were carefully dissected away 
from the cortical grey matter and discarded.
4. The grey matter was then cut to a fine paste (~ 1 mm3 pieces) using 
a scalpel.
5. The paste was transferred to a sterile 50 ml centrifuge tube and 
suspended to 8 ml in preparation medium containing dispase type II 
at a final concentration of 2.5% w/v.
6. The resultant suspension was incubated for 2 hours at 37°C with 
gentle shaking (125 rpm) on a Mini Orbital Shaker S05 (Bibby 
Sterilin Ltd., Staffordshire, UK). In common with the PBMVEC
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isolation, the end point of the enzymatic digestion was visually 
identified by dipping a sterile glass rod into the suspension to 
observe microvessels.
7. The suspension was layered on top of a 30% percoll stock solution 
(20ml; p = 1.032g.mH) and centrifuged for 10 mins (6000g, 4°C) 
using a swing-out Avanti J-25 centrifuge (Beckman Coulter Inc., 
California, USA).
8. The floating layer containing cell debris, fats, myelin etc, was 
carefully aspirated and discarded and the remaining suspension was 
centrifuged at 1700g for 10 min at 4°C. At this stage observation of 
the bottom of the centrifuge tube revealed vibrant red streaks of 
microvessels.
9. The supernatant was carefully aspirated and the microvessel pellet 
suspended to a final volume of 5 ml w ith pre-warmed (37°C) culture 
medium containing lmg-ml*1 (0.1% w /v) collagenase-dispase II 
from Vibrio alginolyticus/Bacillus polymyxa. The suspension was 
incubated for 45 -  60 mins at 37°C w ith gentle orbital shaking (125 
rpm). The suspension was observed microscopically every 10 mins 
from 45 mins onward until clusters of microvascular cells were 
observed.
10. The cell clusters were pelleted by centrifugation for 10 mins (185g, 
4°C) and the supernatant discarded.
11. The pellet was suspended in 10 ml of culture medium and a final 
purification was completed by carefully layering the suspension on
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top of a 30% percoll stock solution (20ml; p = 1.032g.ml1) and 
centrifuging for 10 minutes (700g, 4°C).
12. The supernatant was aspirated and discarded and the capillary 
endothelia fraction, appearing as a pellet at the bottom of the tube, 
was suspended in PBMVEC growth medium and centrifuged 185g 
for 10 mins.
13. The supernatant was once again aspirated and discarded and the 
endothelial cells suspended in PBMVEC growth medium 
supplemented w ith puromycin (4 pg.ml*1) before seeding onto 
culture plastics.
14. A typical isolation from two brains yielded ~ 1 million endothelial 
cells. Isolated cells were cultured immediately after isolation.
3.3.5 Preparation of culture surfaces
Pilot studies showed that an extracellular matrix of rat tail collagen type I 
(RTCI) was essential for the growth of PBMVECs and RBMVECs; without 
this basal lamina, cell attachment was very poor and cells never reached 
confluency. A 1 mg-ml1 stock solution of RTCI was prepared by dissolving 
lyophilised collagen in 0.2% v /v  sterile acetic acid. This stock was stored at 
4°C for up to 6 months. All culture surfaces were coated to a final 
concentration of 3 pg.cnr2 by diluting the RTCI stock solution with sterile 
water to volumes indicated in Table 3.3.
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Table 33  Collagen coating of cell culture surfaces for PBMVEC attachment
Culture surface Surface area 
(per unit)
Volume RTCI stock Volume of dilute RTCI 
solution added to surface
T75 flask 75 cm^ 225 pi 1000 pi
T25 flask 25 cm2 75 pi 500 pi
6 well plate 10 cm2 30 pi 500 pi
24 well plate 1.8 cm2 5.4 pi 200 pi per well
Large inserts 4.7 cm2 14 pi 600 pi per insert
Small inserts 033 cm2 lp l 60 pi per insert
The RTCI solution was applied to the surface and incubated at 37°C for 3 
hours before being dried under laminar flow at room temperature for 18 
hours. Surfaces were washed 3x w ith PBS to remove any residues of acetic 
acid and stored at 2 -  8°C for up to 4 weeks.
3.3.6 Astrocyte co-culture and production of astrocyte conditioned medium
Astrocyte co-culture system comprised growth of the astroglioma cell line 
C6 on a 24 or 6 well plate (basal chamber) until confluent (2-3 days) after 
which PBMVECs or RBMVECs were grown on Trans well™ inserts 
suspended above the C6 culture (apical chamber).
Astrocyte conditioned medium comprised 50% C6 medium (C6 cells grown 
to confluence, medium replaced w ith M199 and collected after 24 hours), 
50% 'double strength' culture medium - M199 supplemented with the 
antibiotics penicillin G (200 units/m l) and streptomycin sulfate (200 
Mg/ml) and 20% heat inactivated fetal horse serum.
Astrocyte conditioned switch medium comprised 50% C6 medium (C6 cells 
grown to confluence, media replenished with DM EM:FI2 and collected
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after 24 hours), 50% DMEM.F12; final medium supplemented with 550 nM 
hydrocortisone.
Any other additions to these specialist media are explicitly stated where 
appropriate in the text
33.7 Culture and sub-cultivation of porcine brain microvascular capillary 
endothelial cells
A frozen vial of PBMVECs was removed from the cryofreezer and rapidly 
thawed (< 5 mins) in a water bath (37°C). The cells were suspended to 10 
ml in culture medium and centrifuged at 185g for 5 min. The PBMVEC 
pellet was suspended in culture medium and deposited onto RTCI coated 
T25-flask, multiwell plates or Transwell™ inserts. After 48 hours, the cells 
were washed vigorously 3x with PBS to remove cell detritus and the 
medium was replaced; microscopic examination at this early stage of 
growth showed islands of endothelial cells. In certain studies indicated in 
the text 1st passage cultures were used. For these studies, after 6 days in- 
vitro (80-90% confluency) PBMVECs were sub-cultivated. Briefly, the cells 
were washed 3x w ith PBS (37°C) and then exposed to Trypsin/EDTA for 30 
seconds. Since endothelial cells are easily damaged during excessive 
exposure to trpysin, the cells were constantly visualized with a reverse 
phase-contract microscope until they began to detach from the culture 
surface, normally w ithin 3 minutes. The detaching cells were collected in 
10ml of culture medium and centrifuged for 5 mins (185g). The pellet was 
resuspended in culture medium and seeded at a density of 5 x 104 cells.cnr2
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on RTCI coated Transwell1** inserts. Primary cultures of brain microvascular 
endothelial cells are recognised to undergo phenotypic d rift upon sub­
cultivation and therefore 1st passage cells were not further sub-cultured.
33.8 Effects of astrocyte co-culture and astrocyte conditioned medium on 
alkaline phosphatase activity in PBMVECs
The responsiveness of PBMVECs to astrocytic induction was determined by 
measuring alkaline phosphatase activity in the presence and absence of 
astrocyte co-culture and astrocyte conditioned medium. Assessment of ALP 
activity on the apical (luminal) membrane of PBMVECs was undertaken 
using protocols previously described[20] but w ith modifications. 
Specifically, frozen PBMVECs were grown to confluence ± C6 co-culture in 
PBMVEC growth medium (7 days) followed by switch medium (24 hours) 
or in astrocyte conditioned medium (7 days) followed by astrocyte 
conditioned switch medium (24 hours). Confluent monolayers were 
washed 3x w ith PBS then incubated (up to 40 min, 37°C) w ith 1 ml of 10 
mM p-nitrophenyl phosphate in 0.7 M 2-amino-2-methyl-1-propanol and 1 
mM MgCh (pH 10.2). Termination of reaction was achieved through 
addition of 200 pi of 1 N NaOH. After transferring 200 pi of supernatant to a 
96 well plate, p-nitrophenol levels were determined by UV/VIS 
spectrometry (405 nm) to afford determination of alkaline phosphatase 
activity.
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33.9 Permeability of PBMVECs and RBMVECs to paracellular and 
transceHular probes
Assessment of the permeability of PBMVECs and RBMVECs to the 
hydrophilic paracellular probe PH]sucrose and to the lipophillic 
trancellular probe [14C]diazepam was carried out day 7 post seeding on 6.5 
mm Transwell™ Clear inserts and 24 hours post media switch to fully 
express BBB properties (8 days total growth in-vitro). Thirty minutes 
before commencing the study, medium in the apical and basal chambers of 
Transwell™ inserts was removed and replaced with serum-free DM EM: FI 2. 
Probe transport in the apical to basal direction (A -  B) was initiated by 
adding 200 pi of DMEM:F12 (serum free) containing 0.5 pCi (0.018 MBq) 
each of PH]sucrose (0.1 pmol) and [14C]diazepam (0.1 nmol) to the apical 
chamber affording sucrose-diazepam data for a given study to reflect 
transport across the exact same monolayer. At predetermined time points 
(5,10, 20, 30, 45, 60 and 90 min), 200 pi samples were collected from the 
basal chamber and replenished w ith fresh DMEM:F12 (serum free). 
Quantitation of radiolabeled probe accumulation in the basal chamber was 
determined using liquid scintillation (Wallac 1409, PerkinElmer Life 
Sciences, Boston, MA, USA).
Cumulative transport of probes as a function of time in the A -  B direction 
was determined and the apparent permeability coefficients (p) xlO*6 cm.s_1 
calculated using Equation 3.1:
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dJLf
 «■ p  x A  x Co Equation 3.1
d t
Where dM/dt represents the rate of change in cumulative mass of probe 
transferred from A -  B; A represents the area of the Transwell7** membrane 
and Co is the original concentration of radio-labelled probe in the apical 
(donor) chamber (assumed to remain constant; <5% loss).
33.10 Ultra-structural morphology of PBMVECs
Light micrographs of confluent monolayers of PBMVECs were recorded 
after 7 days in-vitro using an Olympus 1X50 inverted microscope with 
image acquisition via an Olympus DP10 automated digital processor. 
Qualitative assessment of cellular gross morphology and vesicular 
populations w ithin PBMVECs grown on Transwell7** inserts was examined 
by transmission electron microscopy (T.E.M.). PBMVECs were grown from 
frozen stocks either in PBMVEC culture medium (7 days) followed by 
PBMVEC switch medium (24 hours) or w ith C6 co-culture. Cells were fixed 
and embedded for T.E.M. using methods previously described[76]. 
Specifically, Transwell™ insert membranes were fixed for 1 hour at room 
temperature with 1% glutaraldehyde and then post-fixed with neutrally- 
buffered osmium tetroxide in veronal acetate buffer for 1 hour at room 
temperature. Post-fixed membranes were dehydrated using 100% ethanol 
and then embedded in Araldite (CY212) resin. Sections of 70 nm depth 
were mounted on mesh copper grids and contrasted with saturated uranyl 
acetate and Reynolds' lead citrate. T.E.M. examination and image
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acquisition was conducted in a Philips CM 12 transmission electron 
microscope at an accelerating voltage of 80kV.
33.11 P-gp expression in PBMVECs
33.11.1 P-gp immunoblot analysis
Confluent monolayers of PBMVECs grown from frozen stocks were 
harvested and processed for Western blotting; an in-depth list of materials 
and a complete procedure for Western blotting is detailed in Chapter 5. 
Cells were collected in lysis buffer (50 mM Tris (pH 7.5), 1% Triton-X, 5 mM 
EGTA, 150 mM NaCl, 60 mM n-octyl-glucoside) containing protease 
inhibitors and incubated at 4°C for 20 min. Total protein in the lysed 
sample was measured using a Bio-Rad protein assay k it w ith an equal mass 
of protein (10 pg) loaded onto and resolved by 7.5% SDS-PAGE before 
being electro-blotted (0.2 pm pore diameter). Pre-stained molecular weight 
markers were run concurrently in order to determine molecular size. The 
primary antibody probe (monoclonal P-gp C219 antibody, ID Labs, Inc. 
Ontario, Canada) was diluted 1:100 and incubated with the membrane for 
16h at 4°C The membrane was washed 3x in TBS-T(0.5%) and then 
incubated w ith a 1:2000 dilution of the secondary reporter antibody (HRP 
conjugated rabbit anti-mouse, Dako, Cambridge, UK) for 1 hour at room 
temperature. The membrane was washed 6x with TBS-T(0.5%) before the 
chemiluminescent signal was generated and recorded onto Hyperfilm ECL. 
Image acquisition was undertaken on GS-700 densitometer with Molecular 
Analyst Software (Bio-Rad, Hemel Hempstead, UK).
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33.11.2 Rhodamine-123 accumulation-retention
A rhodamine-123 transport assay was used to assess the functional 
expression of P-gp w ithin PBMVEC cultures amplified from frozen stocks. 
Confluent monolayers of PBMVECs (day 8 post-seeding, 7 days growth 
medium then switch to serum free medium containing 550 nM 
hydrocortisone for 24 hours prior to study) were washed 3x with PBS and 
the cells disaggregated by trypsin/EDTA. The cells were suspended (5 x 10s 
cellsjnl*1) in DM EM containing 1% FBS and the fluorescent probe 
rhodamine-123 (0.2 pg.ml1), in the presence or absence of the P-gp 
inhibitor verapamil (40 pM). The cells were incubated on an orbital shaker 
for 1 hr at 37°C - this phase representing cellular accumulation of 
rhodamine-123. At the end of the incubation the cell suspension was 
centrifuged (lOOg for 5 min), washed 3x in PBS and 50% of the population 
aliquoted and put on ice ready for flow cytometric analysis. The remaining 
50% of the cell population was suspended in fresh DM EM (1% FBS) ± 
verapamil (40 pM) but devoid of rhodamine-123. Efflux of intracellular 
rhodamine-123 accrued w ithin the cells during the accumulation phase 
proceeded over a 2 h incubation period at 37°C, after which the cells were 
washed in PBS and aliquoted for flow cytometric analysis; this population 
represents rhodamine-123 cellular retention. The cellular associated 
fluorescence of rhodamine-123 was collected on a FACScan flow cytometer 
using the FL-1 band pass filter.
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33.12 mRNA expression of key BBB components in PBMVECs and RBMVECs
33.12.1 Total RNA extraction
Total RNA was harvested from PBMVEC monolayers grown from frozen 
stocks cultured to day 8 post-seeding (7 days astrocyte conditioned growth 
medium followed by 24 hour exposure to astrocyte conditioned switch 
medium). RNA was harvested w ith an RNEasy (Protect) K it (Qiagenf West 
Sussex, UK) according to the manufacturers protocol. Specifically, cells 
were cultured in 6-well plates and lysed in-situ w ith 350 pi of Qiagen lysis 
buffer. The lysate was collected with a rubber policeman and after passing 
through a sterile 20-gauge needle five times to ensure complete 
homogenization, was transferred to a microcentrifuge tube. The lysate was 
treated w ith 350 pi of 70% v /v  ethanol and mixed well by pipetting. The 
lysate was transferred to an RNEasy spin column and centrifuged 15 sec at 
8000 g w ith the flow-through discarded. The RNA trapped on the silica 
membrane of the spin column was washed w ith a series of proprietary 
buffers followed by centrifugation (15 sec, 8000 g) to remove 
contaminants. Finally the RNA was eluted by loading 30 pi RNAse/DNAse 
free water onto the column, centrifuging (15 sec, 8000 g) and collecting the 
flow-through. The extracted RNA was quantified and its purity assessed by 
UV spectrophotometry (Genequant Pro, Amersham, UK) at 260 nm and 280 
nm.
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33.112 Reverse transcriptase polymerase chain reaction (RT-PCR)
RNA extracted in 3.3.12.1 was used in reverse transcriptase polymerase 
chain reaction (RT-PCR). Reverse transcription (RT) reaction mixture and 
thermocycling program are show in Table 3.4 and Table 3.5 respectively.
Table 3.4 Reverse transcription mixture.
RT component f20 ul total volume) Volume fid )
(OTP's (10 |iM ) 2.0
DTT (0.1 M) 2.0
First strand buffer (5x) 4.0
MMLV-rt (200 U.pl*1) 1.0
pdN6 (50 ng.pl*1) 2.0
RNA(1 Mg.ii!*1) 1.0
RNAsin 0.5
Ultraspec1" DEPC treated water 7.5
Table 3.5 Thermocycling program.
Tbermocy ding step Temperature (#C) Time (m in)
1. Denaturing 95 5
2. Incubation 4 5
3. Addition of MMLV-rt & RNAsin
4. Binding 25 10
5. Extension 42 42
6. Denaturing and termination 95 5
RT mix was stored at -20°C until required for polymerase chain reaction.
PCR amplification primers were designed using the web based design 
program Primer 3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). Primer pairs were designed to have 
between 18 and 27 bases w ith an optimal melting point (Tm) of 60°C 
(range 57°C to 63°C) and with a GC content between 45% and 60%. 
Primer-dimers were avoided by ensuring 3'- and 5’- ends of the forward 
and reverse primers were not complementary.
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Table 3.6 highlights the accession number for porcine mRNA [Sus scrofa) 
and primer sequences for the genes studied, principally tight junctional 
elements (Zonulae occludens 1 (ZO-1), Claudin-1, Claudin-3, Claudin-5 and 
occludin), efflux transporters (P-glycoprotein (MDR-1), brain multidrug 
resistance protein (BMDP) and the multidrug resistance associated 
proteins, MRP-1 & MRP-2) and nutrient transporters and receptors 
(organic cation transporter 1 (OCT-1), organic anion-transporting 
polypeptide A & C (OATP-A & OATP-C), GLUT-1 the principal brain glucose 
transporter, neutral amino acid transporter 1 (NAA-1), cationic amino acid 
transporter 1 (CAA-1) and Leptin receptor).
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Table 3.6 RT-PCR for tight junction elements, carrier mediated transporters and hormone 
receptors in primary porcine brain microvascular endothelial cells grown from frozen stocks 
to confluence (7 days) using astrocyte conditioned growth media followed by a 24 hr switch 
to serum free astrocyte conditioned media containing hydrocortisone (550 nM). The table 
shows the GenBank mRNA accession number for primer design, primer sequence and 
expected size afPCR product
Gene Product Access. No. Primer Sequence Size
(bp)
Tight junctional 
components
Claudin-1 AJ318102 F: ctgccccagtggaagattta 
R: caacagtggccacaaagatg
223
Claudin-3 AY625258 F: ccagatgcagtgcaaagtgt 
R: acgatggtgatcttggcttt
180
Claudin-5 AJ318103 F: aaggtgtacgactcggtgct 
R: gccgcctgtgagagctac
174
ZO-1 AJ318101 F: cagcacagtgcctaaagctg 
R: gtgggaggatgctgttgtct
230
Occludin
Transporters
U79554 F: ggcctgcaggagtacaagag 
R: tccgcagatcccttaacttg
161
GLUT-1 X17058 F: cttcactgtcgtgtcgctgt 
R: cacgatgctcaggtaggaca
154
NAA-1 AY375264 R: caatgtggagctgaaagcag 
F: cagccaggatcaaagagagg
161
CAA-1 AY371320 F: catcaaaaactggcagctca 
R: tggtagcgatgcagtcaaag
185
OCT-1 AY238476 F: ctcgaagaggaggtcgtcac 
R: cggtcgatgatgaggagaat
236
OATP-A Goh etal[77] F: ccatgctcacacaaatagagagac 
R: gatgccaacaaaagtccaat
520
OATP-C 
Hormone receptors
Goh et al[77) F: aggtattctaaagaaact 
R: ctgaccatactgttgctctac
744
Leptin receptor
Drug resistance 
transporters
NM_001024587 F: ccggaatgatgcaggtctat 
R: gaaatggtttcaggctccaa
249
BMDP NM.214010 F: ttatccgtggtgtgtctggt 
R: cacgatgctcaggtaggaca
175
MDR-1 AF403245 F: atggcagtgggacaggttag 
R: ggtcgagtggggtagttgaa
188
MDR-1 (human) Goh et al[77] F: ggcatttacttcaaacttgtc 
R: gcttggtgaggatctctccagctttg
502
MRP-1 AF403246 F: gcagatcacgcgatacttga 
R: gtccaggtcgtctcggtaac
219
MRP-2 
Positive Control
Goh etal[77] F: aaatgtgtcttttcctgg 
R: taagattctgaagaggcgattt
325
B-actin Gohetal[77] F: actatcggcaatgagcggttc 
R: agagccaccaatccacacaga
288
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An examination for key BBB transporter mRNA transcripts was also made 
in RBMVECs (Table 3.7).
Table 3.7 RT-PCR for carrier mediated transporters including drug resistance transporters in 
freshly isolated primary rat brain microvascular endothelial cells grown to confluence (7 
days) using astrocyte conditioned growth media followed by a 24 hr switch to serum free 
astrocyte conditioned media containing hydrocortisone (550 nM). The table shows the 
GenBank mRNA accession number for primer design and primer sequence.
Gene Product Access. No. Prim er Sequence
Transporters
GLUT-1 NM.138827 F: gcctgagaccagttgaaagc 
R: gagtgtccgtgtcttcagca
OCT-1 NM.012697 F: ctcccatctatgtgggcatc 
R: ctggttccagtccacctcat
0ATP1 50572 F: atcagtttcatctactcacttacagcc 
R: agaaacaggaaatgacacaggagtgag
0ATP2 NM.131906 F: ctcatattcagggggcttca 
R: gttcggtggcaaacagttct
PEPT1 NM.057121 F: ccagctgacaagcataaacg 
R: cccacactagaagggtgtgc
PEPT2 NM.031672 F: cgggtctgctaagtttgagg 
R: caagctagcctctggattgg
Drug resistance
transporters
MDR-la S96559 F: catccagaacgcagacttga 
R: ctcgcatggtcacagttcat
MDR-lb X61104 F: accatccagaacgcagactt 
R: acctcaaatactcccagctca
MRP-1 AY170916 F: gcgatcacccatgagtttct 
R: ggatgatgatgacagctcca
MRP-2 NM.012833 F: gacggttggattctgtcacc 
R: cacctgttggaggtaatccag
Positive Control
B-actin NM_031144 F: agccatgtacgtagccatcc 
R: ctctcagctgtggtggtgaa
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Polymerase chain reaction mix and thermocycling program are detailed in 
Table 3.8 and Table 3.9 respectively.
Table 3.8 Polymerase chain reaction mixture.
PCR component (23.7 id total volume) Volume fu l)
dNTP’s (5 |iM ) 2.5
Forward primer (10 pmoL|iH) 2.5
Reverse primer (10 pmoLpl1) 2.5
MgCh (25 mM) 1.0
RT mix (100 ng+il1) 1.0
Taq polymerase buffer (lOx) 2.5
Taq polymerase (5 Units.pl1) 0.2
UKraspec"' DEPC treated water 11.5
Table 3.9 Thermocycling program.
Thermocyding step (30 cydes) Temperature (°C) Time (sec)
1. Denaturing 94 30
2. Annealing 60 45
3. Chain extension 72 45
To examine PCR products, samples were electrophoresed (90 volts, 1.5 hrs)
through a 2% agarose gel containing 1 pg.ul1 ethidium bromide and 
visualized under UV ligh t Negative controls comprised RT-PCR reactions 
minus cDNA and/or primers.
3.3.13 Effects of C6 co-culture on caveolin-1 expression in PBMVECs
Cryopreserved PBMVECs were grown to confluence on Transwell” * inserts 
w ith either PBMVEC growth medium followed by PBMVEC switch medium, 
astrocyte co-culture (C6 grown on the floor of basal chamber) or astrocyte 
side-by-side culture (C6 grown on underside of insert direct in apposition 
to PBMVECs). Cells were processed for Western analysis for caveolin-1 and 
its phosphorylated form. Cell harvest and processing was completed using 
standard protocols as previously described in section 3.3.11.1 and in detail 
in chapter 5. The primary antibody probe was a rabbit anti-caveolin-1
135
Chapter 3
polyclonal antibody diluted 1:4000. Incubation of the primaiy antibody 
with the membrane was for 16 hrs at 4°C The secondary reporter antibody, 
a HRP conjugated swine anti-rabbit diluted 1:2000, was incubated w ith the 
membrane for 1 hr at room temperature. Chemiluminescence signal was 
generated and recorded onto Hyperfilm ECL Image acquisition was on a 
GS-700 densitometer w ith Molecular Analyst Software (Bio-Rad, Hemel 
Hempstead, UK).
33.14 Identification of ceil-surface binding phage
A schematic of the biopanning procedure can be seen in Figure 3.2. In total 
four rounds of phage display were conducted against confluent monolayers 
of either mouse (b.End3), rat (RBE4) or porcine (PBMVECs) brain 
microvascular endothelia. Cells were cultured until confluent on 60 mm 
Petri dishes before incubation with blocking buffer (1% w /v BSA in PBS) 
for 60 mins at 4°C to reduce non-specific binding. The blocking buffer was 
aspirated and the cells were exposed to 2 x 1011 plaque forming units of 
Ph.D.1,,-C7C library in a total volume of 1ml ice-cold DM EM for 1 hr at 4°C; 
incubation at 4°C was to inhibit endocytosis and thus prevent phage 
internalization. The supernatant, containing phages that do not bind to 
cells, was aspirated and discarded. Phages that bind with limited affinity 
were removed w ith lOx TBS-T(0.5%) washes. Membrane bound phages 
were recovered from the cell surface w ith 3x glycine buffer elutions. The 
third eluate was neutralized w ith glycine neutralization buffer then 
amplified in E. coli. After purifying and titering the phage as previously
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described (Chapter 2) an aliquot constituting 2 x 1011 pfus of phages served 
as input for the next iterative round of panning; in total four rounds of 
panning were completed against each cell line before the identity of the 
displayed peptides were determined by gene sequencing using standard 
Big Dye v3.1 chemistry on an ABI Prism 3100 genetic analyzer.
1) P h D C 7C "* lib rary  
phages are exposed to 
confluent monolayers of 
BBB cells for 1 Iv at 4°C
2) Non-binding phages are 
washed away with 10x ice- | il 
cold TBS-T (0.5%) washes.
.
fI 5) Amplified phages serve 
I as input into the next 
\  iterative panning round. 4x ROUNDS
* Mill
3) Bound phages are 
eluted with 3x glycine 
elutions (pH 2.2).
4) Phages in the 3rd 
glycine elution are 
a mp l i f i e d  in the  
bacterial host (E. coli).
Figure 3.2 Schematic representation of the biopanning procedure used to isolate peptide- 
phages from the PhDC7C™ library that bind in-vitro blood-brain barrier microvascular 
endothelia. In total, three cell lines were explored: (i] primary porcine brain microvascular 
endothelial capillary cells (ii) the mouse brain microvascular endothelia cell line b.End3 and 
(Hi) the rat brain microvascular endothelia cell line RBE4.
137
Chapter 3
33.15 EUSA analysis
To monitor for phage enrichment at each panning round, ELISA analysis 
was undertaken. Essentially, phages from the amplified 3rd glycine elution 
from rounds 1-3 were applied to confluent monolayers of the respective 
BBB microvascular endothelial cell culture and the extent of binding 
determined through ELISA. Specifically 2 x 1011 plus of amplified phage 
stock (in 100 pi of DMEM) was applied to confluent monolayers for 1 hr at 
4°C The phage solution was aspirated and the cells washed lOx with 200 pi 
TBS-T (0.5%). Cells were then exposed to 100 pi of DMEM containing a 
1:5000 dilution of HRP/anti-M13 mAb for 1 hr at 4°C. The antibody 
solution was aspirated and the cells washed 3x with 300 pi of deionised 
H2O before addition of 100 pi of HRP substrate (o-phenylenediamine (OPD) 
in DMEM). After 15 minutes the OPD was quenched with 50pl of 2.5 M 
H2SO4 and the optical absorbance at 492 nm recorded; negative control was 
insertless phage.
33.16 Statistical analysis
Statistical analysis was performed using Graphpad Prism (Graphpad 
Software; California, USA). Results were expressed as mean ± standard 
deviation (SD) unless otherwise stated. Statistical significance between 
multiple groups was assessed using a two-way AN OVA followed by a post 
hoc Bonferroni test Single group differences were determined using a one­
way ANOVA followed by Dunnett's post hoc or by two-tailed Student's t- 
test P < 0.05 was considered significant
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3.4 Results
3.4.1 Ultra-structural morphology of PBMVECs
Prior to the studies described in section 3.3 a significant number of 
preliminary investigations and observations were undertaken to progress 
the establishment of the isolation protocol and maintenance of the 
resultant cultures. Notably, the source and activity of the digestive enzymes 
dispase II and dispase-collagenase, the composition of the collagen matrix 
(type I vs IV), the mass of collagen coated per unit area, the technical 
procedure for coating and the substitution of horse serum for bovine serum 
all significantly improved the model quality i.e. growth to confluency 
without significant visual contamination w ith non-endothelial cells. In 
addition small but nevertheless incremental improvements in the model 
were achieved by investigating seeding density, freezing and thawing 
processes and the composition of astrocyte conditioned media. Together 
these investigations formed the groundwork for a robust and reproducible 
isolation protocol that yields — 25 m illion primary microvascular capillary 
endothelial cells per brain, sufficient to culture 100 cm2 at a density of 250 
K cells.cm"2. Cells cryopreserved in M199 supplemented with 20% horse 
serum and 10% DMSO could be rescued from frozen and cultured without 
apparent phenotypic d rift (gross morphology and permeability to 
radiolabeled probes) at least 1 year from cryopreservation. Freshly 
isolated, frozen primary and first passage PBMVECs attained confluency 
w ithin 7 days of seeding (2.5xl05 cells.cnr2) w ith a doubling time estimated
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to be ~ 36 hr. Growth rate was not affected by astrocyte co-culture or 
astrocyte conditioned medium. In the first 48 hours after seeding, 
PBMVECs preferentially grew as microvascular endothelial islands 
gradually expanding to form confluent monolayers with an elongated 
'spindle* like morphology (Figure 3.3A &  Figure 3.3B) that is 
characteristic of brain microvascular endothelia. PBMVECs cultured from 
cryopreserved stocks imaged under T.E.M. maintain a squamous 
morphology (perinuclear thickness ~ 2 pm) extending peripherally to thin 
attenuations (~ 0.3 pm) (Figure 3.3C) that overlap neighbouring cells and 
are locked together via morphologically evident tight junctional complexes 
(Figure 3.3D). Non-coated membrane invaginations (average diameter 60 
-  80 nm) morphologically consistent w ith caveolae could be observed at 
both the basolateral and apical domains of the cell (Figure 3.3E), the 
numerical density and topography of which did not alter significantly when 
exposed to astrocyte co-culture or astrocyte conditioned medium (data not 
shown). This was true even when C6 astrocytes were cultured in direct 
apposition with PBMVECs (side-by-side co-culture) separated only by a 
thin porous membrane (0.4 pm or 3 pm pore size) that afforded direct 
physical contact between astroglial endfeet and PBMVECs. In a limited 
number of micrographs electron dense membrane invaginations that are 
characteristic of clathrin coated pits could be observed (Figure 3.3F) but 
these were observed w ith an apparent lower numerical density relative to 
caveolae.
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Figure 3.3 Microscopy of PBMVECs (day 7, confluent monolayer) grown on Transwell~ clear 
membrane inserts. (A & B) Light micrographs (x200 and x500 magnification respectively) 
revealing a characteristic elongated “spindle" like morphology. (C) Ultrustructural 
transmission electron microscopic (T.E.M.) image highlighting the squamous morphology of 
PBMVEC cell monolayers; bar = 200 pm. (D) Monolayers of PBMVECs cultured in the presence 
of C6 cells retain a squamous morphology, display vesicles on the apical and basal membrane 
(denoted by dashed arrows) and additionally yield the generation of tight junctional 
complexes (denoted by solid arrows); bar = 200 nm. (E) T.E.M. analysis of the apical 
plasmalemma of PBMVECs reveals the presence of non-coated invaginations (denoted by 
solid arrows) and non-coated intracellular vesicles (denoted by dashed arrow) both of which 
are morphologically consistent with caveolae; bar = 200 nm. (F) T.E.M. of the apical plasma 
membrane showing a single invagination consistent with the electron rich coat of a clathrin 
coated pit (denoted by arrow); bar = 200 nm.
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3.4.2 Upregulation of alkaline phosphatase in PBMVECs by C6 conditioned 
media
In-vivo brain microvascular endothelia expresses significant levels of 
alkaline phosphatase [78], a recognised marker of the microvascular 
endothelial cell phenotype. Reductions in ALP synthesis result in a loss of 
expression on the luminal membrane w ithin 48 hours of in-vitro culture. 
Studies have shown that exposure of in-vitro primary brain microvascular 
cultures to astrocytic cells re-establishes ALP synthesis[79]. To determine 
whether PBMVECs were responsive to astrocytes or to astrocyte 
conditioned medium, luminal ALP activity was determined. PBMVECs were 
cultured until confluent (7 days) in either astrocyte conditioned medium or 
w ith astrocyte co-culture after which ALP levels were compared to 
untreated cells. Untreated cells and cells cultured in astrocyte conditioned 
medium displayed a low level of constitutive ALP activity (Figure 3.4A). 
However, co-culturing PBMVECs w ith C6 astrocytes led to significant 
increases in ALP activity w ith the earliest time point (10 mins) showing a 
six-fold increase in ALP activity compared to untreated cells and to cells 
exposed to astrocyte factors (Figure 3.4B). Over the time course of the 
experiment the ALP activity in the C6 astrocyte co-culture group declined, 
as a result of both ALP exhaustion and the absence of C6 cells whilst 
conducting the experiment but s till remained significantly higher than 
untreated cells (Figure 3.4B). These results indicate that astrocytes 
influence the BBB phenotype of endothelial cells in-vitro but astrocyte
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conditioned medium is incapable of mimicking co-culture in re-establishing 
ALP expression.
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Figure 3.4 Alkaline phosphatase activity on die luminal membrane of PBMVECs. (A) The 
constitutive expression of ALP in untreated cells and cells exposed to astrocytic factors in the 
form of astrocyte conditioned medium (ACM) is low. Co-culturing PBMVECs with C6 
astrocytes leads to a significant upregulation in ALP activity that diminishes with time as C6 
are withdrawn at the commencement of die study but remains significantly higher than 
untreated cell and cells exposed to astrocytic conditioned medium. (B) At the first time point 
in the study (10 min) PBMVECs co-cultured with C6 astrocytes have 6-7 fold greater ALP 
actitvity titan untreated cells and cells exposed to astrocyte conditioned medium. Data are 
mean ± SD (n =6). * signifies a statistically significant (  P < 0.05) difference compared to 
untreated cells.
3.4.3 Expression of vesicle associated proteins in PBMVECs
Whilst caveolae appear to be the predominant morphologically evident 
vesicle type within in-vivo brain microvasculature, as previously discussed, 
intact tissue studies indicate a much lower numerical density of vesicles in 
the BBB compared to peripheral capillary beds[80]. To determine if the 
low-density of vesicles reported within brain microvasculature reflects 
reduced caveolin-1 expression, caveolin-1 comprising the major structural 
and functional protein of caveolae, an examination of caveolin-1 levels in
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PBMVECs was undertaken. Figure 3.5 shows immunoblots of caveolin-1 
from lysates retrieved from a range of porcine and rat tissues as well as 
from freshly isolated porcine brain microvascular endothelia, 
cryopreserved primary cultured PBMVECs (approximately 1 month post 
cryopreservation), 1st passage PBMVECs and from two epithelial cell lines, 
A431 and M AI04, widely used in caveolae research. Initial observations 
revealed whole brain tissue from both rat and porcine species contained 
low to neglible levels of caveolin-1 compared to lung tissue when loaded at 
equivalent milligrams of total protein (Figure 3.5A). This is to be expected 
as the microvasculature comprises < 0.1% of brain tissue volume, although 
it is recognised that caveolin-1 is present not only in brain endothelial cells 
but also astrocytes and some specific neuronal populations [81,82] but still 
combined these constitute a very small fraction of total brain tissue volume. 
In stark contrast, the expression of caveolin-1 w ithin freshly isolated 
PBMVECs approximated (per mg of total protein] that of both MA104 and 
A431, cells that are recognised to express abundant quantities of caveolin-1 
(Figure 3.5A). Comparison of the levels of caveolin-1 in freshly isolated 
brain microvascular cells and cells grown in primary culture (from frozen 
stocks) or cells taken through a single passage revealed no difference in 
caveolin-1 expression (Figure 3.5B). Curiously, ciyopreserved and first 
passage PBMVEC cells displayed a significantly greater degree of 
phosphorylated caveolin-1 compared to freshly isolated cells (Figure 
3.5B).
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a  Signal over-expression reveals 
slight caveolin-1 expression 
in whole brain
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Figure 3.5 Western blot analysis of caveolin-1 in whole tissues, PBMVEC cells and model 
caveolin-1 cell lines A431 and MAI04. (A) Porcine and rat whole lung tissue shows 
considerable expression of caveolin-1, but significantly there is little expression in whole 
brain tissues. Freshly isolated porcine brain microvascular endothelia, lysed immediately 
after isolation, shows a significant expression of caveolin-1, comparable with that of A431 
and MA104, cell lines widely used in the study of caveolae and caveolin. (B) Consistent 
expression of caveolin-1 is confirmed in freshly isolated, primary and 1st passage cultures of 
PBMVECs. Caveolin-1 in its phosphorylated (activated) state was observed in PBMVECs and 
1st passage culture but not freshly isolated endothelia. All lanes were loaded with equivalent 
total protein (10 pg).
Neither astrocyte co-culture nor astrocyte conditioned medium had any 
effect on the expression of caveolin-1 or phosphorylated caveolin-1 
(pCaveolin-1) in primary PBMVECs grown from cryopreserved stocks 
(F igure 3 .6 ). This was true even when C6 astrocytes were grown in direct 
apposition to PBMVECs by growing C6 cells on the underside of Transwell™
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inserts (0.4 pm and 3.0 pm pore size) such that astrocytic endfeet could 
invade the Transweir* and intimately contact the endothelial cells.
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Figure 3.6 Western blot analysis of caveolin-1 and phosphorylated (activated) caveolin-1 
(pCaveolin-1)  in cryopreserved PBMVECS co-cultured with astrocytes (ACC) or exposed to 
astrocyte conditioned medium (ACM). Neither ACC nor ACM had any effect on expression of 
caveolin-1 or its activated phosphorylated form. This was true even when astrocytes were 
grown in direct apposition to PBMVECs in a 'side-by-side' culture system (SS) that allows 
astrocytic endfeet to invade the Transwellm membrane and intimately interact with the basal 
membrane of PBMVECs
3.4.4 mRNA expression of key BBB components in PBMVECs and RBMVECs
Confirmation of mRNA expression of tight junctional components and 
carrier transporters in PBMVECs cultured from frozen stocks of PBMVECs 
was accomplished by undertaking RT-PCR upon RNA extracted from 
confluent monolayers of PBMVECs (three separate isolations) exposed to 
C6 astroglial factors during culture; the analysis was limited to genes that 
have been identified in the pig genome and can be found in the pig database 
at http://www.ncbi.nlm.nih.gov/projects/genome/guide/pig/.
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Table 3.6 and Table 3.7 details mRNA accession number (Genbank) used 
for PCR primer design for PBMVECs and RBMVECs respectively, the primer 
sequences subsequently designed and the expected PCR product size. 
Positive expression of tight junctional elements and transporter mRNA 
transcripts was confirmed for all genes examined for in PBMVECs with the 
exception of claudin-3, MRP-2, OCT-1, OATP-A and OATP-C (Figure 3.7). In 
RBMVECs, positive expression was confirmed for all transporters examined 
for with the exception of OCT-1 and 0ATP2 .The house-keeping gene 0- 
actin, a positive control for the RT-PCR, was confirmed for each PCR run to 
be present and of reproducible signal strength. Negative PCR controls 
comprised minus RT enzyme and minus cDNA. An absence of genomic DNA 
contamination was confirmed for each sample.
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Figure 3.7 mRNA expression of tight junctional elements and transporters within two 
representative PBMVEC isolations (A) mRNA transcripts were confirmed for tight junctional 
elements ZO-1, Claudin-1, Claudin-5 and Occludin but expression of Claudin-3 was not 
observed in any isolation. (B) Transcripts for the principle glucose transporter GLUT-1 were 
confirmed as was expression for the multidrug resistance transporters MDR-1 and brain 
multidrug resistance protein BMDP. Note bands < lOObp in Control are cDNA from RT-PCR 
minus primers and do not represent mRNA transcripts.
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3.4.5 Functional expression of the P-gp efflux transporter in PBMVEC cells
After confirming P-glycoprotein (MDR-1) expression at both the mRNA 
level using RT-PCR (Figure 3.7B) and the protein level using Western 
analysis (Figure 3.8 inset), functional assessment of P-gp mediated efflux 
within PBMVEC cells grown from frozen stocks was undertaken. This was 
accomplished using a flow-cytometric assay to monitor accumulation and 
retention of the fluorescent P-gp substrate rhodamine-123 in the presence 
and absence of the selective P-gp inhibitor verapamil (40 pM). Verapamil, 
by inhibiting efflux transporter function, increases cell-associated 
rhodamine-123 at the end of both accumulation and retention phases in P- 
gp positive cell lines. Figure 3.8A and 3.8B shows the respective 
accumulation and retention of rhodamine-123 in PBMVEC cells. Verapamil 
exposure leads to a significant (P < 0.05) increase in rhodamine-123 
accumulation of approximately 350%, while at the end of the retention 
phase, a more sensitive indicator of P-gp functionality, verapamil exposure 
significantly increased (P < 0.05) cell-associated rhodamine-123 by ~ 
750%. These data confirm the functional expression of P-gp within 
PBMVECs.
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Figure 3.8 Functional P-gp activity in PBMVEC cells. Intracellular accumulation (A) and 
retention (B) of rhodamine-123. Accumulation -  Cells were incubated for 45 min at 37°C in 
media containing rhodamine-123 ± verapamil. Retention -  After an accumulation phase cells 
were washed with PBS and rhodamine-123 effluxed over 90 min at 37°C in rhodamine-123- 
free media ± verapamil. Data are expressed as % of rhodamine-123 control (100%) as mean 
i  S.D. (n = 6). * signifies a statistically significant (P < 0.05) difference compared to respective 
control. Inset A: strong and consistent signal strength in Western blot analysis for P-gp in 
four batches of PBMVECs.
3.4.6 Permeability assessments in PBMVECs
After confirming that cryopreserved stocks of PBMVECs were responsive to 
astrocytes, the permeability properties of confluent monolayers of 
PBMVECs were assessed in the presence or absence of astrocyte co-culture 
or astrocyte conditioned medium. Exposing PBMVECs to soluble astroglial 
factors in small Transwell™ inserts (6.5 mm diameter; 0.33 cm2) resulted in 
TEER measurements across the monolayers of up to 75.0 ± 1.7 H.cm2 at day 
8 post-seeding. Exchanging the culture medium for a 'switch' medium that 
was serum free but supplemented with physiological concentrations of 
hydrocortisone (550 nM) and modulators of cAMP for a 24 hr period
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resulted in significantly increased TEER levels up to a maximum of 185 ± 
16 £l.cm2. Whilst these data do not correlate favorably with in-vivo 
measurements of BBB TEER (1500 -  2000 ft.cm2[83,84]) the small surface 
area of the inserts accounts at least partially towards this. Cultures grown 
on small diameter inserts (ideal for high-throughput solute screening) have 
a relatively small ratio of monolayer surface area to transverse area at 
intercellular junctions. In large inserts (4.7 cm2) the ratio is far greater and 
TEER values are significantly higher (in the supervisor's laboratory up to 
834 ± 136 n.cm2 with C6 co-culture[85]) and more closely correlate with 
in-vivo TEER.
The discriminative power of a BBB model to paracellular and transcellular 
probes is often a better measure of monolayer restrictiveness than TEER. 
Therefore, to further characterize the paracellular barrier within cultured 
PBMVECs, the permeability of confluent monolayers to the paracellular 
probe PH]sucrose and to the transcellular probe [14C]diazepam was 
determined within the same insert such that the permeability to each probe 
reflects the same cell monolayer. Figure 3.9 shows the variability between 
three different isolations. Whilst all isolations showed significant 
difference (p < 0.05) between sucrose and diazepam permeability 
coefficients within a given isolation, there was no significant difference in 
sucrose or diazepam permeabilities between isolations and the isolation 
protocol developed as detailed in 3.3.3 was thus shown to be highly 
reproducible.
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Figure 3.9 Permeability to sucrose and diazepam probes in three PBMVEC isolations. 
PBMVECs were thawed from frozen stocks and cultured in growth medium for 7 days. The 
permeability to sucrose and diazepam was then determined. All isolations show a significant 
difference (p<0.05) between sucrose and diazepam permeability coefficients i.e. 
discrimination between paracellular and transcellular pathways. However no statistically 
significant difference was observed between isolation batches. No difference in permeability 
to diazepam was observed between cell isolations and blank RTCI coated inserts indicative of 
PBMVECs offering limited resistance to transcellular passage of solutes. Conversely the 
significant difference in sucrose permeability between isolations and blank inserts shows that 
PBMVECs restrict paracellular diffusion pathways. Data represent mean ± SD (n = 4-6). * 
signifies a statistically significant difference (P < 0.05) between sucrose and diazepam 
permeability co-efficients, f  signifies a statistically significant difference (P < 0.05) between 
sucrose permeabilities in PBMVECs and blank inserts.
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Whilst the batches showed discrimination between paracellular and 
transcellular pathways, the level of discrimination is relatively limited, at 
least in comparison to other primary models, and so a range of culture 
conditions were investigated to try to improve barrier restrictiveness. 
Physiological concentrations of hydrocortisone (550 nM) along with 
exposure to modulators of cAMP have previously been shown to decrease 
barrier permeability at the BBB[18,19, 25, 86, 87]. To understand if these 
factors could improve the PBMVEC model, the culture medium on confluent 
monolayers (day 7 in-vitro) was replaced by a switch medium (serum free 
with hydrocortisone] or switch medium with cAMP modulators (Ro20- 
1274 & CPT) for 24 hours prior to the permeability study. Figure 3.10 
shows that the switch medium combined with exposure to cAMP 
modulators resulted in significant increases in barrier restrictiveness as 
evidenced by decreases in permeability to sucrose in comparison to non­
treated cells. Cells undergoing a switch procedure without cAMP 
modulators showed numerical but not significant decrease in permeability 
compared to switch alone.
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Figure 3.10 Effect of hydrocortisone and cAMP elevators on the permeability of PBMVECs to 
paracellular and transcellular probes. After 7 days culture in growth medium, serum was 
withdrawn from confluent monolayers of PBMVECs and cells were exposed for 24 hours to 
either hydrocortisone (550 nM; Switch) or hydrocortisone and cAMP elevators (Ro20-1274, 
20 pM; CPT, 250 pM; Switch + cAMP). Hydrocortisone alone did not lead to an increase in 
paracellular restrictiveness. Exposure to hydrocortisone and the cAMP modulators resulted in 
a statistically significant reduction in sucrose permeability indicative of enhanced 
paracellular restriction. In all treatments, statistically significant discrimination between 
paracellular (sucrose) and transcellular (diazepam) probes was observed. Data represent 
mean ± SD (n = 4). * represents a statistically significant difference (P < 0.05) between 
sucrose and diazepam permeability co-efficients, f  represents a statistically significant 
difference (P < 0.05) between sucrose permeabilities compared to control untreated cells.
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Many studies, including those in the supervisor's laboratory[88], have 
shown increases in paracellular restrictiveness of in-vitro BBB models 
following exposure to astrocytes or astrocyte co-culture. Figure 3.11 
shows that PBMVECs cultured in astrocyte conditioned medium and 
undergoing a switch procedure, including exposure to cAMP, have a 
sucrose permeability of 8.6 ± 1.1 x 10-6 cm.s1 which is more restrictive than 
the 10.4 ± 1.4 x 10-6 cm s1 for switch and cAMP exposure alone. PBMVECs 
co-cultured with astrocytes and undergoing a switch procedure, including 
exposure to cAMP, were even more restrictive as evidenced by a sucrose 
permeability of 7.5 ± 0.7 x 10-6 cm.s_1.
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Figure 3.11 Effect of hydrocortisone and cAMP elevation combined with exposure to 
astroglial factors or astrocyte co-culture on PBMVEC permeability to paracellular and 
transcellular probes. PBMVECs were cultured until confluent (7 days) in astrocyte 
conditioned medium or in the presence of astrocyte co-culture and then switched to a serum 
free medium containing hydrocortisone and cAMP elevators for 24 hours before transport 
studies were conducted. In all treatment groups statistically significant discrimination 
between paracellular and transcellular probes was observed. Exposure of PBMVECs to 
astrocyte conditioned medium followed by the switch procedure at day 7 resulted in a 
statistically significant increase in paracellular restrictiveness as evidenced by a reduction in 
permeability to sucrose. Co-culturing the cells with astrocytes followed by the switch 
procedure at day 7 resulted in a further significant reduction in sucrose permeability 
compared to both untreated cells and cells exposed to astroglial factors. Data are mean ± SD 
(n = 4-6). * represents a statistically significant difference (P < 0.05) between diazepam and 
sucrose permeability co-efficients, f  represents a statistically significant difference (P < 0.05) 
between sucrose permeabilities compared to control untreated cells.
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Primary rat brain microvascular endothelia was isolated as a comparator 
for PBMVECs. Restrictiveness to the paracellular marker sucrose was 
examined with C6 co-culture, a switch procedure and with co-culture and 
switch combined. Figure 3.12 shows that RBMVECs do not provide a 
restrictive paracellular barrier, at least in comparison to PBMVECs, and 
were unresponsive to astrocytic factors.
30-i
Figure 3.12 Permeability to sucrose in freshly isolated rat primary brain microvascular 
endothelia. Cells did not exhibit significant paracellular restrictiveness under any of the 
conditions investigated.
The data in Figures 3.9 -  3.12 are summarised in Table 3.10 and include 
sucrose and diazepam permeability data under all conditions tested and
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also the ratio between sucrose and diazepam to show the level of 
discrimination between die paracellular and transcellular pathway. These 
data clearly indicate that the greatest paracellular restriction is achieved in 
PBMVECs co-cultured with astrocytes and undergoing a switch procedure 
with hydrocortisone and modulators of cAMP. However, the discrimination 
between paracellular and transcellular pathways is the same when the co­
culture model or conditioned medium model are exposed to 
hydrocortisone and cAMP modulators.
Table 3.10 Permeability coefficients for sucrose and diazepam across PBMVEC monolayers 
grown alone, in the presence of C6 co-culture or exposed to C6 astroglial factors during 
growth. As a comparator, permeability of RBE4 and primary rat brain microvascular 
endothelia and the membrane alone is shown. The ratio of permeabilities (diazepam:sucrose) 
is indicative of the level of discrimination of the BBB model between transcellular and 
paracellular probes. Untreated PBMVECs discriminate between the paracellular and 
transcellular pathways although the discrimination is relatively limited (diazepam.sucrose = 
1.8 ± 0.6). The greatest discrimination combined with the lowest permeability to sucrose was 
observed when cells were both co-cultured with astrocytes until confluent and then exposed 
to hydrocortisone and the cAMP modulators Ro20-1274 and CPT. Data are mean ±SD (n = 4- 
6).
Permeability co-efficient 
fx 10*6 cn^s-1) Ratio
Blood-brain barrier model [14C] Sucrose PH] Diazepam diazepam:sucrose
PBMVECs 13.0 ± 0.7 23.4 ±1.1 1.8 ± 0.6
PBMVECs with switch 12.9 ± 1.7 22.8 ± 1.7 1.8 ± 0.1
PBMVECs with 'switch' + cAMP 10.4 ±1.4 22.8 ± 1.4 2.2 ± 0.2
PBMVECs exposed to C6 astroglial 
factors with 'switch' + cAMP
8.6 ± 1.1 26.1 ± 1.3 3.0 ±0.3
PBMVECs with C6 co-culture and 7.5 ± 0.7 22.2 ± 0.1 2.9 ± 0.1
with 'switch' + cAMP
Primary rat BBB with C6 co-culture 17.6 ± 5.0 - NA
RBE4 45.46 ± 2.5 - NA
Membrane (polyester, 0.33 cm2) 
Membrane (polyester, 0.33 cm2) 
collagen coated
21.0 ± 0.73 
18.6 ± 3.3
26.4 ±0.9 
24.7 ± 1.5
1.3 ± 0.005 
1.2 ± 0.04
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3-4.7 Selection of brain microvascular endothelia cell surface binding 
peptkfle-phages
A series of in-vitro biopanning experiments, detailed in section 3.3.14, were 
conducted against confluent monolayers of porcine (PBMVECs), rat (RBE4) 
and mouse (b.End3) brain microvascular endothelia to identify cell surface 
binding peptides; prelim inaiy studies revealed that even after short 
exposure times, in-vitro BBB models were not restrictive to the passage of 
inserdess-M13 across cell monolayers. Ph.D.1M-C7C library phages were 
incubated w ith cell monolayers at 4°C to block endocytic processes that 
would internalize the phages. After four rounds of panning against each of 
the respective cell lines, the pool of phages recovered in the final 3rd glycine 
elution were gene sequenced collectively to identify if  a common motif had 
been selected. I f  there is sufficient penetration of the phage population with 
clones displaying a common motif, sequence traces w ill expose this despite 
'contamination' w ith phages that do not display the motif. In each cell line 
investigated, the gene sequence for the pool did not indicate a conserved 
m otif or sequence. This is in contrast for example to biopanning studies 
against streptavidin where sequencing of the collective pool of phage in the 
3rd glycine elution of the third round o f panning revealed a common 
sequence of AC-GTFIHPQ-CGGGS that was present in sufficient copy 
number to dominate the population. In addition ELISA studies to monitor 
phage binding after each round of panning did not reveal any binding above 
background insertless-phages suggestive of a failed selection protocol (data 
not shown).
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Nevertheless a number of clones from each cell line recovered in glycine 
elution 3 of round 4 were sequenced individually (see Table 3.11) and 
these were inputted into a BLAST search to identify any homologies with 
known peptides or proteins that traverse or interact with the BBB.
Table 3.11 Amino add sequences of brain microvascular endothelial cell surface associated
phage clones.
Cell line Peptide sequence
b.End3 AC-NTSVSKU-CGGGS
AC-NSPRHWT-CGGGS
AC-THPIHQH-CGGGS
AC-SNGFSRS-CGGGS
AC-PTQGPHN-CGGGS
PBMVEC AC-NDPLHTT-CGGGS
AC-NPVGFQY-CGGGS
AC-KFLQTSC-CGGGS
AC-DSRATAS-CGGGS
AC-PSHPQAL-CGGGS
RBE4 AC-NELGHYQ-CGGGS
AC-KANNHYH-CGGGS
AC-SIHSPRV-CGGGS
AC-NLTLKNL-CGGGS
AC-SPGHGRL-CGGGS
AC-LDTSPRL-CGGGS
BLAST analysis revealed that sequence NTSVSKW shares significant 
homology with a region of the V3 loop of HIV GP120, which studies have 
shown has a role in the cellular uptake of HIV[89]. In studies that parallel 
those described in detail in chapter 4, this phage clone was co-injected into 
a rat along with inserdess phages to assess brain accumulation but 
unfortunately the clone did not show any increased entry into the brain 
compared to insertless phages (data not shown).
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3.5 Discussion
The research and development of brain therapeutics and brain targeting 
vectors would benefit significantly from the availability of a robust and 
reproducible in-vitro cell culture model that mimics the in-vivo blood-brain 
barrier in terms of morphology, barrier restrictiveness and biochemistry 
that would complement both in-situ brain models and in-silico assessments 
of drug physicochemical properties. Classically both industry and academia 
have utilized immortalized epithelial cell lines for mid to high throughput 
screening of potential CNS active therapeutics[90]. Unfortunately the non­
cerebral origin of these cell lines often lim it their use as predictors of CNS 
penetration since differences in both architecture and biochemistry 
commonly result in a poor correlation between in-vitro and in-vivo 
permeation. An in-vitro blood-brain barrier model that more closely 
resembles die in-vivo blood-brain barrier architecture would provide a 
system to address both fundamental mechanistic aspects of BBB drug 
transport and quantitative drug permeation. The potential for in-vitro BBB 
models to serve as high throughput permeability screens to determine 
whether lead compounds that show activity on the bench top are likely to 
accumulate in the central nervous system at a sufficient concentration to 
result in a therapeutic effect is of significant interest within the 
pharmaceutical industry. With many brain microvascular models lacking a 
sufficiently restrictive paracellular pathway the establishment of a robust 
and reproducible model remains a continuing challenge. It must be noted 
that membrane partitioning effects, active influx and efflux transporters
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and metabolic systems unique to the BBB phenotype contribute to a 
dynamic overall barrier permeability and should be accounted for in any 
model developed. Primary cultures of non-transformed BBB endothelial 
cells retain the closest phenotype to the in-vivo environment however 
perceived technical challenges and high costs associated with isolation, at 
least in comparison to transformed cell lines, has dissuaded many 
researchers from exploiting primaiy resources. The low cell yield from rat 
and mice brains and the ethical and tissue constraints associated with 
isolating human BBB cell models has meant that the isolation of bovine and 
porcine material has received the most attention. Whilst isolations of 
bovine and porcine material are time-consuming, a large amount of 
material is isolated which is often discarded either because the material is 
not required or because there is insufficient time to culture all the material 
at once. The ability to store the isolated primaiy material for extended time 
periods without loss of cell viability, phenotype or function when recovered 
would benefit researchers immensely. In this chapter characterization of 
primary cultures of porcine brain microvascular endothelial cells recovered 
from cryopreserved stocks was undertaken to assess their usefulness as a 
pharmaceutical blood-brain barrier model and specifically as a model to 
afford the selection of phages that bind brain microvasculature. PBMVECs 
were isolated by enzymatic digestion of homogenates of porcine brain grey 
matter tissue firstly by dispase and then collagenase/dispase. Density 
centrifugations through Percoll gradients were used to separate 
microvascular capillaries from other tissue types after the first digestion
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and then to separate microvascular capillary fragments from cellular debris 
after the second digestion. Each porcine brain (<5 month old pigs) yielded 
approximately 25 million endothelial cells providing sufficient material for 
many studies based upon an initial seeding density of 250 k.cnr2. The 
isolated cells were cryopreserved in 10% DMSO, 20% Horse serum and 
70% M199 to yield 10 vials per brain i.e. 2.5 million cells per vial. Cells 
could be recovered from frozen stocks at least 12 months after 
cryopreservation with no apparent loss in cell viability retaining a plating 
efficiency of 50-60% PBMVECs and RBMVECs (isolated as a comparator 
for PBMVECs) had a clear requirement for an extracellular matrix without 
which cell colonies did not spread and confluency was never achieved. 
Coating culture surfaces with rat tail collagen type I at a density of 3 pg.cnr2 
proved successful for all applications used in the studies in this chapter. It 
must be noted that the source of collagen was critical in establishing 
optimal growth of PBMVECs and all studies were undertaken using collagen 
from Roche Applied Biosciences; collagen obtained from alternative 
suppliers led to inconsistent growth patterns. In addition, the technique of 
coating was important, with experimentation in the production of collagen 
gels using ammonia unsuccessful, as were collagen concentrations less than 
3 pg.cnr2 and greater than 5 pg.cnr2. In contrast to Galla’s work, no 
significant difference was observed in culture reproducibility with different 
combinations of collagen (Type I/IV), fibronectin or laminin[91].
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Microscopic examination of PBMVECs cultured from cryopreserved stocks 
revealed a gross morphology consistent with endothelial architecture, 
specifically a spindle-like, squamous and attenuated morphology with cell 
dimensions typical of other brain microvascular cells. In electron 
micrographs adjacent endothelial cells were seen to overlap and were 
locked* together by tight-junctional complexes. In support of these 
observations, RT-PCR confirmed mRNA transcripts for tight-junctional 
elements including zonnula occludens 1, occludin, claudin-1 and the 
endothelial specific claudin-5.
Increases in ALP activity when PBMVECs are cultured with C6 astrocytes 
indicated their responsiveness to astrocytic factors although astrocyte 
conditioned medium did not result in significant increases in ALP activity. 
In contrast, exposure of PBMVECs to C6 conditioned medium as well as 
when co-cultured with C6 astrocytes profoundly increased barrier 
restrictiveness as evidenced by significant reductions in permeability to the 
paracellular probe sucrose. In addition, a switch strategy first described by 
Galla and co-workers [2 7] was adopted whereby when the monolayer 
reached confluence (day 7) serum was withdrawn from the culture and 
supplemented with physiological concentrations of hydrocortisone and 
with Ro20-1274 and CPT (modulators of cAMP)[27]. Consistent with the 
findings of Galla et al[27] the switch procedure led to increased barrier 
restrictiveness particularly when cAMP modulators were incorporated into 
the switch procedure. It was clear however that the most restrictive
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phenotype was observed with PBMVECs co-cultured with C6 astrocytes and 
undergoing the switch strategy leading to a diazepam:sucrose ratio of ~ 3 
compared to ~ 1.8 for cells cultured without any treatments. Whilst the 
PBMVEC model developed is partially responsive to astrocyte conditioned 
medium (increases in paracellular restrictivness but unresponsive in ALP 
assessments), co-culture with astrocytes was deemed superior. 
Unfortunately, the understanding of the exact identity and concentrations 
of astrocytic factors required for upregulation of various BBB phenotypic 
markers remains poorly understood and indeed some research groups 
have failed to isolate primary BBB cells that respond to astrocytic factors 
either in conditioned medium or when in co-culture and almost without 
exception continuous cell lines are unresponsive[88]. It is clear that the 
dynamic interplay, both physical and biochemical, between astrocytes and 
brain microvascular endothelia is complex. A full and detailed analysis to 
characterize both the identity and concentration of soluble factors secreted 
by astrocytes, using such techniques as mass spectrometry and 
chromatographic techniques, whilst laborious would prove invaluable in 
further optimizing BBB models.
In contrast to other investigators the aim of the studies has been to utilize 
only primary cultures or PBMVECs retrieved from cryopreservation and 
not early passage cells where phenotypic drift can become an issue. 
Primary monolayers cultured in the absence of astrocyte factors retained 
modest barrier restrictivness with sucrose permeabilities > 10 x 10'6 cm.s1
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and with some discrimination between paracellular and transcellular 
pathways (ratio sucrose:diazepam ~ 2). This is superior to primary bovine 
cultures (sucrose permeability 10-24 x lO'6 cm.s'1), primary rat cultures 
(sucrose permeability with C6 co-culture 18 x 10-6 cm.s1), immortalized rat 
cells (sucrose permeability -  35 x 10-6 cm.s1) and immortalized murine 
models (sucrose permeability with C6 co-culture ~ 20 x 10-6 cm.s1). Co- 
culturing PBMVECs with astrocyte factors followed by a switch procedure 
and exposure to modulators of cAMP led to a significant enhancement of 
paracellular barrier restrictiveness as evidenced by low absolute 
permeabilities to sucrose of ~ 7.5 x lO^cm-s*1 in PBMVECs co-cultured 
with C6 and subject to the switch procedure. It is worth noting that the 
permeability and bioelectric properties of PBMVECs examined in this 
chapter were all made on ‘small’ Transwell™ inserts (surface area 0.33 cm2) 
to provide a high-throughput model of the BBB. Our own studies[85] have 
shown that when PBMVECs are cultured on large inserts (4.7 cm2), a 
greater restriction in the paracellular pathway is observed particularly with 
astrocyte co-culture Table 3.12. As previously described this is largely due 
to the relatively small ratio of monolayer surface area to transverse area at 
intercellular junctions (leakiest area) in small inserts compared to large.
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Table 3.12 Permeability coefficients for sucrose and propranolol across PBMVEC monolayers 
cultured on large inserts (4.7 cm2)  either alone or in the presence o/C6 co-culture or exposed 
to C6 astroglial factors during growth. Adapted from [85], PBMVECs grown on large inserts 
co-cultured with C6 and undergoing a switch procedure with cAMP modulation have a 
transcellulanparacellular discrimination ratio of ~ 11.5 this compares ~ 3 under the same 
conditions but grown on small inserts.
Blood-brain Permeability co-efficient Ratio
barrier model  f x IQ-6 cm-c<)_ propranoloksucrose
________________________ f!4Cl Sucrose [3H1Propranolol_________________
PBMVECs 12.1 ± 1.3 25.4 ±1.8 2.1 ± 1.4
PBMVECs exposed to C6 
astroglial factors with 
‘switch’ + cAMP
8.8 ± 1.2 26.0 ± 1.3 2.95 ± 1.1
PBMVECs with C6 co- 1.6 ± 1.0 18.4 ±0.7 11.5 ± 0.7
culture and ‘switch’ + cAMP
Blood-brain barrier specific endocytic, transcytotic and transporter 
systems that either deliver nutrients into brain parenchyma or efflux 
potentially toxic xenobiotics away from brain parenchyma are an essential 
feature of the BBB and their identification in any BBB model is a 
distinguishing feature compared to in-vitro models of non-cerebral origin. 
Brain microvasculature is highly selective with respect to vesicular 
mediated transport with morphometric studies revealing a decreased 
numerical density of vesicles within brain microvasculature. However, 
highly regulated endocytic and transcytotic processes at the BBB are an 
essential requirement for the delivery of solutes into brain parenchyma and 
are a feature of normal BBB physiology. Within PBMVEC cells, membrane 
vesicles of both caveolae and clathrin coated pit morphology were evident 
with the apparent density of caveolae greater than clathrin coated pits 
(although detailed morphometric analysis was not undertaken to confirm 
this). This is consistent with studies that have shown strong staining of
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caveolin-1 at the immunohistochemical level in brain microvascular 
endothelial cells as a component of the caveolar compartment[81]. Given 
the effects of astrocytic interaction on PBMVEC cell phenotype, it is not 
unreasonable then to question if  astrocytes have an effect on the expression 
of caveolin-1 which, given the direct association of this integral membrane 
protein and key structural element with caveolae, may subsequently lead to 
changes in numerical density of caveolae vesicles or indeed alterations in 
topography. Immunoblot analysis of caveolin-1 revealed strong expression 
in freshly isolated primary, cryopreserved primaiy and first passage 
PBMVECs that was not affected by either co-culture with astrocytes or 
exposure to astrocyte conditioned medium. The phosphoiylated form of 
caveolin-1 demonstrated strong expression in cryopreserved primary and 
first passage PBMVECs and was not affected by exposure to astrocytic 
factors. However, expression of phosphorylated caveolin-1 in freshly 
isolated PBMVECs was consistently negligible. Whilst evidence is beginning 
to emerge that an up-regulation in phosphorylated caveolin-1 may be 
associated with BBB breakdown, this is normally accompanied by up- 
regulation in total caveolin-1 [92]. This was not observed in cryopreserved 
primary or first passage cells. It is curious that in non-brain endothelia, an 
up-regulation in phosphorylated caveolin-1 (with total caveolin-1 
remaining consistent) is associated with increased caveolae vesicle budding 
and with increased vesicle internalization and therefore reflects the 
inherent endocytic capacity of the cell[93]. This warrants further 
investigation in porcine brain microvascular endothelia.
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Carrier transporters play a key role in nutrient and drug entry and efflux 
from the brain. Whilst the pig genome is not fully sequenced, a range of 
putative genes for carrier transporters of pharmaceutical interest have 
been identified and mRNA transcripts for these transporters were 
examined for. Positive expression was confirmed for drug efflux 
transporters (MDR-1, MRP1 and BMDP), cation transporters (OCT-1) and 
cationic and neutral amino acid transporters (CAA-1 and NAA-1 
respectively). Additionally, positive expression was confirmed for the long 
form of leptin receptor (OB-Rb), which has a long intracellular domain 
essential for signal transduction purposes. Ob-Rb, expressed within the 
cerebellum and hypothalamus on neuropeptidergic neurons, plays a key 
role in the regulation of food intake and energy expenditure[94, 95]. Its 
presence within brain microvascular endothelia is curious and requires 
further exploration since it is the short form, OB-Ra, that is thought to be 
the predominant receptor form at the BBB and is responsible for leptin 
transport into the brain[96]. The presence of the organic anion 
transporting polypeptide transporters OATP-A and OATP-C and the 
multidrug resistance transporter MRP2 could not be detected. Whether 
MRP2 is truly absent at the blood-brain barrier is a topic of intense debate 
with many laboratories failing to detect MRP2 within brain microvascular 
endothelia either at the mRNA transcript or protein level (reviewed in 
[97]). However, in certain disease states, for example epilepsy, unequivocal 
immunohistochemical staining has been observed, particularly in rats [97]. 
The expression and topography of drug resistance transporters at the BBB
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remains a controversial subject since investigations into their presence 
have often yielded variable and conflicting results depending on both 
culture conditions and species. A general consensus suggests P-gp, MRP2, 
MRP4, MRP5 and BCRP are expressed on the luminal membrane pumping 
xenobiotics out of the brain, whilst MRP1 is located on the basal membrane 
pumping into the brain parenchyma[98f 99]. It is widely accepted that in- 
vitro brain microvasculature, both primary and continuous, retain 
relatively poor efflux transporter activity compared to the in-vivo 
counterpart Studies to determine P-gp activity in PBMVECs highlighted a 
strong and active P-gp efflux as evidenced by Western blot signal and 
functional data using the P-gp substrate rhodamine-123 and the selective 
P-gp inhibitor verapamil. It is difficult and indeed sometimes misleading to 
make direct comparisons between in-vitro and in-vivo transporter activity, 
however in P-gp knockout mice (m drla -/-) an approximate 10-fold greater 
accumulation of digoxin is observed compared to wild-type mice; the 7-fold 
greater retention of rhodamine-123 in PBMVECs with P-gp chemically 
knocked out using verapamil compares favourably with this[100].
Having successfully isolated and characterized a primary BBB model that 
retained a phenotype similar to the in-vivo BBB, a series of phage display 
studies were conducted against the luminal surface of in-vitro monolayers 
of PBMVECs, and for comparison two immortalized cell models, mouse 
b.End3 and rat RBE4. In preliminary studies to determine whether 
monolayers could be used for transendothelial screening of phage display
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libraries, BBB models were not found to be restrictive enough to prevent 
insertless phages crossing the cell monolayers. This was supported by 
other studies concurrently undertaken within the laboratory by a colleague 
who showed primary alveolar epithelial monolayers displaying varying 
TEER of 200 - 1000 fLcm2 afforded varying degrees of translocation of 
insertless phage from apical (luminal) to basal surfaces. In other words the 
tighter the paracellular barrier then the less wild-type phage was 
translocated. In contrast using an ex-vivo lung model where the alveolar 
barrier is fully intact within the correct 3-dimensional architecture showed 
the insertless phage were essentially excluded from transport across the 
barrier[101]. Therefore a series of panning studies were conducted against 
confluent BBB monolayers with the aim of isolating peptides that bound 
brain microvasculature to increase residency time of a therapeutic cargo at 
the BBB. These studies were not particularly successful given that a 
common peptide or peptide motif was not identified. This probably is not 
that surprising given the landscape of the apical plasmalemma and all the 
different proteins and receptors that are on display for interaction. 
However, of note a peptide with sequence AC-NTSVSKW-CGGGS was 
identified in phage panning studies against b.End3 that shares homology 
with the V3 loop of HIV GP120. William Banks has shown in a series of 
elegant in-vitro and in-vivo studies that GP120 is a potent stimulator of 
adsorptive endocytosis at the BBB in a species independent manner and is 
at least partially responsible for free HIV virus uptake into the brain[102- 
104]. This may only be a partial route of entry given the studies of
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Kanmonge which have shown that GP120 is able to downregulate a host of 
tight junctional proteins that include ZO-1, ZO-2 and occludin which results 
in loss of paracellular restrictiveness at the BBB[105-107]. Unfortunately, 
in-vivo studies in the rat suggested that peptide AC-NTSVSKW-CGGGS does 
not enhance phage uptake into the brain however a detailed examination of 
its distribution in mice, the species from which its was identified in phage 
studies, is probably needed before it can be totally discounted.
In conclusion, this chapter has described the characterisation of a primary 
cell culture model of the blood-brain barrier derived from porcine tissue. 
This characterization focused on monolayer barrier properties, specifically 
the discrimination of the paracellular pathway from the transcellular 
pathway, and upon endocytic transport pathways and carrier mediated 
transporters and assessed the influence of various astrocyte co-culture 
conditions. The astrocyte factors were provided by either co-culture with 
C6 astroglioma cells or by collecting secreted factors from C6 cells and 
supplementing growth medium with these factors. The C6 astroglioma cell 
line is widely used, described in the literature as a surrogate for primary 
astrocytes. Consistent with previous reports successful isolation and 
culture of primary brain microvascular endothelial cells was achieved, with 
cells retaining phenotypic and functional characteristics similar to the in- 
vivo cell type. In contrast to previous reports primary cells were 
successfully cryopreserved for periods up to 12 months without loss of 
phenotype. Caveolae membrane vesicles were a prominent feature of the
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phenotype as was the formation of tight junctional complexes. The 
presence of astrocyte factors either within conditioned medium or utilizing 
co-culture system was essential in generating a highly restrictive barrier 
capable of discriminating transcellular and paracellular markers. Exposure 
to astrocyte factors did not appear to overtly affect the morphological 
appearance or topography of vesicles nor alter the expression of Caveolin-1 
although it must be noted that the level of phosphorylated caveolin-1, an 
important marker of caveolae endocytic function, varied between freshly 
isolated brain microvascular cells in primary culture or first passage. RT- 
PCR was used to undertake a comprehensive transport characterization 
using primers that were designed against known porcine genes and mRNA 
transcripts were identified for ABC efflux transporters, glucose and amino 
acid transporters, leptin receptor and tight junctional proteins. Functional 
expression of P-glycoprotein mediated efflux was also confirmed in this 
model. These studies progress the characterization of a valuable primary 
brain microvascular culture model that w ill find resource with academic 
and industrial researchers especially since the primary cells can be 
cryopreserved for extended periods of time and recovered by the user 
when required without loss in phenotype or functionality. PBMVECs, along 
with b.End3 and RBE4 cells, were used in phage display studies focusing on 
identifying peptides that interact with the blood-brain barrier but such 
studies did not reveal any candidate peptides.
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4.1 Introduction
4.1.1 Delivery of peptides to the brain
Macromolecules including peptides and proteins show great potential as 
therapeutic agents to treat a wide variety of brain disorders. However, for 
many of these therapeutics the physical and metabolic barriers, as well as 
the efflux carriers expressed at high levels in the brain microvasculature 
present a major obstacle to the entry o f biologies into the brain. In addition, 
systemic pharmacokinetic issues such as extensive binding to plasma 
proteins, high systemic clearance or small volume of distribution which 
give rise to a short elimination half-life reduce the exposure of a potential 
therapeutic to the brain microvascular cells. Nevertheless, many 
endogenous regulatory peptides and proteins do cross the BBB via 
endocytosis or via specific, saturable transport systems to achieve active 
concentrations in the brain. As a consequence, the BBB vascular barrier 
may afford opportunities for the therapeutic delivery of macromolecules 
not least due to the dense distribution of microvasculature at the BBB 
(intercapillary distances of — 40 pm) that means, w ith sufficient vascular 
exposure, peptides and proteins that transcytose the barrier have ready 
access to the entire brain.
The exposure of brain microvasculature to a therapeutic is largely a 
function of its systemic pharmacokinetics and some of the difficulties 
associated w ith brain delivery can be negated by tailoring the systemic 
pharmacokinetic (PK) profile o f the therapy. Brain-derived neurotrophic
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factor (BDNF), a ~ 14 KDa protein that supports the survival, growth and 
differentiation of new neurons, has a saturable transporter at the BBB 
delivering BDNF to brain parenchyma[l] but unfavourable systemic PK 
issues including a short half-life and an unstable enzymatic profile result in 
limited exposure of brain microvasculature to BDNF[2]. Whilst the 
development of complex carrier mediated systems for the delivery of BDNF 
has been an active area of research [3-7], modifying the systemic 
pharmacokinetic profile of BDNF may lead to significant increases in brain 
concentrations comparable to targeted BBB delivery vector conjugates.
Whilst for certain therapeutics it may be possible to utilise non-vascular 
routes into the brain that effectively bypass the BBB such as the nasal 
passages, the leakier (cf BBB) choroid plexus, the circumventricular organs 
and via direct intrathecal and intracerebroventricular administration, it is 
clear from the literature that in the main the exploitation of endocytic, 
transcytotic and carrier mediated transporter pathways remain the focus of 
attention in delivering biomacromolecules across the BBB.
4.1.2 Evidence of endocytic activity at the BBB
Morphometric studies have been undertaken to determine microvascular 
vesicular densities within a broad range of tissues across a range of species 
(reviewed in [8]). In the main vesicular densities are reported from 
electron microscopic examination of tissue obtained from whole animals 
perfused with a fixative. Whilst there are issues in obtaining robust
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quantitative data by such an approach due to procedural artefacts, the 
consensus is that BBB vesicle density ranks amongst the lowest reported 
for all tissue types (see Table 4.1).
Table 4.1 Density of endothelial vesicles in capillaries from various tissues (adapted from[8])
Group Tissue Number of vesicles per pm2
Low density Brain 14.00 ± 13.20
Testis 8.80 ± 5.02
Ovary 10.60 ±3.98
Medium density Pancreas 41.7 ± 13.74
Intestine 33.3 ± 12.73
Lung 30.9 ± 15.52
High density Cardiac muscle 70.35 ± 20.70
Skeletal muscle 92.6± 22.41
Diaphragm 66.4 ± 20.65
A confounding issue in morphometric analysis is that some of the apparent 
cytoplasmically-free endocytic vesicles remain connected to the 
plasmalemma. For example three-dimensional reconstructions of ultrathin 
tissue sections reveal that nearly all of the apparently free vesicles are 
attached to the cell membrane and most vesicles are fused with each 
o th e r[9 -ll]. Nevertheless, electron micrographs of BBB endothelia 
generally depict individual, free vesicles approximately 50 -  100 nm in 
diameter, in addition to omega-shaped 'caveolae-like' invaginations of the 
plasmalemma. Whilst caveolae appear to be the predominant vesicle type 
at the BBB[12,13], several studies have reported expression of clathrin and 
observation of clathrin coated pits w ithin in-vitro BBB models and isolated 
capillaries[12-14]; functionality of these clathrin vesicles at the BBB has 
been evidenced by the internalisation of transferrin receptor[15-19].
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A significant number of studies have been conducted demonstrating a 
variety of endocytic mechanisms that are evident at the BBB. Using classical 
markers such as HRP[20], dextran and lucifer yellow[21-23], fluid phase 
endocytosis has been observed both in-vitro and in-vivo within brain 
endothelia. However, the ubiquity of fluid phase endocytosis throughout all 
tissue cell types coupled with a low rate of turnover does not make for an 
appealing therapeutic delivery route into the brain. Adsorptive endocytosis 
(AE) at the BBB is better defined, occurring at both a greater rate and 
extent than fluid phase; for example, within in-vivo mouse brain 
microvasculature[24] wheat germ agglutinin (WGA), an established marker 
of AE, undergoes endocytosis at a rate 10-fold greater than HRP. More 
relevant to therapeutic deliveiy however, are the diverse range of 
macromolecules that have been identified to undergo receptor mediated 
endocytosis and transcytosis (RMT) at the BBB. These include, amongst 
others, the transferrins, various hormones, cytokines, microorganisms and 
toxins (for a detailed review see [25]). In principle exploiting an RMT 
pathway should afford selective and potentially efficient delivery to brain 
parenchyma. Whilst the development of strategies to exploit endocytic and 
transcytotic pathways are still in their infancy, impressive results have 
been documented where the targeting of particular receptors has afforded 
significant delivery of a therapeutic cargo to the brain (see Table 4.2 for 
examples).
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Table 4.2 Selection of key studies that highlight the use of RMT to deliver a payload Into the brain. TfR -  transferrin receptor; OX-26 -  mouse MAb to rat TfR; 803 
- rat MAb to mouse TfR; CRM197 -  mutated diphtheria toxin; LRP -  low density lipoprotein receptor-related protein; P97 -  melanotransferrin; IR -  insulin 
receptor.
Target
Receptor
BBB Targeting vector Study
species
Payload Comments Ref
Rat TfR OX-26 MAb (Hydrazone linker) Rat Methotrexate Up to 47-fold greater brain penetration with conjugated MTX vs. [26]
(MTX) free MTX
Rat TfR OX-26 MAb (Biotin/avidin) Rat VIP 65% increase in cerebral blood flow; no increase with free VIP [27]
Rat TfR OX-26 MAb (Chemical linkage) Rat Nerve growth Prevents loss of striatal choline acetyltransferase immunoreactive [28]
factor neurons following quinolinic acid administration
Rat TfR OX-26 MAb (Biotin/avidin) Rat Polyamide nucleic 28-fold increase in brain uptake compared to PNA alone [29]
acids (PNA)
Rat TfR OX-26 MAb (Disulphide bridge) Primates Recombinant CD4 5-fold increase in CD4 brain uptake cf. non conjugated [30]
Rat TfR OX-26 MAb (PEGylated Rat Daunomycin Increased brain uptake of 0X26 conjugated liposomes versus free [31]
liposomes) daunomycin or un-conjugated liposomes
Rat TfR OX-26 MAb (PEGylated Rat Beta galactosidase Beta galactosidase expression throughout the brain. Luciferase [32]
liposomes) & luciferase gene expression 30- 100-fold greater than naked plasmid
Rat TfR Rat anti-TfR (IgG3; Rat Antisense peptide- Brain uptake of antisense therapy 15-fold greater when conjugated [33]
biotin/avidin) nucleic acid to Ab
Rat TfR Human Tf (PEGylated Rat Azidothymidine 3-fold increase in AZT concentration in the brain with Tf [34]
nanoparticles) conjugated nanoparticles compared to un-conjugated.
Mouse TfR 8D3 MAb (Biotin/avidin) Mouse PNA to huntingtin 3-fold increase in brain uptake with conjugated PNA vs. free [35]
HB-EGF CRM 197 (Primary amine) Guinea
gene
HRP 2-fold increase in HRP activity within an in-vitro model of the BBB [36]
Pig when conjugated to CRM917; increased uptake in-vivo
Human IR 83-14 MAb (Biotin/avidin) Monkey (3-amyloid peptide 10-fold increase in brain volume of distribution compared to free [37]
LRP P97 (cross-linking) Mice Adriamycin 20-35% increase in survival of mice with intracranial tumours [38]
compared to free adriamycin
LRP Polysorbate80 apolipoprotein E Mice Dalargin; Variety of biological responses within the CNS cf. uncoated [39,40]
coating (nanoparticles) loperamide, 5-FU nanoparticles
co
00
Chapter 4
4.1.3 Cell penetrating peptides
In the early 1990s intense research was ignited into the use of cell 
penetrating peptides (CPPs) or protein transduction domains (PTDs) as 
they have been termed, for the intracellular delivery o f therapeutic 
material. This followed the observation that short peptide motifs (16 -  20 
AAs) from the homeodomain of Antennapedia protein w ith in  Drosophila 
species rapidly transfer across plasma membranes in a receptor-, 
temperature- and energy- independent manner [41, 42]. CPPs are short 
amphiphilic amino acid motifs (< 30 amino acid residues) derived from 
native proteins or modifications thereof and represent the minimum amino 
acid m otif that facilitates membrane translocation. W hilst CPPs are 
represented by a diverse collection of amino acid motifs, they share several 
common attributes notably a highly cationic chemistry w ith preserved 
amphipathicity. The early cell biology studies that suggested endocytic 
processes do not play a significant role in CPP internalization [41-44] were 
soon disputed and it is now recognised that many CPPs do display a 
temperature- and energy- dependent uptake process characteristic o f yx) 
endocytosis and, at least for some CPP^ endocytdsis can be considered tj*e 
major if^ rp o t exclusive mechanism of plasma cell membrane 
translocation[45]. ^  ^
&  c C  ^  ^
Surprisingly there are only a handful o f reports detailing the exploitation of 
CPPs to enhance the delivery of therapeutic cargos to the brain despite 
pharmacokinetic and pathological evidence of a HIV-derived CPP (Tat)
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penetrating into brain parenchyma[46]. The BBB associated CPP research 
to date has been pioneered by Rouselle's laboratory who have reported 
using various CPPs to enhance brain uptake o f the anticancer agent 
doxorubicin[47-49], the beta-lactam antib iotic benzylpenicillin[50], the 
encephalin analogue dalargin[51], and the opioid analgesic morphine-6- 
glucoronide[52]. Perhaps it  is the ubiquitous uptake o f CPPs by all tissues 
that has prevented significant investment in optim izing the delivery o f CPPs 
to the CNS.
4.1.4 Phage display and BBB delivery
The molecular diversity o f receptors on the lum inal endothelial cell surface 
o f different vascular beds represents an exciting opportunity for targeted 
molecular therapy and imaging [53]. The inherent accessibility o f vascular 
endothelium to the blood coupled w ith  the heterogeneity o f receptor 
expression and localization may allow the selective delivery of therapeutics 
to particular tissue vasculature. Combinatorial technologies such as phage 
display can be screened against endothelial surfaces from specific tissue 
types either in-vitro or in-vivo and may offer greater diversity for 
interaction compared to classical techniques such as proteomic or antibody 
based mapping via mass spectrometry or hybridoma technology. To date a 
number of vascular beds have been explored by phage display in normal 
and pathological tissues w ith  varying degrees of success (for detailed 
reviews see [54-60]). The prim ary aim of such studies has been the 
identification o f peptides that either (i) increase residency tim e at a
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particular vascular bed or (ii) mediate the transport of a cargo across a 
biological barrier. A good example o f (i) is the phage display identification 
o f peptides that contain an av-integrin binding m otif (NCR)[61] that is 
recognised to promote cell adhesion[62]. When coupled to doxorubicin the 
peptide enhanced drug efficacy against human breast caner xenografts in 
nude mice and also reduced systemic toxicity[61]. An example of the latter 
(ii) is the phage display selection o f a peptide w ith  sequence 
CWWMGFQQVC that interacts w ith  polymeric I receptor[63] that mediates 
epithelial transcytosis o f polymeric immunoglobulins.
4.1.5 Objectives
In this chapter a series o f rat in-vivo phage display strategies were 
employed to identify peptides that mediate phage transduction across the 
blood brain barrier to gain access to the brain parenchyma and specifically 
to access brain grey matter. Subsequently, whole body tissue distribution 
studies were undertaken for a select peptide-phage clone compared to that 
o f insertless phages.
In parallel, an in-silico physiologically based pharmacokinetic model was 
developed and utilised to gain a quantitative perspective o f the extent of 
brain delivery that can be expected to be achieved for macromolecules w ith 
different systemic pharmacokinetics and w ith  different affinities for brain 
parenchyma, i.e. as if  a BBB targeting vector was active. These in-silico data
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were used to provide context to the peptide phage tissue distribution 
studies.
4.2 Materials and methods
4.2.1 Materials
Materials used in phage studies are detailed in Chapter 2.
4.2.2 Animals
Male SD rats (450 -  500 g) were purchased from Harlan Laboratories 
(Bicester, UK). Rats were housed in regular cages and conditions and were 
acclimatized for 1 week before studies conducted. A ll rats had food and 
water ad libitum. All experiments were conducted using protocols 
approved by Cardiff University Joint Biological Services Unit.
4.2.3 In-vivo selection of brain homing peptides
The details o f the phage display selection methodologies employed for the 
identification of brain homing peptides are detailed in Figure 4.1.
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Strategy 1
1). IV . administration of 10’1 
ptus ot Ph.D.C7C peptide library.
2). After 15 mns, rat is perfused 
with 100ml ice-cold saline followed by 
100ml glycine buffer (pH 2.2)
3). The brain alone is harvested 
The capillaries are depleted, the 
accessory organs are removed 
and the grey matter collected 
The grey matter is homogenised 
and washed
4) Phage associated with the 
brain grey matter are amplified 
and purified and serve as input
tor the next round (total x3 rounds).
5). Finally, brain targeting phage 
are sequenced
Strategy 2
1). I V administration of 1011 
plus of Ph D -C7C peptide library
2) After 15 mms. rat is perfused 
with 100ml ice-cold saline
3) Organs are harvested, 
homogenised and washed 
individually.
4 ). Phage within the tissue 
samples are amplified, purified 
and pooled, serving as input 
lor the next round (total of 4 
rounds
5) After 4 iterative rounds, brain 
specific phage are isolated in a 
final fifth round. In round 5 only the 
phage associated with the brain from 
round 4 are injected.
After 15 mms, rat is perfused 
with ice-cold saline fol lowed by 
a low pH glycine buffer
The brain alone is harvested 
The capillaries are depleted, the 
accessory organs are removed 
and the grey matter collected
6). Brain targeting phage
and phage associated with the 
capillaries are sequenced
BRAIN
K DNE\
L IV E R
Gi TRACT c
Q m a ll A. 1 a r n ao i  I k ill a  L arg e ;
intestine
Figure 4.1 Schematic representation of in-vivo bio panning procedures used to isolate brain 
homing peptide-phages. The Ph.D.™-C7Clibrary was injected into male SD rats then either: (i) 
In “Strategy 1“ the brain was harvested following saline and glycine perfusions to remove 
vascular bound phage. The accessory organs were removed, the capillaries depleted and the 
grey matter homogenized and washed. The phages associated with the grey matter were 
amplified, purified and served as input in the next iterative round (three rounds in total) 
before phages within grey matter and capillaries were sequenced, OR (ii) In "Strategy 2" all 
the major organs were harvested, homogenized and washed, phages recovered and then 
amplified, purified and pooled to serve as input in the next iterative round (four rounds in 
total). A final fifth round was used to select brain specific peptide phages whereby only the 
brain-associated peptide phages from round four were injected. The grey matter was isolated 
from the capillaries and the peptide-phage associated with both grey matter and capillaries 
sequenced.
LUNG
HEART
LIVER
Gl TRACT 
Small & Large 
Intestine
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• Standard selection of phage libraries in-vivo (Strategy 1)
Male SD rats (450 -  500 g) were injected intravenously w ith 100 pi o f saline 
(0.9%) containing 1 x 1011 pfiis o f the Ph.D.™-C7C cyclised 7-mer disulphide 
constrained peptide-phage library. A fter 15 minutes circulation time the rat 
was perfused through the pulm onaiy artery w ith 100 ml ice-cold saline 
followed by 100 ml ice-cold glycine buffer (pH 2.2) to strip the vasculature 
of binding phages. The brain was removed and stored in ice-cold DMEM 
containing 1% BSA and 0.5 mM PMSF (DMEM-PI) to protect phage from 
proteolytic degradation. White matter and brain accessory organs were 
carefully dissected away from grey m atter and discarded. The grey matter 
was then homogenized in a Dounce homogenizer and washed 3x w ith 5 ml 
of DMEM-PI; tissue was centrifuged at 3000g for 5 mins between each 
wash. The vasculature was depleted from the grey matter by centrifuging 
the tissue on a 33% percoll gradient (6000g, 10 mins) and collecting the 
grey matter fraction that floats to the surface. The grey matter was then 
incubated for 15 mins at room temperature w ith 2ml of an overnight 
culture of E. coli (incubated at least 18 hrs). A lOOpl aliquot was removed 
for plaque assay and the remaining culture added to 20 ml LB broth and 
incubated for 4.5 hours at 37°C. Phages were purified using a double PEG 
precipitation as previously described in chapter 2 and inputted into 
subsequent rounds of selection; in total, three rounds of selection were 
completed. An aliquot of phages associated w ith brain grey matter and 
capillary vasculature from the final round of panning were gene sequenced
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using standard Big Dye v3.1 chemistry on an ABI Prism 3100 genetic 
analyzer.
* Synchronous selection of phage libraries in-vivo (Strategy 2)
Male SD rats (450 -  500 g) were injected intravenously w ith 100 pL of 
saline (0.9%) containing 1011 plaque forming units (pfus) o f the Ph.D.™-C7C 
library. After 15 mins the rat was perfused with 100ml ice-cold saline 
through the pulmonary arteiy. Major organs (brain, lung, heart, liver, 
kidneys, spleen and testicles) were removed and stored in DMEM-PI over 
ice. The organs were homogenized individually in a Dounce homogenizer 
and then amplified separately as described in Strategy 1. Phages were 
purified by a double PEG precipitation procedure. Amplified phages from 
each organ (1 x 1010 pfus) were pooled and used for the subsequent round 
of in-vivo selection. After four such rounds, a brain selection round was 
performed where only brain-associated phages from round 4 were injected 
(1 x 1011 pfus). After a 100ml ice-cold saline perfusion followed by a 100 ml 
ice-cold glycine buffer (pH 2.2) perfusion to strip the vasculature of binding 
phages, the brain was harvested. White matter and brain accessory organs 
were removed and, as described for Strategy 1, the grey matter was 
homogenized, the vasculature depleted and the phage associated with grey 
matter and capillary vasculature recovered. An aliquot of the final fifth 
round phages associated with brain grey matter or vasculature were gene 
sequenced using standard Big Dye v3.1 chemistry on an ABI Prism 3100 
genetic analyzer.
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42.4 In-vivo distribution of phages
1 x 1011 pfus each o f a selected lib ra ry  phage clone and insertless-M13 
phage were co-injected in to  male SD rats (total volume 100 pi). A t tim e- 
points 7 ,1 5 ,45 ,9 0  and 180 mins a blood sample was taken and the animal 
perfused w ith  100 ml ice-cold saline followed by 100 ml ice-cold glycine 
buffer. The brain, heart, liver, kidneys, spleen, large intestine (~  lg ), small 
intestine (~  lg ), muscle (~ lg  from  thigh) and testicles were harvested. The 
w hite  m atter and accessory organs were dissected from  the brain grey 
m atter and discarded. The grey m atter was homogenized, washed 3x w ith  
DMEM-PI and the vasculature isolated using a percoll gradient as 
previously described. A ll other tissue was homogenized and washed 3x 
w ith  DMEM-PI. The tissues were then incubated w ith  2ml o f an overnight 
culture o f ER2738 at room temperature fo r 15 mins before addition o f 8 ml 
o f LB broth fo r a fu rther 30 mins. Phage content was then determ ined by 
plaque form ation assay in the presence o f IPTG/X-gal in the top agar.
Pharmacokinetic parameters were calculated in Graphpad Prism by fittin g  
phage blood data to a biexponential equation, C(t) = Ae~ kAl + Be-^ 1, where 
C(t) = phage.ml*1 o f blood. The area under the blood concentration-tim e 
curve and tissue concentration-tim e curve (AUC) was calculated by the 
linear trapezoidal rule and blood clearance (CL) from  CL = Dose /  AUC 0-oo.
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4.2.5 Phage amplification errors
The expression o f peptides on the p ill coat protein o f M13 in the Ph.D.™- 
C7C library may result in amplification defects if  the displayed peptides 
block the interaction o f p ill w ith the f-pilus on E. coli. p ill on insertless 
phages has unrestricted access to the f-pilus such that for the same input of 
insertless and lib rary phages, am plification in E. coli for a given time may 
result in higher copy numbers o f insertless phages. This would 
overestimate the accumulation o f insertless-M13 in a tissue. To address this 
issue, 100 pfus each o f library phages and insertless phages were incubated 
w ith  2 ml o f an overnight culture of E. coli for 15 minutes after which 8ml of 
LB broth was added and the culture incubated for a further 30 minutes; this 
parallels the protocol undertaken to quantify phage numbers in tissues 
during distribution studies. A 1 ml aliquot o f culture was then removed and 
the number o f phages determined by plaque formation assays.
4.2.6 Tissue stability
To determine whether phage stability in different tissues impacted upon 
apparent in-vivo accumulation and distribution, the stability o f a library 
phage clone (AC-SYTSSTM-CGGGS) and insertless-M13 was determined in 
ex-vivo tissue and blood. Samples of blood (1ml), brain grey matter ( lg ) and 
liver ( lg ) were harvested from a term inally anaesthetised ra t The tissue 
was then homogenized in 1 ml pre-warmed DMEM (37°C); im portantly 
DM EM did not contain protease inhibitors. To each tissue or blood sample 
was added 2 x 1011 pfus o f either lib rary phage clone or insertless-M13. At
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pre-determined intervals (15, 45, 90 mins) a 200 pi sample of tissue or 10 
pi o f blood was removed and the number of phages in the sample 
determined by plaque formation assay. The number o f phages in the tissue 
or blood sample at each time point was compared to the number of phages 
in a DM EM only control.
4.2.7 Effects of perfusion on phage numbers
To ensure that saline and glycine perfusion did not damage the integrity of 
the brain vasculature to result in an apparent increased accumulation of 
phages, the uptake o f peptide-phages (AC-SYTSSTM-CGGGS) into grey 
matter was assessed w ith  and w ithout saline and glycine perfusions. 
Briefly, 1 x 1011 pfus o f phage were injected intravenously into two male SD 
rats. After 15 minutes, one o f the rats was perfused w ith 100ml ice-cold 
saline followed by 100ml glycine buffer and one rat was not perfused after 
exsanguination. The brains were then harvested and stored in DMEM-PI 
over ice. Grey matter was isolated as previously described and the 
capillaries depleted. Plaque form ation assay was used to determine the 
number o f phages in brain grey m atter and associated w ith capillaries.
4.2.8 Physiological based pharmacokinetic (PBPK) simulations
The structure o f the PBPK model developed and detailed in Figure 4.2 is 
based on a model reported in the literature [64]. Mass balance equations 
were w ritten for all tissue compartments based on drug partition into the 
tissue, assuming a w ell-stirred system w ith  perfusion rate lim ited
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distribution, and drug elimination due to tissue clearance in the eliminating 
compartment.
BRAIN r
BLOOD
HIGHLY PERFUSED 
TISSUE
POORLY PERFUSED 
TISSUE
EUMINATING TISSUE
Figure 4.2 Schematic overview of the compartments included in the PBPK model.
For the brain compartment and non-eliminating compartments, the 
differential equation had the following form:
dC r 1 
dt ~ Vt
O t C t iQr.Cbiood -  ——-------- CLt.Cblood Equation 4.1
kp
For the eliminating compartment, the differential equation had the 
following form:
d C a  =  — (q b C m m * -QuCt‘
dt Vei \  kp
Equation 4.2
For the blood compartment, the differential equation had the following 
form:
dCm" i  = -  CA)) Eq
dt VBlood
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The parameters in the equation re fer to blood flow  (Q), concentration (C), 
volume (V), extraction ratio  (E), tissue pa rtition  co-efficient (kp), clearance 
(CL) and tim e (t). The subscripts refer to tissue (T), cardiac output (Heart), 
blood (Blood), arteria l (A), venous (B) and elim inating tissue (El). 
Physiological parameters used in the model are detailed in Table 4.3.
Table 4.3 Rat physiological parameters used in whole body PBPK model (adapted from[65])
Organ Organ volumes per 
body weight f L/kg)
Organ blood volume (% 
cardiac output)
Compartment
Brain 0.0057 1.5 Brain
Uver 0.0366 1.6 Eliminating
Kidney 0.0073 19 Eliminating
Heart 0.0033 5 High Perfusion
Lung 0.005 - High Perfusion
Spleen 0.002 1.7 High Perfusion
Gut 0.027 14.4 High Perfusion
Other 0.1577 9.41 High Perfusion
Muscle, skin. 0.636 47 Low Perfusion
bone
Model simulations were conducted in Stella (Version 9.03; Isee Systems, 
Lebanon, USA) a numerical integration software package that 
sim ultaneously solves systems o f coupled firs t-o rder d ifferentia l equations; 
a schematic o f the model can be seen in F igure 4.3.
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T tftftf
Figure 4.3 Schematic of the pharmacokinetic model built in Stella to predict brain 
concentrations of drug.
A series of concentration vs. time-course curves were simulated for 
changing affinity for the brain and changing extraction ratio within the 
eliminating compartment. The tissue affinities within the highly perfused 
and poorly perfused compartment were kept at a constant value of 2 based 
on the assumption that any targeting moiety would increase affinity for 
brain alone.
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4.3 Results
4.3.1 Analysis of in-vivo phage recovery and peptide sequences
In-vivo phage tissue distribution studies have shown wild-type insertless 
phages are essentially excluded from entry into brain parenchyma[66, 67]. 
If the uptake of peptide-phages into brain parenchyma is significantly 
increased in comparison to insertless phages, then this may be a direct 
consequence of the displayed peptide and would be a sequence-specific 
event The translocation process may involve a non-toxic action and as 
such, find u tility  in the delivery of experimental therapeutic 
macromolecules to the brain.
W ithin this chapter a series of in-vivo panning studies were undertaken by 
injecting peptide phage library into the systemic circulation of rats, the aim 
o f which was to isolate brain homing peptides. Those peptide-phages that 
may be selectively associated w ith brain parenchyma were subsequently 
recovered and the displayed peptides identified. The details of these 
selection strategies are outlined in Figure 4.1. Isolation strategy 1 was 
designed solely to select for those phages that enter brain parenchyma. In 
contrast, isolation strategy 2 was designed to simultaneously select for 
phages that enter different tissues in a single ra t Strategy 2 has previously 
been exploited by Renata Pasqualini[68] and co-workers who identified 
peptide motifs that were specific for particular organs. Its reported 
advantage is the minimization o f animal numbers required to identify 
peptide phages that 'home' to different tissues. In both strategies a saline
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perfusion was employed to remove the blood from the tissues and as such 
the freely circulating peptide-phages. This was followed by a low pH glycine 
perfusion to strip the vasculature o f binding peptide phages. Subsequently 
the brain was harvested, brain white m atter and brain accessory organs 
(choroid plexus, brain stem, circum ventricular organs etc) were removed 
and brain capillaries were depleted using established techniques[69]. 
These processes afforded the recovery o f phages associated w ith grey 
matter and not other areas o f the brain; many CNS disorders are localized 
to grey matter, which contains the neural cell bodies that process sensory 
and motor information.
Analysis o f phage recovery from tissues analysed in isolation strategy 1 
rounds 1-3 i.e. where only phages from the brain were harvested and 
injected in iterative rounds o f panning (F igure 4.4) showed that there was 
a progressive increase in the percentage o f phage input recovered from 
brain grey matter. This is in contrast to the other organs harvested that, 
w ith  the exception o f liver, showed decreased accumulation w ith 
progressive selection rounds. Combined, these data indicate enrichment 
for a population o f peptide-phages that home to the brain.
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Figure 4.4 Peptide phages recovered from organs in isolation strategy 1. The number of 
phages recovered from brain grey matter progressively increases between selection rounds. 
This is in contrast to the other organs harvested where the number of phages decreases. 
These data imply enrichment of a population of peptide phages that home to the brain.
Analagous data are not presented for isolation strategy 2 because all the 
phages recovered from each organ were amplified in each panning round. 
Large variations in the number of phages recovered from each organ would 
mean that removing samples for titration before amplification would 
deplete the recovered phages unequally from each organ and may bias later 
rounds of selection.
Increases in phage recovery with successive rounds of selection in isolation 
strategy 1 Figure 4.4 gave confidence that the selection protocol was
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successful and therefore an extensive number of phage clones were gene 
sequenced from strategy 1 and strategy 2 to determine the identity of the 
displayed peptide. Table 4.4 highlights a subset o f the sequences analysed 
from strategy 1 and 2 that were present in multiple copy number in the 
phage population isolated. In isolation strategy 1, the most common 
sequences identified were AC-PDVPHPA-CGGGS and AC-STASTQA-CGGGS, 
each present as 1.5% of the population recovered. In strategy 2, two 
peptide-phages were recovered AC-SYTSSTM-CGGGS and AC-SNTSSTT- 
CGGGS, sharing a common m otif AC-SxTSSTx-CGGGS and which combined 
comprised — 25% of the recovered population. AC-PDVPHPA-CGGGS from 
isolation strategy 1 and AC-SYTSSTM-CGGGS from isolation strategy 2 
were also recovered from the depleted brain capillary fraction as well as 
from brain grey matter. This is a significant find as it  supports the 
hypothesis that phages displaying certain peptide sequences may gain 
access to grey matter through an intracellular route at the BBB rather than 
bypassing it via leaky paracellular areas of the BBB or via other barriers 
such as the choroid plexus.
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Table 4.4 Amino acid sequences of brain homing peptides isolated in multiple copy number 
from strategies 1 and 2. Data are presented as percentage of total colonies sequenced: (i) 
Strategy 1: ~ 450 colonies sequenced from grey matter and 48 colonies sequenced from 
microvasculature; (ii) Strategy 2: ~ 150 colonies sequenced from grey matter and 48 colonies 
sequenced from microvasculature.
Peptide sequence Frequency Strategy
Grey Matter Brain Microvascular 
Capillaries
AC-SYTSSTM-CGGGS 17% 19% 2
AC-SNTSSTT-CGGGS 6% - 2
AC-TIENPRA-CGGGS 6% - 2
AC-PDVPHPA-CGGGS 1.5% 13% 1
AC-STASTQA-CGGGS 1.5% - 1
AC-HTLHGSA-CGGGS 1.3% - 1
AC-TISFDRY-CGGGS 1.3% - 1
AC-KQAASQQ-CGGGS 1% - 1
AC-NARTSLF-CGGGS 1% - 1
AC-EPEKPRT-CGGGS 1% - 1
AC-SVSSYNS-CGGGS <1% - 1
AC-DATNLTM-CGGGS <1% - 1
AC-NRTAAPL-CGGGS <1% - 1
AC-SLMKSPE-CGGGS <1% - 1
AC-VRANMTA-CGGGS <1% - 1
AC-TDPGQSA-CGGGS <1% - 1
AC-TRTSHHN-CGGGS <1% - 1
AC-DSTQTRQ-CGGGS <1% - 1
AC-LPTAQNS-CGGGS <1% - 1
AC-PMSQNSL-CGGGS <1% - 1
AC-HQGVGTT-CGGGS <1% - 1
AC-NREHPNT-CGGGS <1% - 1
AC-PVHMARN-CGGGS <1% - 1
AC-HNQIYPQ-CGGGS <1% - 1
AC- PNSNSKL- CGGGS <1% - 1
AC-PNNHSRH-CGGGS <1% - 1
AC-TQADLAK-CGGGS <1% - 1
AC-HQTSLLM-CGGGS <1% - 1
AC-VPHDRTS- CGGGS <1% - 1
AC-IPSGLLQ-CGGGS <1% - 1
AC-NNMTNTVI-CGGGS <1% - 1
AC-QGHQSGS-CGGGS <1% - 1
AC-TQPARSQ-CGGGS <1% - 1
AC-PNSMHSS-CGGGS <1% - 1
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Increasing affinity for target is generally accompanied by the emergence of 
a common m otif in the amino acid sequences of virtually all the displayed 
peptides e.g. HPQ for streptavidin binding peptides. To determine any 
patterns w ithin the amino acid residues of the displayed peptides, an 
analysis was undertaken to determine the incidence of each amino acid at 
the seven randomized positions in the displayed peptide. The results for 
both isolation strategy 1 and isolation strategy 2 of this analysis can be seen 
in Figure 4.5 and Figure 4.6 respectively. It is quite apparent in both 
strategies that serine (S) and threonine (T) constitute a significant 
percentage of the total residues for the clones sequenced and particularly 
serine at residues 1, 4 and 5 i.e. AC-SXXSSXX-CGGS. Of note, the most 
common clones identified in strategy 2, AC-SYTSSTM-CGGGS and AC- 
SNTSSTT-CGGS, contain serines at these positions. It is also clear that 
certain residues are not favoured in the sequences, most notably the 
aromatic amino acids phenylalanine (F), tryptophan (W) and to a lesser * 
extent tyrosine 00- These findings are not the result of library bias since 
the amino acids are evenly distributed throughout the seven randomized 
positions in phage clones in the Ph.D.™-C7C library [70].
207
Chapter 4
Percent of 
residues
< Position
Amino acid
Percentage occurrence
Residue position
Residue 1 2 3 4 5 6 7
S 14.21 9.35 14.81 13.23 17.66 13.77 11.49
P 14.73 14.29 13.51 10.94 8.05 12.73 5.22
T 13.95 12.21 11.69 6.62 8.05 7.01 13.32
H 10.08 3.64 6.23 10.43 11.17 10.13 6.53
N 8.79 8.83 6.23 8.14 9.09 7.27 2.61
K 8.01 4.68 4.42 5.09 2.86 5.19 4.18
Q 4.65 6.49 7.53 7.12 5.71 8.83 11.49
L 4.13 4.68 3.90 4.58 6.49 5.97 7.05
E 3.36 1.82 3.38 1.02 2.60 1.04 2.09
V 2.58 2.08 3.90 2.04 1.82 2.08 2.87
1 2.58 2.86 1.56 2.04 0.52 0.26 2.61
D 2.84 4.94 2.60 4.33 4.16 0.78 1.04
A 2.58 7.27 8.57 6.87 5.45 5.45 9.40
R 1.55 7.01 4.16 3.31 5.71 10.13 3.92
M 1.81 2.60 2.34 3.05 1.82 0.78 5.74
G 1.03 3.64 2.86 3.82 6.49 5.71 2.09
C 1.29 0.52 0.00 0.25 0.00 0.00 1.04
Y 0.78 1.30 1.56 2.29 1.82 1.56 4.18
F 0.78 0.78 0.26 3.31 0.52 1.30 2.09
W 0.26 1.04 0.52 1.53 0.00 0.00 1.04
Figure 4.5 Distributions of amino acids observed at seven randomized positions in phages 
recovered from brain grey matter in isolation strategy 1.
208
Chapter 4
Percent of 
residues
< Position
Amino acid
Percentage occurrence
Residue position
Residue 1 2 3 4 5 6 7
S 33.33 13.73 17.65 31.37 41.18 11.76 13.73
P 13.73 1.96 1.96 7.84 11.76 5.88 7.84
T 11.76 7.84 31.37 9.80 3.92 33.33 17.65
H 5.88 3.92 3.92 11.76 5.88 5.88 9.80
N 1.96 11.76 5.88 7.84 7.84 3.92 3.92
K 1.96 0.00 1.96 3.92 0.00 1.96 0.00
Q 7.84 1.96 1.96 1.96 0.00 9.80 1.96
L 7.84 11.76 3.92 5.88 5.88 7.84 3.92
E 1.96 5.88 5.88 0.00 0.00 1.96 0.00
V 1.96 0.00 1.96 0.00 3.92 0.00 1.96
1 1.96 5.88 0.00 1.96 0.00 0.00 1.96
D 0.00 3.92 3.92 0.00 0.00 0.00 0.00
A 0.00 5.88 7.84 9.80 3.92 0.00 7.84
R 3.92 3.92 0.00 1.96 7.84 5.88 5.88
M 0.00 0.00 1.96 1.96 7.84 0.00 21.57
G 3.92 0.00 3.92 0.00 0.00 5.88 1.96
C 1.96 0.00 0.00 0.00 0.00 0.00 0.00
Y 0.00 19.61 1.96 3.92 0.00 1.96 0.00
F 0.00 1.96 3.92 0.00 0.00 3.92 0.00
W 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Figure 4.6 Distributions of amino acids observed at seven randomized positions in phages 
recovered from brain grey matter in isolation strategy 2.
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An analysis of the physicochemical properties of the high frequency clones 
identified in strategy 1 and 2 can be seen in Table 4.5. In the main, the 
peptides identified were not primarily composed of hydrophobic residues 
suggesting they are unlikely to partition into the plasma membrane to 
affect translocation of the phage particle into the endothelial cell by 
diffusion. In any case diffusion seems unlikely given the short 15 minute 
phage circulation before perfusion and harvesting which would not be 
sufficient to afford significant diffusion across a cell, particularly of a 
particle the size of a phage.
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Table 4.5 Physicochemical properties of high frequency clones identified in isolation studies. 
Calculations were made using a peptide property calculator from Innovagen (Innovagen AB, 
Lund, Sweden).
Sequence NetCharge 
at pH 7.0
Pi Average
hydrophilicity
% hydrophilic 
residues
AC- SYTSSTM- CGGGS 0 5.9 -0.5 43%
AC- PDVPHPA- CGGGS -0.9 4.9 0.1 14%
AC- STASTQA-CGGGS 0 6 -0.1 43%
AC-HTLHGSA-CGGGS 0.2 8 -0.5 14%
AC-TISFDRY-CGGGS 0 6.7 -0.1 43%
AC-KQAASQQ-CGGGS 1 10.1 0.4 71%
AC-NARTSLF-CGGGS 1 11 -0.2 43%
AC- EPEKPRT- CGGGS 0 7.1 1.7 57%
AC-SVSSYNS-CGGGS 0 5.9 -0.3 71%
AC-DATNLTM-CGGGS -1 3.1 -0.2 29%
AC-NRTAAPL-CGGGS 1 11 0 29%
AC-SLMKSPE-CGGGS 0 6.9 0.5 57%
AC- TQAOLAK- CGGGS 0 6.7 0.4 43%
AC-HQTSLU1-CGGGS 0.1 7.8 -0.8 29%
AC-VPHDRTS-CGGGS 0.1 7.8 0.6 43%
AC-IPSGLLQ-CGGGS 0 6 -0.7 29%
AC-NNNTNTW-CGGGS 0 6 -0.5 57%
AC-VRANMTA-CGGGS 1 11 -0.1 29%
AC-TDPGQSA-CGGGS -1 3.1 0.4 43%
AC-TRTSHHN-CGGGS 1.2 11 0.2 43%
AC-DSTQTRQ-CGGGS 0 6.8 0.8 71%
AC-LPTAQNS-CGGGS 0 6 -0.3 43%
AC-PMSQNSL-CGGGS 0 6 -0.3 57%
AC-HQGVGTT-CGGGS 0.1 7.8 -0.4 14%
AC-NREHPNT-CGGGS 0.1 7.9 0.8 57%
AC-PVHNARN-CGGGS 1.1 11 -0.4 29%
AC-HNQIYPQ-CGGGS 0.1 7.8 -0.6 43%
AC-PNSNSKL-CGGGS 1 10.1 0.3 71%
AC-PNNHSRH-CGGGS 1.2 11 0.4 57%
AC-QGHQSGS-CGGGS 0.1 7.8 0.1 57%
AC-TQPARSQ-CGGGS 0.1 11 0.4 57%
AC-PNSMHSS-CGGGS 0.1 7.8 -0.1 57%
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There was also a pattern in the isoelectric point of the peptides displayed 
on the phages recovered in isolation strategies 1 and 2 (Figure 4.7) with 
the majority (over 90%) contained within a bimodal pattern having a pi of 
either 6-8 or 9-11. Virtually none of the displayed peptides had a pi 
between 8 and 9.
1 20 n 
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Figure 4.7 Distribution of isoelectric points of phage peptide motifs identified in isolation 
strategies 1 and 2.
From the sequence analysis detailed above for the original panning 
strategies three peptide-phage clones were taken forward to determine 
their potential in homing to the brain: (i) AC-PDVPHPA-CGGGS; isolated in 
strategy 1 and displaying the highest frequency in both brain grey matter 
and capillary fractions, (ii) AC-SYTSSTM-CGGGS; isolated in strategy 2 
displaying the highest frequency in both brain grey matter and capillary 
fractions and (iii) AC-TQPARSQ-CGGGS; isolated in strategy 1 and having a 
pi of 11 which is similar to the cell penetrating peptides.
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4.3.2 Phage amplification errors
Before undertaking brain homing studies of the three clones detailed above, 
the relative amplification of libraiy phages was compared to insertless 
phages. Insertless phages represent an almost ideal control, however, the 
insertless phage may display some preferential differences in its 
interactions with E.coli over peptide phage clones. As the detection of 
peptide phage and insertless phage virions in the brain and other tissues 
requires a 45-minute amplification with E. coli there was a need to address 
if a displayed peptide may interfere with the interaction of p ill with the 
bacterial F-pilus and thus slow amplification of peptide phage virions in 
comparison to insertless phage. To address this, peptide-phage AC- 
SYTSSTM-CGGGS was co-incubated with insertless phage in a culture of £  
coli (OD600 ~ 0.5) for 45 mins before the number of peptide-phages and 
insertless phages were determined by plaque assay. Table 4.6 shows that 
for the same input of peptide phage library and insertless phages, the rate 
of growth of insertless phages is some 2.4 ± 0.4 times faster than library 
phages. This clearly has major implications in tissue distribution studies 
since the amount of insertless phages that enter a given tissue (as 
determined by plaque formation assay) w ill be an overestimate by a factor 
of 2.4. Therefore, the results described for the relative (viz insertless) 
phage tissue distribution studies in this chapter have been corrected to 
account for the relative amplification rates of insertless and library phages 
over 45 mins.
213
Chapter 4
Table 4.6 shows comparison of the amplification of SYTSSTM-M13 with insertless phages. 
Peptide- and insertless- phages were co-infected in equal quantities into a culture of E. coli 
After 45 minutes, the number of insertless phages was 2.4 ± 0.4 times greater than peptide 
phages. This methodology parallels that used to recover phages from tissue.
Number of 
SYTSSTM-M13
Number of 
inserdess-M13
Ratio of insertless phages to 
peptide phages
Study 1 140 340 2.4
Study 2 200 400 2.0
Study 3 140 380 2.7
Mean 160 ±35 373 ± 31 2.4 ± 0.4
4.3.3 Ex-vivo stability of SYT5STM-M13 and insertless-M13
Proteases have been shown to significantly reduce the infectivity of phages 
by cleaving the N-terminal globular domain of the p ill protein preventing 
interaction w ith the F-pilus[71-73]. Since phage tissue distribution was 
monitored by plaque forming assay which measures viable phage particles 
there is the concern that in-vivo exposure to rat proteases would degrade 
phages and therefore the number of phages recovered from a tissue would 
significantly underestimate the true number entering the tissue. This could 
be different for different tissues and therefore undermine any tissue- 
selectivity assessments. Further, the fact that the displayed peptide is 
fused to p ill raises the question as to whether the displayed peptide would 
protect p ill from proteolytic digestion leading to the higher recovery of 
lib ra iy phages from tissue compared to insertless. To address these issues, 
phages were incubated (37°C) w ith fresh homogenates of liver and brain 
and w ith blood. The recovery of peptide or insertless phages from these 
tissue samples after set periods of time (15,45 and 90 mins) was compared 
to the recovery from phages sim ilarly incubated in DMEM; stability of both 
library and insertless phages has been confirmed in DMEM over 24 hours
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(data not shown). Whilst the recovery of phages from tissue was variable 
(as a result of the inherent errors in phage titration techniques which have 
been estimated as ~  25%[74]), Figure 4.8 shows that, in comparison to 
phages similarly incubated in DMEM, there was no significant decrease in 
either library or insertless phage viability in any of the tissues investigated.
SYTSSTM-M13
■  Blood
■  Brain
□  Liver T
insertless-M13
■  Blood
■  Brain 
a  Liver
Figure 4.8 Ex-vivo stability ofSYTSSTM-M13 and insertless-M13. Brain and liver were excised 
from terminally anesthetised rats and a blood sample was removed. Brain and liver were 
homogenized in DMEM (37°C) and then lm l aliquots of tissue and blood were incubated with 
phages, either SYTSSTM-M13 or insertless-Ml3. At the indicated time-points a sample of 
tissue and blood was collected and the number of phages determined by plaque formation 
assay. Comparison of the number of phages recovered with a sample of phages similarly 
incubated in DMEM alone revealed that there was no significant degradation at any time 
point investigated. Data are means ± SD expressed as percentage control (n = 3).
4.3.4 Effects of perfusion on phage numbers
There was some concern that perfusion procedures would result in damage 
to the brain microvasculature allowing phages that ordinarily would not 
enter the brain to 'leak' in. The recovery of phages from brain grey matter 
and capillary fractions was therefore determined in two animals, one
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perfused with saline and glycine and the other not perfused. Figure 4.9 
shows that saline and glycine perfusions drastically reduce the number of 
phages recovered from grey matter and the brain capillary fraction. This 
suggests two points, firstly saline and glycine do not appear to damage the 
BBB to allow phages to 'leak' into the brain and secondly, the perfusion 
strategy is successful in removing phages from residual blood within the 
brain and from the surface of the brain capillaries.
4.0x1006'
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Figure 4.9 Effects of perfusion on phage recovery from grey matter. Saline and glycine 
perfusion (perfused on histogram]  remove freely circulating phages and phages attached to 
vasculature resulting in reduced recovery from grey matter.
4.3.5 Fifteen minute brain uptake of selected peptide-phage clones
To analyse the capacity of selected phage clones AC-PDVPHPA-CGGGS, AC- 
SYTSSTM-CGGS and AC-TQPARSQ-CGGGS to home to the brain, each clone
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was co-injected, w ith an equal number of insertless phage, into a rat and 
allowed to circulate for 15 minutes before the animal was sacrificed and 
perfused w ith saline and glycine. The brain was harvested, the white matter 
removed and the capillaries depleted before the number of peptide and 
insertless phages in grey matter was determined by plaque formation 
assay. Table 4.7 shows the ratio of peptide-M13 phage to insertless-M13 
phage for each of the three peptide-phage investigated. Only SYTSSTM-M13 
preferentially enter brain compared to insertless-M13 after a 15-minute 
circulation time. It should be noted that this was a simple pre-screen and 
these data were only determined in a single rat for each peptide phage 
clone.
Table 4.7 Brain homing capacity of select peptide phage clones. Only phage clone AC- 
SYTTSTM-CGGGS was observed to enter brain grey matter preferentially compared to 
insertless phage.
Displayed Peptide Ratio Peptide-Phage: Wild-type in grey matter 
at 15 mins fn = 1)
AC-SYTSSTH-CGGGS 8
AC-TQPARSQ-CGGGS 0.3 (i.e. > 3-fold greater insertless enter the brain)
AC-PDVPHPA-CGGGS 1
4.3.6 In-vivo tissue distribution of SYTSSTM-M13
With SYTSSTM-M13 showing greater uptake at 15 minutes compared to 
insertless-M13, extensive in-vivo tissue distribution studies were 
undertaken to construct a detailed in-vivo pharmacokinetic profile. Equal 
quantities of SYTSSTM-M13 and insertless-M13 were co-injected into rat, 
allowed to circulate for 7,15, 45, 90 or 180 minutes before the rats were 
terminally anaesthetised and perfused with saline and glycine to clear 
blood and vasculature of circulating phage. After harvesting the brain grey
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matter and other major organs the number of SYTSSTM-M13 recovered 
from each tissue was compared to the recovery of insertless-M13; each 
time point was undertaken in triplicate (i.e. n= 3 animals) on the same day 
using the same prepared dose of phage. Figure 4.10 shows the 
distribution of SYTSSTM-M13 and insertless-M13 in brain grey matter and 
Figure 4.11 shows the distribution in blood, heart, lung, liver, kidney, 
spleen, testicles, small and large intestine, and muscle. The data reveal that 
only in brain grey matter is the peak concentration of SYTSSTM-M13 
significantly greater than insertless-M13 (p < 0.05) with a mean ratio of 3.4 
(corrected for amplification error). It is clear however that in comparison 
to other tissues analysed, the uptake of phages into brain grey matter is 
relatively minor with the peak concentration of SYTSSTM-M13 
representing just 2.1 x 10*4 % of injected dose; this compares to 18% of 
injected dose in the liver although the liver is recognized as the primary 
elimination route for phages[66]. Further, phages did not appear to persist 
in brain grey matter, or most of the other organs, for any significant time 
with after 180 minutes neither SYTSSTM-M13 nor insertless-M13 
detectable in brain grey matter.
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Figure 4.10 Pharmacokinetic profile of SYTSSTM-M13 and insertiess-M13 in brain grey 
matter of male SD rats. lxlO11 pfits of SYTSSTM-M13 and insertiess-M13 were co-injected 
intravenously into male SD rats At the indicated time intervals rats were terminally 
anaesthetized before perfusion with ice-cold saline and ice-cold glycine (pH2.2). The brain 
and major organs were then harvested. The white matter and accessory organs were 
separated from the rest of the brain and discarded. The capillaries were extracted from the 
grey matter using density centrifugation. The number of phage particles in brain grey 
matter was then determined by plaque formation assay. The experimentally determined 
Cmax (45 mins) for SYTSSTM-M13 was found to be significantly greater than insertless-M13. 
* represents a statistically significant difference (P < 0.05j  compared to insertless-M13. Data 
are presented as mean ± SD (n=3 for each timepoint) and incorporate an amplification error 
factor of 2.4.
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Figure 4.11 Pharmacokinetic profile of SYTSSTM-M13 and insertiess-M13 in the major organs 
of male SD rats (continued on next page). 1 x 1011 pfiis of SYTSSTM-M13 and insertiess-M13 
were co-injected intravenously into male SD rats. At the indicated time intervals, the animals 
were terminalfy anaesthetized before perfusion with ice-cold saline and ice-cold glycine 
(pH2.2). The number of phage particles in each tissue was then determined by plaque assay. 
No significant difference was observed between Cmax for SYTSSTM-M13 and insertless-ml3. 
Data are presented as mean (h-3 for each timepoint) and incorporate amplification error 
factor.
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Figure 4.11 continued. Pharmacokinetic profile of SYTSSTM-M13 and insert!ess-M13 in Che 
major organs of male SD rats.
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Other points to note are the exact same PK profile of SYTSSTM-M13 and 
insertless-M13 in the blood (see Table 4.8) with both phage types 
undetectable at 180 minutes. These are an important find since they show 
that SYTSSTM-M13 does not circulate for longer in the blood to provide 
greater opportunity for uptake.
\
Table 4.8 Blood pharmacokinetic parameters of SYTSSTM-M13 and insertless-M13 following 
intravenous administration. Parameters were determined using equations detailed in 4.2.4.
SYTSSTM-M13 insertless-M13
AUC pfus-mH.min 7.78x10“ 7.89 x 10“
ki ml-mirr1 0.086 0.087
K2 m lm in1 0.3711 0.3740
ti /2 4  min 1.868 1.853
ti /2 4  min 8021 7.923
Cl mLmin^.rat1 0.129 0.127
r2 0.9996 0.9978
A better measure of phage uptake into a tissue than Cmax is the area under 
the curve (AUC). AUC gives a measure of the total exposure of a given tissue 
to phages, for example a long, low concentration exposure may be as 
important as a shorter but higher concentration. Table 4.9 shows the total 
AUCs, calculated from mean phage data, for SYTSSTM-M13 and insertless- 
M13 in each of the tissues investigated. Once again the AUC data reinforces 
the view that the brain is a relatively minor distribution route for phages. 
However, comparison of the ratio of brain AUCs reveals a substantially 
greater uptake of SYTSSM-M13 in comparison to insertless-M13 4-fold 
greater uptake). Notably, uptake is also substantially greater for heart 
3.6 fold) and liver (~ 3.3 fold) but the ratio of AUC in blood is ~ 1. Data are 
corrected for amplification errors in insertless-M13.
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Table 4.9 AUCs calculated from experimentally determined tissue distributions of SYTSSTM- 
M13 and insertless-M13. The fold increase in AUC of SYTSSTM-M13 compared to insertless- 
M13 is greatest for brain although considerable increases were also observed for heart and 
liver. Of note; the AUC for blood is the same for SYTSSTM-M13 and insertiess-M13. AUCs were 
calculated using the trapezoid rule from mean distribution data.
Tissue AUCsvtsstm-m i3(o-«)
(pfu&min)
AU Cbnemcss-M13(0-.) 
(pfusjnin)
Ratio
AUC SYTSSTM-M13 I AUC
towrttara M13
Brain 1.09 x 107 0.27 x lO 7 4.018
Lung 2.82 x 10® 2.66 x 10® 1.062
Heart 2.47 x lO 9 0.69 x 109 3.557
Liver 3 .74x1 0“ 1.12 x 10“ 3.336
Kidneys 1.44x10® 0.91 x 10® 1.582
Spleen 0 .8 0 x 1 0 “ 1.53 x 10“ 0.525
Large intestine (1 g) 3.77 x 107 2.16 x lO 7 1.745
Small intestine (1 g) 1.69 x lO 7 1.61 x 107 1.052
Muscle (1 g) 1.57 x lO 7 1.38 x 107 1.138
Testicle 1.51 x 107 2.16 x lO 7 0.734
Blood flm ll 7 .78x1 0“ 7 .8 9 x 1 0 “ 0.985
In comparison to some tissues, the rate of perfusion of the brain is 
moderate and since rate of perfusion determines exposure of a tissue to 
phages, AUCs reported in Table 4.9 w ill always indicate that highly 
perfused tissues accumulate greater quantities of phages. To compensate 
for this AUCs were standardized for perfusion rate, the results of which are 
shown in Table 4.10 (ratios of SYTSSTM-M13:insertless-M13 remain the 
same); rat organ perfusion rates were obtained from[75]. These data now 
suggest that the uptake of SYTSSTM-M13 into the brain is not as minor a 
route of distribution as would at firs t be suggested. This is demonstrated by 
comparing the AUC of SYTSSTM in the tissues w ith the AUC of SYTSSTM in 
the lung; lung was chosen for comparison because the whole of the cardiac 
output passes through the lungs and yet, corrected for perfusion, very little  
SYTSSTM is taken up in comparison to the other organs. Even when 
corrected for perfusion, uptake of insertless phages into the brain is less
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than the other tissues investigated. Figure 4.12 is a graphical 
representation of the data presented in Table 4.9 and Table 4.10.
Table 4.10 Perfusion adjusted AUCs calculated from experimentally determined tissue 
distributions of SYTSSTM-M13 and insertiess-M13. AUCs have been corrected for exposure of 
tissues to phages, since highly perfused rat tissues will be exposed to greater quantities of 
phages per unit time than poorly perfused rat tissues Whilst the ratio of AUC SYTSSTM-M13 
to AUC insertless-M13 does not change, the tissue distribution is altered. AUCs are calculated 
using the trapezoid rule from mean distribution data and perfusion values were obtained 
from [75].
Tissue AUCsVTS5TM-M13(0-.)
jilin2)
AUCia9erttess-M13(0-„)
(pfu&g-1.ml*1.miii2)
Ratio 
AUC SYTSSTM Tissue: 
AUC SYTSSTM Lung
Brain 7.50 x 1 0 s 1.87 x 10s 5.7
Lung 1.32 x 10s 1.24 x 1 0 s -
Heart 1.98 x 107 0.56 x lO 7 150
Liver 4.41 x 108 1.32 x 108 3341
Kidneys 4.44 x 1 0 s 2.8 x 1 0 s 3.3
Spleen 1.11 x lO 9 2.12 x 109 8409
Large intestine (1 g) 1.92 x 10* 1.11 x 106 14.5
Small intestine (1 g) 5.69 x 1 0 s 5.41 x 10s 4.3
Muscle (1 g) 3.03 x 106 2.66 x 106 22.7
Testicle 6.86 x 106 7.30 x lO 6 52
Blood 7.78 x lO 11 7.89 x 10” -
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Figure 4.12 AUC in major organs and tissues for SYTSSTM-M13 and insertless-M13 co­
administered to male SD rats. (A) Total AUC of SYTSSTM-M13 compared to insertless-Ml3. 
(B) AUCs of SYTSSTM-M13 and insertless-Ml3 adjusted for rat tissue perfusion. Perfusion 
governs exposure of a tissue to phages and given that the rate of brain perfusion is relatively 
low in comparison to other tissues[75] this reduces the exposure of brain microvasculature to 
phages.
4.3.7 Pharmacokinetic simulations of brain uptake
To explore how various pharmacokinetic parameters may impact on the 
accumulation of phages in brain parenchyma, a physiologically based 
pharmacokinetic model (PBPK) was constructed in Stella the details of 
which can be seen in Figure 4.2 and Figure 4.3. The PBPK model was 
based on the structure of the rat circulatory system and used published 
values for rat organ masses and rates of perfusion to reflect convective 
transport of a molecule to the brain via blood flow. The model was 
simplified at the organ level to assume transfer between well-stirred 
compartments such that the effects of intravascular dispersion and 
diffusion are not modelled. Simulations were run to assess the
accumulation of molecule in the brain through:
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(a) varying affinity for brain tissue (Kp[brain] = 0.2, 2 or 20) while 
maintaining a constant extraction ratio in the eliminating compartment 
(simulations run at E = 0.1 and 1) and a constant tissue affinity (Kp[other] = 
2) in the other highly perfused and poorly perfused compartments in the 
PBPK model
OR
(b) varying extraction ratio in the eliminating compartment while 
maintaining a constant affinity for brain tissue (simulations run for either 
Kp[brain] = 0.2 and 20) and constant tissue affinity for highly perfused and 
poorly perfused compartments (Kp[other] = 2). The results of these 
simulations can be seen graphically in Figure 4.13 and summarized in 
Table 4.11 and Table 4.12.
The modelling provided insights into the effects of changing PK on brain 
accumulation. Firstly, for the same extraction ratio in the eliminating 
compartment, any increase in affinity for brain tissue (Kp[brain]) is directly 
reflected by a proportional increase in brain AUC(total) i.e. a 10-fold 
increase in Kp[brain] leads to a 10-fold increase in brain AUC(total) (see 
Table 4.11). The same is not true for peak concentration (Cmax), indeed 
the increase in Cmax may be considerably smaller than the increase in 
Kp[brain], for example w ith an extraction ratio of 1 in the eliminating 
compartment (i.e. a rapidly eliminated molecule), a 100-fold increase in 
Kp[brain] (0.2 -  20) only results in an 8.2 fold increase in Cmax. The
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simulations also show that AUC(total) and Cmax can be increased if  
peripheral pharmacokinetics are modified to extend circulation time. Even 
w ith a poor affinity for brain tissue (Kp[brain] = 0.2), reducing the 
extraction ratio from 1 to 0.1 (i.e. changing from a rapidly eliminated to a 
slowly eliminated molecule) results in an approximate 9-fold increase in 
brain AUC and only a small 1.25-fold increase in Cmax. Together the 
simulations demonstrate that modifying both peripheral pharmacokinetics 
and central affinity w ill achieve the greatest brain accumulation although 
changes in tissue affinity are the most influential factor. For example 
increasing brain affinity from 0.2 to 2 and reducing extraction ratio from 1 
to 0.1 results in a 53-fold increase in brain AUC and a 9-fold increase in 
Cmax. The simulations also show that increasing Cmax is challenging since 
even w ith a 100-fold increase in Kp[brain] and a reduction in extraction 
ratio from 1 to 0.1 Cmax is only increased by approximately 31-fold. Clearly 
this presents an issue when a minimum concentration threshold must be 
reached in the brain (Cmax) for a therapeutic effect
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Figure 4.13 Brain and blood compartment PBPK simulations. (A) Change in brain 
pharmacokinetic profile with increasing affinity for brain tissue (kp = 0.2,2 and 20) when the 
extraction ratio in the eliminating compartment is low (E = 0.1). (B) Change in blood 
pharmacokinetic profile with increasing affinity for brain tissue (kp = 02,2 and 20) when the 
extraction ratio in the eliminating compartment is low (E = 0.1). (C) Change in brain 
pharmacokinetic profile with increasing affinity for brain tissue (kp = 02,2 and 20) when the 
extraction ratio in the eliminating compartment is high (E = 1). (D) Change in blood 
pharmacokinetic profile with increasing affinity for brain tissue (kp = 0.2,2 and 20) when the 
extraction ratio in the eliminating compartment is high (E = 1). (E) Change in brain 
pharmacokinetic profile with decreasing extraction ratio in the eliminating compartment (E 
= 0.1,1) for a peptide with low brain affinity (kp -  0.2). (F) Change in brain pharmacokinetic 
profile with decreasing extraction ratio in the eliminating compartment (E = 0.1, 1) for a 
peptide with high brain affinity (kp = 20). A 10-fold decrease in E results in -  3.7-fold increase 
in Cmax
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Table 4.11 Brain pharmacokinetic parameters calculated from PBPK simulations.
Input Model Parameters Model Predictions
Extraction ratio Kp Brain 
eliminating organs
MRT (mins) AUC Bloody-,) 
(Cone. units.mins)
AUC Brain(o») 
(Cone. units.mins)
Cmax Brain 
(Cone, units)
tMAx Brain (mins)
0.1 0.2 34.41 28.64 5.73 0.1551 2
0.1 2 39.15 28.64 57.28 1.1278 10
0.1 20 90.23 28.64 572.8 3.8341 32
1 0.2 3.34 3.05 1.08 0.1238 1
1 2 3.81 3.05 11.07 0.5343 4
1 20 8.40 3.05 110.6 1.0204 9
tsj
to
vO
Table 4.12 Changes in brain pharmacokinetic parameters with increasing brain affinity and eliminating compartment extraction ratio.
Extraction 
ratio (E)
Change in Brain Kp Fold change in 
brain AUC
Fold change in 
Brain Cmax
Brain kp Change in extraction 
ratio (E)
Fold change in brain 
AUC
Fold change in 
Brain Cmax
0.1 0.2 to 2 (xlO-fold) 10 7.3 0.2 1 to 0.1 5.3 1.25
0.1 2 to 20 (xlO-fold) 10 3.4 2 1 to 0.1 5 .3 2.11
0.1 0.2 to 20 (xl 00-fold) 100 24.7 20 1 to 0.1 5.3 3.75
1 0.2 to 2 (xlO-fold) 10 4.3
1 2 to 20 (xlO-fold) 10 1.9
1 0.2 to 20 (xlOO-fold) 100 8.2
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The simulations also highlighted that care must be taken in interpreting 
differences in tissue concentrations at arbitrary timepoints. Figure 4.14A 
shows the difference in concentration for a given time-point between two 
molecules, both w ith a Kp[brain] o f 20 but w ith extraction ratios in the 
eliminating organs of 0.1 and 1 respectively (brain concentrations for the 
two molecules are shown in Figure 4.14B). The difference in Cmax 
between the molecules is 3.75-fold and the difference in AUCs is 5.3 fold 
(see Table 4.11), however the difference in tissue concentration for a given 
timepoint increases exponentially even when the amount of drug 
remaining in tissue is very small and perhaps of no intrinsic therapeutic 
value.
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Figure 4.14 Difference in tissue concentration at a given timepoint between a drug with 
Kpfbrain] of 20 and extraction ratio of 0.1 in the eliminating organs and a drug with 
Kpfbrain] of 20 and extraction ratio of 1 in the eliminating organs. (A) With increasing time, 
differences in brain tissue concentration exponentially increase even when brain tissue 
concentrations may be negligible. (B) Tissue concentration profile of drugs modelled show 
that differences in AUC and Cmax are only modestly different (53-fold and 3.75-fold 
respectively).
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The simulations provide some interesting context to the phage studies 
undertaken. Since the blood pharmacokinetic profile for SYTSSTM-M13 and 
insertless-M13 were found to be identical, their extraction ratios within the 
eliminating organs must be sim ilarly identical. Therefore the increases 
observed in brain AUC with STYSSTM-M13 must reflect an increase in 
affinity for brain tissue and given the ratio of brain AUCs for SYTSSTM-M13 
and insertless-M13 was 4 this implies SYTSSTM-Ml3 has a 4-fold increase 
in affinity for brain tissue compared to insertless-M13. Of course this 
similarly suggests that the affinity of SYTSSTM-M13 for liver and heart is 
respectively 3.3- and 3.6- fold greater than insertless-M13.
4.4 Discussion
Whilst considerable progress has been made in developing vectors for the 
efficient delivery of biologies across many biological barriers, delivery 
across the BBB and into the brain remains a significant challenge. To 
overcome the lim iting nature of the BBB a range of methods have been 
proposed for the effective delivery of therapeutics including the transient 
opening of the BBB with osmotic agents[76-78] or bradykinin analogs[76] 
and exploitation of specific transport systems at the BBB such as 
transferrin receptor, insulin receptor, monocarboxylate, amine and neutral 
amino acid transporters. More recently interest has grown in the use of 
peptides as drug delivery vectors. Such peptides include peptides designed 
against specific receptors such as LRP[79] or the more general CPPs such as 
SynBl and SynB4 peptides, a new class of vectors derived from the
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antimicrobial protein protegrin 1 originally isolated from porcine 
leucocytes[80-82] and products of pathogens that have the capacity to 
traverse the plasmalemma such as Antennapedia and Tat peptides from 
human immunodeficiency virus. Indeed in studies detailed in chapter 3, a 
peptide sharing significant homology with the V3 loop of HIV GP 120 was 
recovered in panning experiments against mouse BBB endothelia; GP 120 
has been implicated in the entry of HIV into CD4 -/- cells.
Generally the cell penetrating peptides investigated to date are highly 
positively charged and as such stimulate adsorptive mediated endocytosis, 
a ubiquitous route of entiy into the cell that occurs w ithin all vascular beds. 
To afford site-specific delivery of biologies, many researchers are seeking to 
identify peptides that interact w ith vascular addresses on capillaiy 
endothelia w ithin the tissue of interest Phage display has shown promise 
in surveying the molecular landscape w ithin such vascular beds to identify 
unique peptides and peptide motifs that promote cell binding and 
potentially transcytosis.
In the studies described in this chapter, two strategies were employed to 
identify peptides that home to the brain and specifically to brain grey 
matter. In both strategies male SD rats were injected with a peptide-phage 
library that contains 1.2 x 109 unique phage peptide clones and after 15 
minutes circulation time the rats were perfused with ice-cold saline to flush 
the blood from the animal and then a low pH glycine buffer (pH 2.2) to strip 
the vasculature of binding peptides; glycine has been shown to non-
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specifically disrupt phage peptide interactions without rendering the 
phages non-infective. Both saline and glycine buffer were checked prior to 
each study to ensure they were iso-osmotic and therefore unlikely to 
damage vasculature. The low pH of the glycine perfusion may have been 
expected to damage the vasculature but experiments that examined the 
effects of saline and glycine perfusion on phage uptake did not suggest this 
was so. In strategy 1, three rounds of selection were undertaken in which 
only phages from the brain served as input into iterative rounds of 
selection. Specifically, the brain was harvested, the white matter removed 
and the capillaries depleted to leave grey matter from which phages were 
recovered. Of note, the accumulation of phages within the brain increased 
w ith each iterative round whilst the accumulation in the other organs 
harvested decreased. In strategy 2 a synchronous selection process was 
undertaken based on the studies detailed by Pasqualini and co- 
workers[68]. In the first four rounds of panning, library phages were 
recovered from brain, heart, lung, kidney, liver, spleen and testicle, 
amplified and pooled for the next iterative round of panning. A final fifth 
panning round was undertaken where only the phages recovered from grey 
matter in round 4 were injected. Whilst the overall aim in strategy 2 was to 
identify peptides that mediate the traversal of phages across the BBB and 
into the brain, the phages recovered from the other organs harvested in 
isolation strategy 2 are stored ready for future analysis. This strategy 
would be particularly advantageous in continuing the in-vivo human studies
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pioneered by Wadih Arap and co-workers[53] where it may be critical to 
identify tissue homing peptides to a variety of organs in a single screen.
Gene sequencing of an extensive number of phages recovered from the 
brain in the final rounds of selection in strategies 1 and 2 revealed some 
peptide motifs present in higher frequency. Strategy 2 in particular resulted 
in the isolation of clones present as a significant fraction of the phage 
population, w ith AC-SYTSSTM-CGGGS and AC-SNTSSTT-CGGGS combined 
present as ~ 25% of the pool sequenced; notably, these two peptides share 
a common m otif AC-SxTSSTx-CGGS. In isolation strategy 1 the most 
frequent clones in the population were present at around 1.5% of the pool 
sequenced (AC-PDVPHPA-CGGGS and AC-STASTQA-CGGGS). These results 
raise the question why does strategy 2 appear to be more successful in 
selecting a common motif and clones occurring in higher frequency than 
strategy 1? One would imagine recovering peptide phages from the brain 
alone (strategy 1) would be more efficient in selecting brain homing phages 
than pooling phages recovered from multiple organs (strategy 2). It is 
difficult to address this issue satisfactorily although there may be issues 
surrounding the number of panning rounds undertaken, three for strategy 
1 versus five for strategy 2 and in hindsight it may have been better to 
undertake further selection rounds in strategy 1. However, a frequency 
analysis of the amino acids at the seven random positions in the peptides 
identified in strategies 1 and 2 suggested consistency between the two 
panning strategies indicating that serine residues at positions 1, 4 and 5
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may be important for brain homing. Coincidentally serine residues at 
positions 1,4 and 5 are in agreement w ith in the highest frequency binders 
AC-SYTSSTM-CGGGS and AC-SNTSSTT-CGGGS. A population of phages 
associated with the capillary fraction of the brain were also sequenced and 
w ithin this population AC-SYTSSTM-CGGGS and AC-PDVPHPA-CGGGS 
were identified with a frequency of 19% and 13% respectively. These data 
suggested that AC-SYTSSTM-CGGGS and AC-PDVPHPA-CGGGS may gain 
access to the brain via the microvasculature.
Physicochemical analysis of the primary amino acid sequences of the all the 
peptide-phage clones recovered from the brain in isolation strategies 1 and 
2 (600 sequences in total) revealed the displayed peptides were laigely 
composed of hydrophilic residues. This probably suggests that the peptides 
would not diffuse through the plasma membrane. Of note, the isoelectric 
points of the peptides recovered were mainly between 6 and 8 and 9 and
11. It is interesting to note that the population of phages with pi 9-11 w ill 
be highly cationic in nature, a feature in common with the cell penetrating 
peptides that are thought to interact w ith anionic domains on the 
plasmalemmal glycocalyx to stimulate adsorptive endocytosis as a 
consequence of their isoelectric point[83, 84]. It is recognized that the 
interactions of peptides and proteins w ith surface receptors is dictated by 
pH and pi. For example lactoferrin binds specific receptors on the surface 
of human monocytes to affect iron deposition. When the iron has been 
deposited, there is a subtle change in the pi of lactoferrin from 8.8 to 8.9
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which grossly impairs the rebinding of lactotransferrin to its cognate 
receptor[85]. The pi data obtained for the peptides would therefore at the 
very least discount the peptides from binding certain receptors where 
these pis would be unfavourable. Those peptides with pis greater than 9 
were not extensively investigated in tissue distribution studies because it 
was envisaged that they may act as cell penetrating peptides and enhance 
phage uptake ubiquitously in all tissue types. Notably, sequences AC- 
SYTSSTM-CGGGS, AC-SNTSSTT-CGGGS and AC-PDVPHPA-CGGGS, 
identified in the highest frequency in grey matter and/or capillary fraction, 
are not highly cationic at neutral pH and are therefore unlikely to stimulate 
adsorptive endocytosis.
A search of the SWISSPROT database using the BLAST search engine did 
not reveal any homologies of note with the most commonly identified 
peptides from the selection strategies only corresponding with hypothetical 
proteins, proteins that are predicted from genomic sequencing but the 
expression of which have not been confirmed. This is not uncommon in 
phage display against cellular targets that express a significant diversity of 
receptors and surface markers. Arguably, the goal of phage display is to 
identify novel peptide sequences that interact with target and although this 
gives no indication of the nature of the target, methods such as immuno- 
precipitation can be used subsequently to identify the binding partner.
Based on the results of the initial panning strategies the brain uptake of AC- 
SYTSSTM-CGGS (the most common clone in strategy 2), AC-PDVPHPA-
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CGGGS (high frequency in capillary fraction and grey matter in strategy 1) 
and AC-TQPARSQ-CGGGS (recovered in isolation strategy 1 and highly 
cationic) was compared to the uptake of insertless-M13 15 minutes after 
intravenous administration. The results of these studies suggested that only 
phages displaying AC-SYTSSTM-CGGGS were taken up to a greater extent 
than insertless phages. Whilst the failure of clones PDVPHPA-M13 and 
TQPARSQ-M13 to gain enhanced access to the brain was disappointing, the 
~ 8 fold greater uptake of SYTSSTM-M13 (corrected for amplification 
errors) was encouraging. Some thought was given to using in-vitro BBB 
models to determine permeability co-efficients for SYTSSTM-M13 and 
insertless-M13 but as detailed in chapter 3, the establishment of a highly 
restrictive rat BBB model proved elusive. Therefore, an extensive in-vivo 
distribution study of SYTSSTM-M13 was undertaken. 1 x 1011 pfiis of 
SYTSSTM-M13 and insertless-M13 were co-injected intravenously and the 
number of phages accumulating in the major organs of the body assessed at 
various timepoints from which the AUCs were calculated for each of the 
tissues. In agreement with in-vivo assessments of the biodistribution of 
M13 phages in mice, accumulation was primarily observed in the liver and 
spleen with relatively little  uptake in the brain[67]. Nevertheless, the brain 
AUC of SYTSSTM-M13 was found to be ~ 4-fold greater than insertless-M13 
which suggests a ~ 4-fold greater affinity for brain than insertless-M13. An 
increase in tissue uptake was also observed in the heart (3.6-fold) and liver 
(3.3-fold), although to a lesser extent than the brain, with the remaining 
tissues showing comparable uptake of SYTSSTM-M13 and insertless-M13.
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The increased uptake in tissues other than the brain is not entirely 
unexpected since few receptors or cell surface markers are found 
exclusively in a single vascular bed. For example OX-26 a monoclonal 
antibody that binds transferrin receptor has been intensively investigated 
for the delivery of therapeutic cargos into the brain (see Table 4.2 for 
examples). The density of transferrin receptor at the BBB has been 
estimated as ~ 60,000 receptors per cell[15] whilst for liver it is ~ 120,000 
receptors per cell[86]. Therefore, increases in brain uptake of therapeutic 
cargos conjugated to OX-26 are paralleled in the liver. Indeed, comparison 
of OX-26 uptake with isotypic control results in an 18-fold greater uptake in 
the brain and a 13-fold greater uptake in the liver 5 hours post 
administration[87]. In cases where the sole objective is increased brain 
uptake and accompanying increases in peripheral uptake are not 
important, arguably this doesn't matter. Conversely if  a therapeutic cargo is 
highly toxic, for example a chemotherapeutic agent, site specific rather than 
site selective deliveiy may be of greater im port A limiting aspect of the 
studies undertaken is that accumulation of phage cannot be monitored over 
time within the same animal rather each timepoint requires a separate 
animal (in triplicate for each timepoint). Inherent biological variability 
between animals coupled with the inaccuracy in phage titers results in 
relatively large standard deviations in the data making statistical analysis 
d ifficu lt Nevertheless, only within brain was the peak concentration 
(Cmax) of phages significantly greater (~ 3.4-fold) for SYTSSTM-M13 
compared to insertless-M13.
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Few phage display studies have sought to identify peptides that mediate the 
traversal of the BBB. Pasqualini and co-workers [68] described a tr i­
peptide motif, RGF, that was present in ~ 3.5% of the clones sequenced 
after a third round of selection however subsequent measurements of brain 
accumulation of clones displaying this motif were not undertaken. Fan and 
co-workers[88] utilized a cyclic 7-mer T7 phage display library to identify 
peptides that home to mouse brain; T7 is a lytic phage that infects £. coli. A 
peptide sequence CAGALCY was demonstrated to accumulate in the brain 
approximately 1000-fold greater than insertless-T7 at 2 hours post 
administration; no AUC data was reported. Whilst these results 
demonstrate the utility of phage in selecting brain homing peptides some 
care must be taken in their interpretation. The mice in the study were not 
perfused with any agent to strip the microvasculature of binding phages 
and the white matter, accessory organs and capillaries were left in-situ. 
Therefore the phages recovered represent accumulation in the whole brain. 
Friden[26] and Moos and Morgan[89] demonstrated in the early 1990s that 
only a small fraction of material associated with whole brain actually 
reaches the parenchyma (5 -10%). In the phage studies undertaken in this 
chapter, only brain parenchyma was collected and analysed and perhaps 
therefore, whilst the results described are more modest they may better 
reflect true brain uptake.
To contextualise the peptide phage results obtained, a physiologically based 
pharmacokinetic model was constructed. In their simplest form, the
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simulations showed that increases in affinity for brain tissue are directly 
proportional to increases in AUC, however this was not the case for peak 
concentration Cmax and even relatively large increases in brain affinity 
may only result in modest increases in peak concentration. The simulations 
also highlighted the need for researchers to report AUCs and Cmax not just 
differences in concentration at an arbitrary time-point which can 
unwittingly exaggerate the true enhancement in uptake. More importantly, 
tihe model reinforced the concept that a combination of increasing brain 
affinity AND increasing circulation time is the optimal strategy for 
improving brain accumulation. These data reaffirm that strategies such as 
PEGylation of a therapeutic entity to prolong circulation half-life coupled 
with conjugation to a targeting vector is a considered approach to 
improving brain penetration.
In summary, the aim of the studies in this chapter was to identify peptides 
that home to the brain. A peptide with sequence AC-SYTSSTM-CGGGS 
modesdy increased the accumulation of a supramacromolecular entity into 
the brain with an approximate 4-fold increase in brain AUC. Further 
characterization of this peptide within in-situ brain perfusion models and 
brain microdialysis systems would help to examine brain transport kinetics 
without interference from whole body disposition processes. Clearly, the 
work detailed in this chapter is not at a conclusion and with more time 
many exciting studies can be designed to further investigate the true utility 
of the identified peptide to deliver therapeutics to the brain.
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Chapter 5 Caveolin-1: a novel drug target in Glioma
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5.1 Introduction
5.1.1 The functional role of caveolin-1 in oncogenesis and metastatic 
disease
In recent years, the role of caveolae and caveolins in human health and 
disease has received significant attention in such areas as cancer, muscular 
dystrophy, diabetes, atherosclerosis, Alzheimer's disease and HIV 
(reviewed in [1]). However, it  is w ith in  the field of oncology and specifically 
the pathogenesis of cancer that their study has been particularly focused. 
Traditionally caveolin-1 has been viewed as a tumour suppressor protein 
given its absence in breast, lung and ovarian cancer cell lines derived from 
tumour tissue and not least its ability to inhibit the EGF-R/RAS/ERK 
growth signaling pathway when recombinantly re-expressed in respective 
in-vitro models [1-3]. Further, the gene encoding caveolin-1 is mapped to 
chromosome 7q31.1, a locus frequently deleted, amplified or mutated in a 
variety of common cancers such as those of the breast, prostate and 
kidney[4, 5]. More recently, however, two seminal papers[6, 7] were 
published that described the up-regulation of caveolin-1 in clinical 
specimens of prostate cancer. In these specimens, caveolin-1 was shown to 
drive the aggressive features o f prostate cancer including invasion and 
development of androgen resistance[6, 7]. Following on from this a 
succession of clinical papers were published correlating caveolin-1 over­
expression w ith disease progression in a diverse range of cancer types 
including amongst others lung, pancreas, kidney and colon[2,8].
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Despite significant studies into the role of caveolin-1 in cancer development 
and progression, its precise function remains complex and controversial; 
caveolin-1 has been described variously as a tumour suppressor or tumour 
promoter depending on the tumour type and disease stage. This dual 
function is perhaps best exemplified in breast cancer. Studies undertaken 
w ith caveolin-1 knockout mice [9, 10] and cells derived from breast 
carcinomas [11,12] have shown that the loss of caveolin-1 from mammary 
cells is sufficient to promote the pathogenesis o f breast cancer. These 
pathological features include activation of the EGF-R/RAS/ERK signaling 
pathway, increased cell proliferation, initiation of mammary hyperplasia 
and enhanced anchorage independent growth leading to invasion and 
metastasis. On the other hand, several clinico-pathological studies, 
including those within the supervisor's laboratory[13], have shown that 
caveolin-1 over-expression correlates w ith the aggressive features of 
certain breast cancers, most notably the basal-like and inflammatory 
invasive subtypes[14-16]. Table 5.1 shows the cancers in which caveolin-1 
expression is elevated in primary tumours compared to matched normal 
tissue and positively correlates w ith poor clinical outcome. Notably, 
positive expression of caveolin-1 correlates w ith post-operative disease 
recurrence, increased invasive and metastatic potential and increased 
chemotherapeutic resistance, that, altogether are suggestive of an 
aggressive phenotype.
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Table 5.1 Carcinomas in which raised caveolin-1 expression correlates with poor clinical 
prognosis (adapted from [17]).
Tissue Tum our type Ref
Esophagus Squamous cell carcinoma (oral cavity) [18-20]
Pancreas Ductal adenocarcinoma [21]
Intraductal papillary-mucinous tumour [22]
Colon Adenocarcinoma [23]
Liver Hepatocellular carcinoma from cirrhotic liver [24-26]
Kidney Clear cell renal carcinoma [27-30]
Bladder Urothelial carcinoma [29-32]
Squamous cell carcinoma [30, 32]
Prostate Androgen sensitive and insensitive adenocarcinoma [6, 33-38]
Breast Ductal carcinoma [6, 39]
Basal-like carcinoma [39,40]
Lung Non-small-cell lung cancer [41,42]
Pleomorphic carcinoma [43]
Squamous cell carcinoma [44,45]
Adenocarcinoma [46]
Thyroid Papillary carcinoma [47,48]
Brain Glioma [49, 50]
Meningioma [51]
Mesenchyme Ewing's sarcoma [52]
Caveolin-1, a scaffolding protein, prim arily exerts its actions through a 
cytoplasmically oriented scaffolding domain (CSD; AAs 82-101) that binds 
partner proteins that contain a caveolin binding motif[53]. Caveolin-1 
thereby compartmentalizes signaling molecules w ithin caveolae serving as 
a checkpoint for signaling cascades. This signaling is controlled through 
direct interaction o f partner proteins w ith  CSD. Specifically caveolin-1 is 
considered to serve as a molecular brake which inhibits the intrinsic kinase 
activity o f a diverse range of signaling molecules via the action of the CSD. 
[54]. Many signaling molecules and growth factor receptors have been 
shown to interact w ith CSD including tyrosine kinases (Src family), 
glycoslyl phosphatidylinositol-linked proteins, endothelial n itric  oxide 
synthetase (eNOS), PKC isoforms and H-Ras, heterotrimeric G protein [55].
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In addition, caveolin-1 has been shown to regulate a number of genes 
involved in tumourigenesis and tumour progression notably BRCA1, IGFR, 
cydin D l, ERa and survivin[56]. Such interactions in cell signaling and gene 
pathways confer on caveolin-1 a regulatory role in tumour proliferation, 
differentiation, apoptosis and invasion.
5.1.2 Molecular mechanisms of caveolin-1 in cancer progression
Whilst the precise role of caveolin-1 in cancer progression remains to be 
fully elucidated a number of key molecular mechanisms have been 
described. Caveolin-1 appears to promote metastatic potential through a 
general role in cell motility, recycling membrane material on the receding 
face and inserting membrane material into the leading edge thus providing 
cellular locomotion[57]. Additionally, a number of in-vitro studies have 
revealed a positive interaction of caveolin-1 w ith GTPases that are critical 
in promoting cell m otility [58-60]. Further, caveolin-1 probably plays some 
role in the loss of cell-cell contacts in invasive carcinomas; caveolin-1 
localises to both adherens (zonula adherens) and tight (zonula occludens) 
junctions to stabilize epithelial and endothelial barriers[61, 62]. 
Intracellular sequestration o f membranous caveolin-1 has been shown at 
least in-vitro  to increase invasive capacity[63].
The subcellular localization of caveolin-1 is influenced by post-translational 
modifications of various domains w ith in  the protein which in turn serves to 
modify the overall function of caveolin-1 [64]. Phosphorylation of tyrosine,
255
Chapter 5
most notably tyrosine 14, via src-family kinases results in the 
redistribution o f cavolin-1 to integrin-rich focal-adhesion zones and the 
recruitment of a c-src/grb-7 signaling complex which leads to activation of 
the RAS/RAF/ERK cascade and uncontrolled proliferation[65, 66]. Also 
phosphorylation o f caveolin-1 at serine 80 has been shown to shuttle 
caveolin-1 into a secretory pathway resulting in a loss of intracellular 
caveolin-1, an event that is proposed to subvert tumour suppressive 
activity[67]. There is evidence to suggest secreted caveolin-1 may act as an 
autocrine or paracrine tumour-promoting factor in prostate cancer. 
Specifically, caveolin-1 secreted by high-grade androgen insensitive 
prostate cancer cells can be taken up by low grade, caveolin-1 negative and 
androgen sensitive prostate cancer cells where it increases both cell 
viability and clonal growth[68, 69]. Further, this secreted caveolin-1 can 
also be taken up by tumour endothelial cells leading to a number of 
angiogenic activities such as tubule formation, cell migration and nitric 
oxide production [70].
Metastatic spread requires a relaxation o f cell-cell and cell-matrix 
interactions. Caveolin-1 links extracellular matrix components to the 
cytoskeleton and thus influences matrix-dependent growth. In normal 
tissue, caveolin-1 appears to act as a sensor for cell detachment which 
triggers caveolin-1 endocytosis, down regulation o f integrin signaling 
leading to detachment induced apoptosis[71, 72]. Overexpression of 
caveolin-1 allows tumour cells to escape anchorage-dependent growth
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through an integrin-mediated mechanism that results in up-regulation of 
survival pathways that include IGF-1/PI3K/AKT[73, 74]. Caveolin-1 is also 
involved in the remodeling and proteolysis o f extracellular matrix. A 
number of proteases and their regulatory partners, co-localise to caveolae 
and/or are activated by caveolin-1 including cathepsin B, pro-urokinase 
plasminogen activator (pro-uPA), GPI-anchored urokinase-receptor 
(uPAR)[75, 76], matrix metalloproteases (M T l-M M P ,M M P -2 /9 /ll/13 ) and 
its inducer EMM-PRIN(CD147)[77-79]. Dysregulation o f these components 
can lead to unrestricted degradation o f extracellular matrix and increased 
invasive capacity.
5.1.3 Caveolin-1 and astrocytomas
Whilst the number of published articles reporting the function of caveolin-1 
in the pathogenesis o f cancer (breast, prostate, lung, RCC, and colon; see 
table Table 5.1) has increased dramatically during the last decade, the 
number that have specifically focused on its role in glioblastoma are few. 
Several independent gene expression and immunohistochemical studies 
conducted w ith human tissue have consistently reported the up-regulation 
of caveolin-1 in advanced astrocytomas [49, 50, 80-82]. In these studies 
caveolin-1 was mostly associated w ith  grade III oligoastrocytomas and 
grade IV glioblastomas [49] but was reported as absent from the grade II 
oligodendrogliomas. However, recent work by Cassoni and co-workers 
[50] utilized an extended cohort (n = 65) of oligodendroglioma specimens 
and found that caveolin-1 expression could be detected in 22% of all cases
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of this glioma subtype. Specifically, patients w ith oligodendrogliomas that 
stained positive for caveolin-1 had significantly poorer survival than those 
patients whose tumours were caveolin-1 negative. Collectively, these 
clinico-pathological studies support the premise that caveolin-1 serves as a 
tumour promoter in astrocytoma[50].
Surprisingly, only two papers to date have specifically set out to examine, 
mechanistically, the contribution o f caveolin-1 to the phenotype of 
astrocytoma. The first published by Abulrob in 2004 [83] reported the 
expression of caveolin-1 and its association w ith wtEGF-R and recombinant 
EGF-Rvlll in the U87-MG cell line (a grade IV glioblastoma cell line). Here 
they describe the association of wtEGF-R but not the constitutively active 
mutated/truncated EGF-RvIII form. Further, treatment o f U87-MG cells 
w ith specific inhibitors of EGF-R caused an increase in receptor association 
w ith caveolin-1 and caveolae domains. These results allude to the 
possibility of caveolin-1 serving as a tumour suppressor, at least in this cell 
line. However, the authors were ambivalent in their conclusion as to the 
exact role of caveolin-1 in glioblastoma. A second report by Martin et al 
[84], again using the U87-MG cell line, examined the effect of siRNA 
mediated caveolin-1 down-regulation by employing a combination of gene 
array analyses and functional assays. In this work the loss of caveolin-1 
caused an increase in ERK activity, cell proliferation and cell m igration[84]. 
Additionally, integrins were identified as the main set of genes affected by 
caveolin-1 silencing, w ith an up-regulation of a 5 p l (a marker for glioma
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aggressiveness) reported. This latter study proposes that caveolin-1 serves 
as a tumour suppressor and not tumour promoter in glioblastoma.
Evidently, the in-vitro work conducted so far contradicts the clinico- 
pathological studies undertaken. However, it  must be noted that the two in- 
vitro studies conducted to date have both utilized the U87-MG cell line. This 
is a cell line that has certain characteristic features including a w t p53 
status i.e. p53 positive and an absence of EGF-RvIII. Mutations in p53 and 
the presence of EGF-RvIII occur in up to 30% and 60% of all glioblastomas 
respectively, and are associated w ith  the more aggressive clinical features 
of the disease[85, 86]. Therefore, inferences using the U87-MG cell line 
concerning the role of caveolin-1 in pathogenesis of glioma should be 
treated with caution. Clearly, comparative studies of caveolin-1 
contribution to the glioblastoma phenotype are needed in a panel of glioma 
cells w ith different genetic backgrounds and which reflect a broader clinical 
spectrum i.e. cell lines that carry p53 and phosphatase and tensin homolog 
(PTEN) mutations and possess varying levels of EGFR and EGF-RvIII.
5.1.4 Objectives
The aim of this chapter was to investigate the expression and functionality 
of caveolin-1 w ith respect to the pathobiology of a panel of grade IV 
glioblastoma cell lines and to establish i f  caveolin-1 represents a novel 
target for the treatment of glioblastoma. Four cells were selected that vary 
in their known p53 and PTEN status. Mechanistic studies were undertaken
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in an attempt to delineate the signaling pathways responsible for the 
reported up-regulation of caveolin-1 occurring in human glioblastoma.
5.2 Materials & Methods
5.2.1 Materials
Rapamycin was obtained from Cabiochem, (Nottingham, UK). PD 98059 
was obtained from InvivoGen, (Wiltshire, UK). DMSO; glycine; bovine 
serum albumin (BSA); leupeptin; aprotinin; sodium molybdate; 
phenylarsine oxide; NaVCU; NaF and EGTA were obtained from Sigma- 
Aldrich Company Ltd, (Poole,UK). Isotone II diluent was obtained from 
Beckman Coulter, (High Wycombe, UK). All siRNAs were obtained from 
Eurofms MWG/Operon (Ebersberg, Germany). All cell culture mediums and 
Lipoprotein 2000™ were obtained from Invitrogen, (Paisley, UK). 
Acrylamide; ammonium persulphate; SDS; TEMED and Tween 20 were 
obtained from Pharmacia Biotech, (St Albans, UK). Rabbit anti-human 
phospho-S6 polyclonal; rabbit anti-human caveolin-1 polyclonal; rabbit 
anti-human phospho-ERK polyclonal and rabbit anti-human phospho- 
caveolin-1 antibodies were obtained from Cell Signalling Technology, New 
England Biolabs, (Hitchin, UK). HRP conjugated anti-rabbit was obtained 
from Amersham, (Cardiff, UK). Nitrocellulose membranes and Supersignal 
West Dura were obtained from Pierce, (Rockford, USA). Triton-x 100 was 
obtained from ICN Biomedicals Inc, (Ohio, USA). Matrigel® was obtained 
from BD Technologies, (Oxford, UK). Vectashield containing DAPI was 
obtained from Vector Laboratories, Inc. (California, USA).
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5.2.2 Cell lines
The human glioblastoma cell lines U373 MG (p53 mut; PTEN -ve) and T98- 
G (p53 mut; PTEN +ve) were seeded at 1.3 x 104 cells.cm-2 whilst U-87 MG 
(p53 wt; PTEN -ve), A172 (p53 wt; PTEN -ve) were seeded at 2 x 104 
cells.cm*2. All cells were maintained in culture medium comprising DMEM 
supplemented with 10% heat inactivated FBS and the antibiotics penicillin 
G (100 units.ml*1) and streptomycin sulfate (100 pg-ml*1). Cultures were 
maintained at 37°C in a humidified atmosphere (5% C02/95% air) with 
culture medium replenished every 48 hours.
5.2.3 siRNA transfections
As previously described in the literature [87, 88], a synthetic siRNA duplex 
(21 nucleotides) targeting the caveolin-1 mRNA sequence 5'- 
AACCAGAAGGGACACACAGUU-3' was used to down-regulate caveolin-1 
protein expression and an siRNA duplex targeting the firefly luciferase 
(GL2) mRNA sequence 5'-AACGUACGCGGAAUACUUCGA-3' was used as a 
negative control. The duplexes were purchased from MWG/Eurofins 
(Ebersberg, Germany) as unprotected, desalted, and purified siRNA.
U373-MG and T98-G cells were seeded at 1.3 x 104 cells.cm*2, whilst A172 
and U87-MG cells were seeded at 2.0 x 104 cells.cm*2 in 24 well and 6 well 
formats, for growth and Western blot analysis, respectively. After 24h, all 
cells were transfected w ith 70 nmol (0.6ug) for the 24 well format or 
350nmol (3.5 pg) for the 6 well format of siRNA complexed with
261
Chapter 5
Lipofectamine™ 2000 for 4h as recommended by the manufacturer. Briefly 
for 24 well plates (per well) 1 pi of lipofectamine in 50 pi of Optimem was 
complexed with siRNA (70 nmol in 50 pi of Optimem) for 20 mins before 
addition to wells containing 60 pi of Optimem. For 6 well plates (per well) 5 
pi of lipofectamine in 250 pi of Optimem was complexed with siRNA 
(350nmol in 250 pi of Optimem) for 20 mins before addition to wells 
containing 100 pi of Optimem. Four hours after transfection the cells were 
supplemented with Optimem containing serum (FBS) to a final 
concentration of 10%. The cells were harvested 90hrs after transfection for 
cell counts and immunoblotting.
5.2.4 Cell growth analysis
Cell population growth was evaluated by means of trypsin dispersion of the 
cell monolayers (performed in triplicate) following a 72h incubation with 
PD 98059 (10 -  50 pM) or rapamycin (1 nM -  1 pM) or a 90 hour exposure 
to siRNA. Controls were incubated for the same period of time with 
appropriate vehicle or control siRNA (luciferase). Cell counts were 
undertaken by use of a Coulter-counter (Luton, UK). All proliferation 
studies were performed at least three times.
5.2.5 Western blot analysis
5.2.5.1 Preparation of cell lysates
Glioblastoma cell lines, cultured in 6-well plates (surface area 10cm2 per 
well), were incubated at 4°C with 200 pi of lysis buffer (50 mM Tris (pH
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7.5), 1% Triton-X, 5 mM EGTA, 150 mM NaCl, 60 mM n-octyl-glucoside) 
containing protease inhibitors (PMSF, aprotinin, leupeptin, sodium fluoride, 
phenylarsine, sodium molybdate and sodium pervandate). After 15 mins, 
the lysate was collected and centrifuged (13,500g; 15 mins) to pellet 
cellular debris. Lysate was aspirated and stored at -20°C until required.
5.2.5.2 Lysate protein determination
Total protein in cell lysates was quantified using a Bicinchoninic Acid (BCA) 
assay k it (Sigma-Aldrich Company Ltd, Poole, UK) essentially as described 
in [89] but with modifications. Assay reagent was prepared immediately 
before addition to cell lysates by mixing one part BCA solution to fifty parts 
of a 4% w /v  solution of CUSO4.5 H2O. After adding 200 pi of assay reagent to 
25 pi of cell lysate, samples were incubated at 37°C for 30 mins. The 
absorbance of the resultant copper-I-BCA complex was measured at 560 
nm using an Anthos htll m icrotiter reader (Labtech International, East 
Sussex, U.K). Calibration standards of BSA were prepared in the range 200 -  
1000 pg.ml1 in lysis buffer and measured concurrently w ith lysate samples.
5.2.5.3 Gel electrophoresis
Gel electrophoresis was undertaken using the Mini-protean II apparatus 
from Biorad (Hertfordshire, UK). The gel casting apparatus was assembled 
using 1.5 mm spacers and filled w ith a 12 % SDS polyacrylamide running 
gel solution (Table 5.2)
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Table 5.2 Composition of 12 % SDS polyacrylamide running gel solution.
Constituent_________________________ Volume
Tris-HCl, 1.5 M pH 8.8 5 ml
SDS, 12 % w /v  0.1 ml
Acrylamide, 30 % w /v  8 ml
Ammonium persulphate, 10% w /v  0.1 ml
TEMED 0.012 ml
ddH2Q__________  6.6 ml
During polymerization, gels were overlaid w ith isopropanol to prevent 
atmospheric interference during the cross-linking reaction. Once the 
running gel had set (~ 15 min), the isopropanol was removed using blotting 
paper. The running gel was then overlaid w ith a 4% SDS stacking gel 
(Table 5.3)
Table 5.3 Composition of 4 % SDS polyacrylamide stacking gel solution.
Constituent_________________________ Volume
Tris-HCl, 0.5 M pH 6.8 2.5 ml
SDS, 4 % w /v  0.1 ml
Acrylamide, 30 % w /v  1.3 ml
Ammonium persulphate, 10% w /v  0.1 ml
TEMED 0.01 ml
ddH20 6.1 ml
Volumes of cell lysate corresponding to 20 pg of total protein for each 
experimental variable were diluted in an equal volume of 2 x sample 
loading buffer (Table 5.4) which were then heated for 5 mins at 95°C. 
Lysates and molecular markers were then carefully loaded into the gel.
Table 5.4 Composition of loading buffer.
Constituent__________________________ Volume
SDS, 10% w /v  4ml
Glycerol, 20% v /v  2ml
Tris-HCl, 0.2M pH 6.8 2ml
Bromophenol Blue, 0.01% v /v  
DTT, 10 mM
ddH20 __________1.6 ml
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The gel assembly was removed from the casting apparatus and placed 
carefully into a running tank. The tank was filled w ith running buffer (0.025 
M Tris base; 0.192 M Glycine) until the gel was completely submerged 
(~800 ml). Gels were electrophoresed at 200 V for 50 mins.
5.2.5.4 Western blot
Gels were removed from the electrophoretic tank and submerged in ice- 
cold blotting buffer (0.025 M Tris base, 0.192 M Glycine, 20% v /v  
methanol) for 5 mins before protein was transferred from SDS-PAGE gel 
onto nitrocellulose membrane. Nitrocellulose membrane was cut to size 
and prepared for transfer by soaking in blotting buffer for 15 mins. The gel 
was removed from the blotting buffer and the nitrocellulose membrane 
gently placed onto the gel. The gel was then sandwiched firstly between 
filter paper and then between Scotch brite pads. The whole complex was 
then locked inside a transfer cassette and loaded into a gel tank surrounded 
by ice. The tank was filled with blotting buffer and the protein transferred 
over 90 mins by electrophoresis w ith a constant current of 400 mA. The 
nitrocellulose membrane was removed and washed (NaCl, 100 mM; Tris, 
lOmM pH 7.5; 0.1% v /v  Tween 20) before being submerged in blocking 
buffer (5% w /v  non-fat milk in wash buffer) for 1 hr. The membrane was 
then incubated overnight at 4°C w ith primary antibody (1:1000 dilution in 
blocking buffer). The following day the primary antibody was aspirated and 
the membrane was washed 6x w ith washing buffer before incubating w ith 
secondary antibody (1:7000 dilution o f swine anti-rabbit HRP) for 1 hr at
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room temperature. Finally the membrane was washed 6x w ith washing 
buffer. Detection was made in a dark room using SuperSignal® Ultra. 
Detection reagent was prepared as per the manufacturers protocol and was 
spread thinly over the membrane for upto 5 mins. The membrane was 
loaded into an autoradiography cassette and a section of Hyperfilm ECL 
was laid over the membrane before the cassette was sealed. Signal was 
accumulated for 1 minute before the film was developed and fixed. Image 
acquisition was undertaken on a GS-700 densitometer w ith Molecular 
Analyst Software (Bio-Rad, Hemel Hempstead, UK).
5.2.6 Cell invasion assays
The invasive potential of glioblastoma cell lines U373 MG and U-87 MG, was 
investigated in a Matrigel™ invasion chamber. Matrigel™ is a basement 
membrane extract from the Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma, a tumor abundant in ECM proteins particularly laminin, collagen 
IV, heparan sulfate proteoglycans and entactin. Matrigel™ invasion 
chambers have been widely used to study the metastatic potential of 
tumour cells[90-92]. Invasion chambers were prepared by coating 
Transwell™ inserts (8 pm pore size) w ith 50 pi of a 1:3 dilution of 
Matrigel™ in RPMI and incubated at 37°C for 2 hrs. Cells were prepared for 
invasion assays by seeding in 6 well plates for 24 hrs before exposure to 
siRNA or rapamycin. After 72 hrs exposure (total of 96 hrs in-vitro) cell 
monolayers were disaggregated w ith trypsin and each invasion chamber 
was seeded with 50,000 cells (total volume 200 pi). Following a 24 hr
266
Chapter 5
incubation (total time in-vitro of 120 hrs), the Matrigel™ coating was 
carefully removed from the chamber membrane using a sterile cotton bud 
and the chamber was submerged in 3.7% formaldehyde for 10 mins to fix 
the cells. After washing the inserts in PBS, the membrane was carefully 
excised with a scalpel. Once removed, the membrane was mounted cell side 
up on a microscope slide with DAPI Vectashield. Cells were counted from 
micrographs recorded following microscopic examination.
5.2.7 Statistical analysis
Statistical analysis was performed using Graphpad Prism (Graphpad 
Software; California, USA). Results were expressed as mean ± standard 
deviation (SD) unless otherwise stated. Statistical significance between 
multiple groups was assessed using a two-way AN OVA followed by a post 
hoc Bonferroni test Single group differences were determined using a one­
way ANOVA followed by Dunnett's post hoc or by two-tailed Student's t- 
test P < 0.05 was considered significant
5.3 Results
Western blotting of lysates from four cell lines routinely used as in-vitro 
models of grade IV gliomas confirmed the presence of caveolin-1 under 
normal basal conditions (see Figure 5.1) Phosphorylated caveolin-1 was 
also confirmed in A172 (p53 wt; PTEN -ve), U373-MG (p53 mt; PTEN -ve) 
and T 98 G (p53 mt; PTEN +ve) but not in U87-MG (p53 wt; PTEN -ve) (see 
Figure 5.1). Of note, the relative expression of total caveolin-1 in A172 was 
low compared to the other cell lines investigated but the phosphorylated
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caveolin-1 signal was intense and is suggestive that virtually all the 
caveolin-1 is phosphorylated within A172 under basal conditions.
Figure 5.1 Western blot analysis of caveolin-1 and phosphorylated caveolin-1 expression in 
human glioma cell lines. Data are representative of at least three separate experiments.
To assess the role of caveolin-1 in human glioblastoma, its expression was
modulated in the panel of four cell lines, U373-MG, U87-MG, A172 and T 98
G. The siRNA mediated depletion was confirmed at the protein level within
each cell line using Western blotting (Figure 5.2); a control siRNA
sequence against luciferase did not result in any significant change in
caveolin-1. Histograms in Figure 5.2 show that in both p53 wt (U87-MG
and A172) and p53 mt (U373-MG and T 98 G) cell lines, down-regulation of
caveolin-1 results in a significant (p < 0.05) reduction in cellular
proliferation. It should be noted that the control siRNA sequence did
however also result in a significant reduction in growth (particularly for the
U87-MG and U373-MG cell lines) probably as a result of transfection lipid
and is not an uncommon feature of siRNA studies examining the effect upon
cell growth. When re-expressed as a % of control siRNA, then knockdown
of caveolin-1 had a statistically significant (p < 0.05) effect upon cell growth
compared to the control siRNA treatments.
total Caveolin-1
pCaveolin-1
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Figure 5.2 Effect of siRNA-mediated down-regulation of caveolin-1 on cell growth of p53- 
poistive glioma cell lines U87-MG and A172 and p53 mt cell lines U373-MG and T 98 G. 
Treatments are caveolin-1 siRNA or control luciferase siRNA. Representative Western blots of 
caveolin-1 are shown for each cell line. Results are expressed as mean ± SD (n = 4). * denotes 
significance (p < 0.05) versus no-treatment control, f  denotes significance (p < 0.05) versus 
control luciferase siRNA.
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Table 5.5 shows the percentage reduction in cellular proliferation as a 
result of the down-regulation of caveolin-1. At a minimum, down-regulation 
of caveolin-1 results in a ~ 20% (U373-MG) reduction in cellular 
proliferation compared to similarly treated control siRNA cells and in the 
case of A172 by as much as 74%. Of note, the effects of caveolin-1 down- 
regulation on cellular proliferation did not appear to correlate w ith p53 or 
PTEN status.
Table 5.5 Effects of siRNA mediated down-regulation of caveolin-1 on cellular proliferation. 
Data are mean ± SD (n=4). * denotes significance (p < 0.05) versus no-treatment control, f  
denotes significance (p < 0.05) versus control luciferase siRNA
____________ Percentage reduction in proliferation____________
________________ Luc-siRNA vs NT Cavl-siRNA vs NT Cavl siRNA vs Luc-siRNA
U87-MG CpS3 wt) 35.76 ±4.54’ 51.61 ±3.79* 24.67 ± 5.89+
A172(pS3wt) 22.86 ±4.09* 79.89 ± 1.29* 73.93 ± 1.67+
U373-MG (p53 mt) 42.77 ± 8.63* 54.89 ± 4.31* 21.17 ± 7.53+
T98G(pS3mt)_______6.45 ± 5.36*_______ 34.11 ±5.93* 29.57 ± 6.34+___
The influence of caveolin-1 on the invasiveness of glioma cell lines was 
measured in Matrigel invasion chambers. The data show that for U373-MG 
cells, depletion of caveolin-1 significantly (p < 0.05) reduces invasive 
capacity by up to 80% (Figure 5.3); in contrast, in U87-MG cells no 
reduction of invasiveness was observed.
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Figure 5.3 Effect of siRNA-mediated down-regulation of caveolin-1 on invasion of glioma cell 
lines U87-MG and U373-MG through Matrigel. (A) Down-regulation of caveolin-1 in U373-MG 
cells treated with caveolin-1 siRNA results in reduced invasive capacity compared to cells 
treated with luciferase siRNA (~ 80% reduction). Down-regulation of caveolin-1 in U87-MG 
cells treated with caveolin-1 siRNA had no affect on invasive capacity. Data are mean ± SEM 
for 5 fields of view (n = 2 chambers) expressed as percentage control (luciferase siRNA). * 
denotes significance (p < 0.05) versus luciferase siRNA. (B) Representative fields of view of 
Matrigel invasion chambers (x 20 magnification) reveal that U373-MG are generally more 
invasive than U87-MG.
Having shown in cell growth studies (Figure 5.2) and invasion studies 
(Figure 5.3) that elevated caveolin-1 expression correlates with glioma 
aggressiveness, efforts were made to dissect the pathways through which 
caveolin-1 acts. Figure 5.4 shows the effects of caveolin-1 down-regulation
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on phosphorylated (activated) ERK in the U373-MG and U87-MG cell lines. 
In the U87-MG cell line, depletion of caveolin-1, as confirmed by Western 
blot, resulted in a similar depletion in phosphorylated ERK, indicating 
reduced ERK activity. This result demonstrates that caveolin-1 is upstream 
of ERK i.e. caveolin-1 potentiates ERK activity. For cell line U373-MG no 
reduction in activated ERK accompanied the down-regulation of caveolin-1. 
This result suggests that caveolin-1 has no direct effect on ERK or that ERK 
is upstream of caveolin-1 i.e that ERK drives caveolin-1 expression in this 
cell line.
U373-MG
&
A**
total caveolin-1
U87-MG
o r  o ?^ ^ r
total caveolin-1
pERK — pERK -
Figure 5.4 Protein expression of total caveolin-1 and activated (phosphorylated)  ERK in U87- 
MG, U373-MG, A172 and T 98 G following siRNA-mediated down-regulation of caveolin-1. 
Western blots are representative of at least three separate experiments.
Figure 5.6 shows the effects on U373-MG and U87-MG cell growth of the
ERK inhibitor PD 98059 and Figure 5.5 shows representative Western
analyses for total caveolin-1 and activated (phosphorylated) ERK following
exposure to PD 98059. In both cell lines, PD 98059 resulted in
concentration dependent inhibition of cell growth (Figure 5.6). In U87-MG
cells, PD 98059 reduced expression of phosphorylated (activated) ERK but
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had no effect on total caveolin-1 levels. This result is consistent with that 
shown in Figure 5.4 indicating that caveolin-1 is upstream of ERK in the 
U87-MG cell line. In U373-MG, PD 98059 exposure resulted in losses in 
activated [phosphorylated) ERK and total caveolin-1 indicating that ERK is 
upstream of caveolin-1 i.e. ERK activity potentiates caveolin-1 expression.
U87-MG
Rapamycm PD98059
total caveolin-1 
pS6
pERK
U373-MG
Rapamycm PD98059
total caveolin-1 
pS6 
pERK
Figure 5.5 Representative Western blots of caveolin-1, phosphorylated (activated)  56 and 
phosphorylated (activated) ERK in U87-MG and U373-MG cells following exposure to the 
mTOR inhibitor Rapamycin or the ERK inhibitor PD 98059.
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■  U373-MG 
□  U87-MG
PD98059 concentration (uM)
Figure 5.6 Effects of the ERK inhibitor PD 98059 on cell growth in U87-MG and U373-MG cell 
lines. Results are expressed as mean ± SD (n = 4). * denotes significance (p < 0.05) versus no­
treatment control, f  denotes significance (p < 0.05) versus respective U373-MG treatment
Figure 5.7 shows the effects on cell growth of U373-MG and U87-MG
following exposure to the mTOR inhibitor rapamycin and Figure 5.5 shows
representative Western analyses for total caveolin-1, phosphorylated S6
(activated), a downstream marker in the mTOR pathway, and
phosphorylated (activated) ERK in cells exposed to rapamycin. In both cell
lines rapamycin resulted in concentration-dependent inhibition of cell
growth and loss of activated S6. However, it is noted that U373-MG cells
were significantly more resistant to the growth inhibitory effects of
rapamycin than U87-MG cells at all doses examined. Strikingly, rapamycin
had no effect on total-caveolin-1 in the U87-MG but caused a significant
increase in total caveolin-1 expression in U373-MG. The rapamycin
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mediated increase in caveolin-1 in U373-MG was paralleled by increases in 
the expression of phosphorylated (activated) ERK Figure 5.5. This is a 
result consistent with ERK activity driving caveolin-1 expression in the 
U373-MG cell line given that PD 98059 (ERK inhibitor) treatments reduced 
caveolin-1 levels Figure 5.5. Collectively, these results conclude that 
rapamycin increases ERK activity in U373-MG cells, which in turn further 
increases caveolin-1 expression.
□  U373-MG
□  U87-MG
Rapamycin concentration (nM)
Figure 5.7 Effects of the mTOR inhibitor rapamycin on cell growth in U87-MG and U373-MG 
cell lines. Results are expressed as mean ± SD (n = 4). * denotes significance (p < 0.05) versus 
no-treatment control, f  denotes significance (p < 0.05) versus respective U373-MG treatment
Given then that U373-MG cells exposed to rapamycin result in an
upregulation in caveolin-1 (Figure 5.5) and that caveolin-1 promotes
invasion in U373-MG cells (Figure 5.3) it was hypothesized that rapamycin
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treatment of U373-MG may promote invasion. Figure 5.8 shows that 
despite an up-regulation of caveolin-1 following rapamycin treatment, the 
invasiveness of U373-MG is actually reduced following rapamycin 
treatment
■§ 300-i
Figure 5.8 Effect of the mTOR inhibitor Rapamcyin on invasion ofU373 cells into Matrigel™. 
Data are mean ± SEM for 5 fields of view (n =2  chambers).
5.4 Discussion
Examination of caveolin-1 and phosphorylated caveolin-1 in a panel of 
glioblastoma cell lines revealed different degrees of expression of both 
isoforms between the four cell lines. This is the first study to identify 
phosphorylated caveolin-1 in glioma cell lines and is a finding that has
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profound implications for the role of caveolin-1 in tumour pathobiology 
and glioma disease progression per se. Comparing total levels of caveolin-1 
to its phosphorylated form in each of the cell lines it can be concluded that 
the caveolin-1 in both the T98-G and A172 cell lines is virtually all 
phosphorylated. Although treatment with caveolin-1 siRNA affected the 
growth of all the glioma cell lines examined to varying degrees, it is 
interesting to note that the growth of the T98-G and A172 were the most 
sensitive to the loss of caveolin-1, with respectively 29% and 74% growth 
inhibition. This suggests that phosphorylated caveolin-1 in these cell lines 
is important for their proliferative capacity. Indeed, this is a finding 
consistent with a recent study by Felicetti and co-workers[93] who found 
that phosphorylated caveolin-1 was critical for the proliferation of human 
melanoma cell lines. Therefore it can be reasoned that the targeting of 
caveolin-1 in glioma would significantly reduce tumour size and retard 
disease progression.
At this stage it must be acknowledged that the targeted down-regulation of 
caveolin-1 in the U87-MG cell line also inhibited growth by 24.6%, a finding 
in contrast to Martin et al 2009[84]. These latter workers actually found 
that the loss of caveolin-1 increased growth by up to 50%, a finding which 
led them to conclude that caveolin-1 serves as a tumour suppressor in this 
cell line[84]. Of note, these researchers used a biochemical assay of 
proliferation as their end point instead of cell counts as conducted in this 
study. However, the most plausible explanation of the differences reported
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in this study and that o f Martin et al is that different sub-lines o f U87-MG 
exist between laboratories. Well documented examples of different cancer 
cell sub-lines giving varying results exist, these reflect subtle differences in 
their molecular profiles and hence phenotype. Perhaps the most notable 
being the MCF-7 breast cancer cell line[94] and the LnCap prostate cancer 
cell line[68]. The different sub-clones o f U87-MG that are indicated to exist 
probably result from cell heterogeneity w ith in the original U87-MG 
parental cell cultures [95]. Indeed, five distinct populations could be cloned 
from the parental U87-MG cell culture based upon their expression of tissue 
factors alone [95]. Each o f these populations differed in their growth rate 
and led the authors to conclude that such cell culture heterogeneity can 
complicate experiments using molecular manipulation [95]. Nevertheless, 
the reduced U87-MG cell growth following caveolin-1 siRNA treatment 
presented in this present study is consistent w ith the accompanied loss of 
activated ERK (a growth promoting signaling component) following 
caveolin-1 down-regulation (Figure 5.4). Further, no inverse relationship 
between caveolin-1 and ERK was demonstrated in any of the four cell lines 
examined. Coupled w ith  the reduced growth rates evident in all cell lines 
following caveolin-1 knockdown, collectively these results strongly support 
a role for caveolin-1 as a tumour promoter in glioma and not a tumour 
suppressor. This is in agreement w ith  the immuno-histochemical studies 
conducted w ith clinical glioma specimens that show increased caveolin-1 
expression correlates w ith adverse disease parameters [49, 50,80-82]. Also 
it  can be concluded from these studies that the contribution of caveolin-1 to
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the growth of glioblastomas does not occur in a p53 and PTEN dependant 
manner. Hence these studies identify caveolin-1 as novel drug target for the 
treatment of glioma in general, irrespective of their genetic background.
Invasion studies were conducted in the U373-MG and U87-MG cell lines to 
examine the potential role of caveolin-1 in the process of cellular invasion. 
Clearly the targeted down-regulation of caveolin-1 in the U373-MG resulted 
in a dramatic inhibition of 7&2j£% ± 19.5 compared to control luciferase 
siRNA treated cells. No significant effect o f caveolin-1 down-regulation on 
invasion in the U87-MG was observed. It is interesting to note that the more 
invasive U373-MG cells contained phosphorylated caveolin-1. This is 
consistent w ith the reported role o f phosphorylated caveolin-1 in the 
increased invasion o f human melanoma[93] and breast cancer cells [58]. In 
these studies the knockdown of caveolin-1 or transfection w ith a caveolin-1 
mutant that cannot be phosphorylated inhibited invasion and formation of 
foci in semisolid medium [93] and altered focal adhesion kinase signaling 
(FAK) disrupting focal adhesion dynamics which are critical for the 
invasion and metastasis o f cancer cells [58]. Caveolin-1 over-expression has 
also been linked to invasion and metastasis to lymph nodes and distant 
sites in several cancers including kidney [27], breast [14] prostate [96] and 
lung[45], although the phosphorylation status of caveolin-1 in these latter 
clinico-pathological studies was not examined.
Metastasis of gliomas to distant organs is rare and therefore is not a clinical 
issue. However, invasive growth and local in filtration into surrounding
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nerve tissue is a well known characteristic o f glioblastomas and a 
phenomena that lim its the success o f treatment strategies[97]. Further the 
diffuse nature of malignant glioma w ith in  brain parenchyma has long been 
recognized by neurosurgeons when super-radical hemispherectomies 
failed to fully eradicate tumours [98]. Re-growth o f tumour from locally 
invaded cells nearly always occurs and is associated w ith chemo- and 
radio-resistance, giving rise to the possibility that locally invasive glioma 
cells activate cell signaling pathways that mediate resistance to such 
conventional therapies[98]. Therefore based upon the invasion results 
obtained in the U373-MG cell line it can be proposed that caveolin-1 may 
represent a valid target and an alternative treatment strategy for inhibiting 
such localized in filtra tion and treatment resistance. Interestingly, it  is 
increasingly realized that invasive glioma cells show a decreased 
proliferation rate[98]. The loss of caveolin-1 in the U373-MG cell line did 
not retard growth to the same extent as in the other glioma cells lines 
(albeit marginally when compared to U87-MG). This may be reconciled by 
the fact that caveolin-1, or specifically, phosphorylated caveolin-1 has a 
more predominant role in driving invasion than proliferation in the U373- 
MG cell line, as opposed to the A172 cell line where its role may be that of 
driving proliferation. However, it is acknowledged that further work on the 
contribution o f caveolin-1 in the A172 and T98-G cell lines are needed in 
order to support this conjecture.
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It is important to consider factors that may drive caveolin-1 
phosphorylation in glioma cells, given the present study shows that the 
phosphorylation status of caveolin-1 differs between glioma cell lines. This 
may convey different cellular properties and hence impact upon outcomes 
for glioma patients. Src kinase is a well established molecule that mediates 
the phosphorylation of caveolin-1 at tyrosine 14 [65]. This src-mediated 
caveolin-1 phosphorylation is reported to stimulate the subcellular 
trafficking of activated EGF-R to increase cell migration and invasion[66, 
99]. Also src-mediated caveolin-1 phosphorylation is in turn regulated by 
EGF-R. For example in human squamous and epidermoid carcinoma cells 
caveolin-1 is phosphorylated via src kinase upon EGF-R activation[100]. In 
addition aberrant EGF-R status is also shown to induce the src kinase- 
mediated phosphorylation o f caveolin-1. Specifically, cells that over­
express EGF-R or carry EGF-R forms exhibiting mutated truncations w ithin 
the intracellular c-terminus have phosphorylated caveolin-l[101]. Indeed, 
caveolin-1 phosphorylation is maximal when the EGF-R is truncated since 
these forms of the receptor are constitutively activated[101].
These above studies clearly indicate that under certain conditions caveolin- 
1 and EGF-R co-operate to modulate cell behaviour. It is perhaps this 
relationship between EGF-R status and caveolin-1 phosphorylation that is 
most important for glioma and disease progression. Amplification of the 
EGF-R gene and over-expression of EGF-R protein is the most common 
genetic alteration and occurs in about 40% of all primary glioblastomas. Of
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these, up to 75% harbour EGF-R gene rearrangements resulting in the 
increased expression o f both w ild type and mutated EGF-R forms [86]. The 
most common EGF-R mutation in glioblastomas is known as EGF-RvIII and 
is associated w ith increased cell proliferation[102], invasion [103], tumour 
angiogenesis[104] and chemo-resistance[105]. The EGF-R status o f the 
four glioma cell lines used in this study is currently unknown but it can be 
rationalised that their phosphorylated caveolin-1 status may reflect 
underlying alterations in EGF-R. Indeed, the A172 cell line has been 
previously fully characterized w ith respect to EGF-R status by others and 
found to contain EGF-R tandem duplication mutations which, similar to 
EGF-RvIII, arise from rearrangements between introns[106]. It must be 
noted that of the four cell lines used in this study, the A172 cell line 
displayed the highest levels of phoshorylated caveolin-1 when compared to 
total caveolin-1 levels. Given these lines of evidence it  is envisaged that a 
caveolin-1 inhib itor would effectively disrupt the EGF-R-caveolin-1 axis in 
glioma tumour cells and therefore lim it the disease parameters of 
glioblastomas.
One element o f this chapter was a preliminary investigation into the 
signaling pathways that may drive the over-expression of caveolin-1 in 
glioma cell lines, namely that of the ERK and mTOR signaling pathways. In 
the U87-MG cell line, PD 98059 a specific inhibitor o f ERK did not inh ib it 
caveolin-1 expression at any of the doses examined, despite reductions in 
phosphorylated (activated) ERK. This result clearly indicates that in the
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U87-MG cell line, caveolin-1 is not affected by ERK activity. Further, it  can 
be concluded that caveolin-1 lies upstream of ERK and serves to potentiate 
ERK activity; since it was shown that caveolin-1 down-regulation results in 
reduced levels of phosphorylated ERK. How caveolin-1 potentiates ERK 
activity in glioma is unknown but two mechanisms are possible. Firstly, 
caveolin-1 may, as previously mentioned, serve to traffic EGF-R, the major 
upstream activator of ERK and hence allow optimal EGF-R function. 
Secondly, caveolin-1 may increase levels of phosphorylated ERK via the 
inhibition of inhibitory phosphatases such as PP1 and PP2A, for which a 
function for caveolin-1 has been demonstrated in prostate cancer cells 
[107].
Conversely, in the U373-MG cell lines, PD 98059 caused a dramatic 
reduction in caveolin-1 expression, demonstrating that in this glioma cell 
line, caveolin-1 expression is actually driven by ERK activity. Interestingly, 
rapamycin, a specific inhibitor of mTOR, caused up-regulation of caveolin-1, 
an increase that was paralleled by increases in phosphorylated [activated) 
ERK (Figure 5.5). Therefore it can also be concluded that in the U373-MG 
cell line inhibition of the mTOR signaling pathway results in a 
compensatory up-regulation of the ERK signaling pathway leading to 
enhanced caveolin-1 expression. This phenomenon may explain why mTOR 
inhibitors such as rapamycin have met w ith limited success in clinical trails 
for glioma[108]. Indeed, the U373-MG cell line (in which mTOR inhibition 
caused an up-regulation of ERK activity and increased caveolin-1
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expression) was a lot less sensitive to the growth inhibitory effects of 
rapamycin than the U87-MG. This reveals an as yet unidentified pathway 
that limits the action of mTOR inhibitors in glioma. Similar compensatory 
pathways following mTOR inhibition are seen in prostate cancer cells [109], 
although the effects on mTOR inhibition on caveolin-1 expression have not 
been described. Collectively, the results from the inhibitor work conducted 
in the U373-MG and U87-MG cell lines show that caveolin-1 is differentially 
regulated in different glioma subtypes.
In conclusion the work undertaken in this chapter describes for the first 
time that caveolin-1 serves to potentiate the growth and invasion of 
glioblastoma cells and as such serves as a tumour promoter. Its 
involvement in these two different pathological parameters make it an ideal 
and much needed novel drug target for the treatment of glioblastomas. In 
this chapter was also shown how caveolin-1 expression affects and is 
affected by key signaling pathways (a proposed schematic of the role of 
caveolin-1 in the prgression of glioblastoma multiforme can be found in 
Appendix 2). These insights also provide valuable information regarding 
treatment decisions when using molecular targeted therapies such as 
mTOR inhibitors and tyrosine kinase inhibitors for the treatment of 
glioblastomas.
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6.1 Introduction
In recent years it has become apparent that caveolin-1 plays a key role in 
the modulation of signal transduction events[1, 2]. As a corollary any 
alteration in the expression or functioning of caveolin-1 w ill result in 
modified cell signaling potentially leading to pathology[3]. Reports in the 
literature have shown that alteration in expression or functioning of 
caveolin-1 contributes to the aetiology of a wide range of diseases that 
include cancer[4, 5], diabetes[6], degenerative muscular dystrophies[7], 
cirrhosis[8], pulmonary fibrosis[9], atherosclerosis[10, 11], and 
Alzheimer's disease[12]. Indeed the studies detailed in Chapter 5 of this 
thesis demonstrated the positive correlation of caveolin-1 with cellular 
proliferation and invasiveness in glioblastoma multiforme. In addition, 
caveolin-1 plays a role in the pathology of a variety of infectious diseases 
including HIV[13, 14], neonatal meningitis[15, 16], Chlamydia[17], human 
papilloma virus[18,19] and prion disease[20].
Many of the functions of caveolin-1 are mediated through a small 
scaffolding domain (caveolin-scaffolding domain; CSD) located within the 
oligomerisation domain (see Figure 6.1 for the location of the scaffolding 
domain w ithin caveolin-1). The significant role of CSD in caveolin-1 
function was first demonstrated in 1995 when Li and co-workers[21] 
showed that CSD inhibits heterotrimeric G-proteins in GTP hydrolysis 
assays. Subsequently, various laboratories have shown that CSD from 
caveolin-1 not only interacts with G-proteins but with a variety of disparate
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signaling molecules that include EGF-R, Src family tyrosine kinases, PKC 
iso-forms, H-Ras, Neu, and eNOS (a detailed list of these molecules can be 
found in [22]); generally reports have shown the interaction of a signaling 
molecule with caveolin-1 CSD inhibits downstream signaling.
A
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Figure 6.1 Structure and topology of caveolin-1. (A) Membrane topology of caveolin-1. 
Depicted are two caveolin-1 monomers interacting through the scaffolding domain (within 
the oligomerisation domain) to form a dimer. In reality 14-16 monomers interact to form a 
homodimer or if  interaction is with caveolin-2, a heterodimer. (B) Schematic of the various 
domains within caveolin-1. Adapted from [23].
Whilst a caveolin scaffolding domain can be found in all members of the 
caveolin family (caveolin-1, -2, -3), there is only significant homology of 
amino acid sequence between caveolin-1 and caveolin-3 (75%
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conservation); CSD within caveolin-2 is divergent with only 37% of the 
amino acids conserved with respect to either caveolin-1 or caveolin-3 (see 
Figure 6.2). The studies in this chapter are only concerned with the 
scaffolding domain within caveolin-1.
“■ - D G I W K A S F T T F T V T K Y W F Y R 101 Human c a v e o l i n - 1  
cbD K V W I C S H A L E I S T K Y V M Y K 87 Human caveolin -2  
^ D G V W K V S Y T T F T V S K Y W C Y R 74 Human c a v e o l i n - 3
Figure 6.2 Sequence alignment of the caveolin scaffolding domain in the human caveolin gene 
family. Identical residues are boxed and highlighted in blue. Caveolin-1 and caveolin-3 are the 
most closely related (75% conservation) with caveolin-2 divergent (35% conservation).
In 1997 Couett and co-workers[24] used a 10-mer and 15-mer linear
peptide phage library and panned against CSD from caveolin-1 in an effort
to elucidate the protein sequence requirements for interaction with CSD.
They found that virtually all the peptides that bound CSD contained a
conserved motif of either ojXcoXXXXo), coXXXXcoXXco or goXgoXXgoXXco
where o> is an aromatic residue (Phe, Trp or Tyr) and X is any other residue.
Subsequent searches within proteins known to bind caveolin -1 by a variety
of independent researchers (see Table 6.1 for examples) revealed that
such proteins invariably contain one of these ‘caveolin binding domains'
(CBD) within their primary sequence (reviewed in [22]).
Table 6.1 Caveolin binding domains identified in key signaling molecules.
Protein Caveolin binding domain
Gi2a ETEKDLYEKME
eNOS ESAAPESGW
SRC family kinase WSEGILLX
EGF-R w s y g v tv w
PKCa WAXGVLLy
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It is important to note however, that the presence of a caveolin binding 
domain w ith in a protein is not an absolute predicator o f interaction w ith 
CSD and it  is clear that surface exposure of the CBD on the protein is a key 
determinant for interaction. Further, i f  any such interactions occur they 
may be very short-lived such that biochemical determination is likely to be 
extremely d ifficu lt
The mechanism by which the caveolin binding domain interacts w ith 
caveolin-1 CSD remains to be fully elucidated since, to date, CSD from 
caveolin-1 has not been crystallised either alone or w ith a binding partner 
on-board. However, ‘shotgun scanning' of the scaffolding domain with 
phage displaying closely relatecHjomqlogs of CSD from caveolin-1, reveal 
that residues 82, 90, 91, 95, an^97,wl)ich form a helical wheel on the face 
of CSD, are important for interaction w ith eNOS and PKCa[25]. Some 
studies have also suggested that the oligomerisation and deoligomerisation 
through CSD is critical for the modulation of binding affinity to partner 
proteins[26]. As a result any agent that interferes w ith oligomerization 
processes may inh ib it binding of partner proteins and therefore potentially 
alter downstream signaling.
More recently elegant in-vitro and in-vivo studies have been undertaken to 
elucidate the role o f the caveolin-1 scaffolding domain (as opposed to the 
entire caveolin-1 protein) in human health and disease. This has generally 
taken the form of modulating signaling pathways through the intracellular 
delivery of caveolin-1 scaffolding domain via attachment to cell penetrating
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peptides. Bucci and co-workers[27] produced a chimeric protein (AP-CSD) 
o f caveolin-1 scaffolding domain (CSD) and the cell penetrating peptide 
Antennapedia (AP). After demonstrating that exposure of aortic rings to 
AP-CSD inhibited acetycholine-induced relaxation of blood vessels and 
eNOS derived production of n itric oxide, AP-CSD was administered by
J *
intraperitoneal injection into a mouse model of foot-pad inflammation 
(carrageenan, injection into the foot pad). Only the AP-CSD sequence, and 
not the respective AP-scrambled CSD control sequence reduced 
carrageenan-induced foot-pad oedema through the attenuation o f eNOS- 
dependant blood-flow.
Neonatal meningitis, an infectious disorder of the CNS is associated w ith 
the entry o f Escherichia coli K1 into brain parenchyma. Dissemination of the 
bacterium follows transcytosis across brain microvascular endothelium 
w ith in  caveolae[16, 28, 29, 30]. Studies have shown that the interaction of 
caveolin-1 w ith PKCa at the site o f E. coli K1 attachment is essential for 
invasion of the brain endothelia[15, 31]. Sukumaran and co-workers[15] 
have demonstrated that invasion can be blocked either by the over­
expression of a dominant negative form of caveolin-1 that has been 
mutated w ith in  the scaffolding domain such that it  does not bind PKCa or 
by exposure of brain microvasculature to AP-CSD which competes for 
PKCa.
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6.1.1 Objectives
In this chapter a phage display study was undertaken to identify novel 
peptides that bind the caveolin-1 scaffolding domain. Peptides that bind 
the caveolin-1 scaffolding may have u tility  in modulating caveolin-1 
function. The panning experiments used a two-step protocol (see chapter 
2) where a caveolin-1 scaffolding domain biotin conjugate, in solution, was 
the biopanning target before subsequent capture of the conjugate, plus 
bound phages, onto streptavidin paramagnetic beads. The interaction of 
the peptide-phages with caveolin-1 scaffolding domain was subsequently 
assessed on an individual clonal basis using an ELISA assay before those 
clones showing maximal binding were gene sequenced to identify the 
displayed peptides. The peptide sequence of those strongly binding phages 
w ill serve as a chemical framework o f a future research program to develop 
small molecule peptidomimetics interacting w ith CSD to modulate caveolin- 
1 functioning.
6.2 Materials
Materials used in this chapter have previously been detailed in Chapter 2.
6.3 Methods
The general methods for panning and ELISA studies were as described in 
Chapter 2 as used for panning against streptavidin target on magnetic 
beads.
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6.3.1 Preparation of CSD-biotin
CSD-biotin was suspended in 50:50 acetonitrile.HzO containing 0.1% TFA 
to a concentration of lm g .m l1; stock was protected from light and stored at 
4°C for a period of up to 1 month. Stability of this CSD-biotin stock at 1 
month was confirmed using Matrix-assisted laser desorption/ionization 
mass spectroscopy (MALDI-TOF). Samples and matrix for mass 
spectroscopy were prepared by Dr Christopher Morris (Welsh School of 
Pharmacy) and processed in Cardiff University Chemistry department using 
a Waters micro MX MALDI-TOF.
6.3.2 Panning
The Ph.D.-C7C™ cyclised 7-mer disulphide constrained peptide phage 
library was used in panning experiments against CSD-biotin. A schematic of 
the panning experiment can be seen in Figure 6.3. Specifically, 
streptavidin Magnesphere™ paramagnetic particles (SA-PMPs) were 
washed three times w ith phosphate buffered saline immediately prior to 
use. Panning experiments were conducted in 1.5 ml microcentrifuge tubes 
that were blocked w ith Superblock™ (guaranteed biotin-free) prior to use; 
of note we have observed, in contrast to the use of Superblock™, phage 
display experiments conducted w ith  standard BSA or non-fat m ilk blocking 
buffers result in a tendency for selection of streptavidin binding peptides 
(HPQ motif). Plastic binding peptide phages were deleted from the library 
by adding 2 x 1011 pfus of peptide-phages to a microcentrifuge tube. After 1 
hour, the non-binding phages i.e. those remaining in supernatant were
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transferred to a microcentrifuge tube containing 10 mg of SA-PMPs and 
incubated at room temperature for 1 hour w ith gentle rocking. The SA- 
PMPs w ith bound streptavidin binding phage were then pelleted using a 
rare earth metal magnet (neodymium). The supernatant was then 
transferred to a microcentrifuge tube containing 40 pmoles (~0.12pg) of 
CSD-Biotin in 100 pi of TBS; CSD being the primary target After 1 hour, 10 
mg of SA-PMPs were added to bind the biotin on the CSD and thereby afford 
the collection of peptide-phage binders to the CSD-biotin target; lOmg of 
SA-PMPs binds 47 pmoles of biotin which should be sufficient to bind every 
molecule of CSD-biotin (40 pmoles) in the supernatant After a 15 minute 
incubation, the SA-PMPs were pelleted by magnet The SA-PMPs were 
washed lOx w ith TBS-T(0.5%) before being exposed to 3x 5 minute glycine 
buffer elutions (200 pL) during which the SA-PMPs were sonicated. The 
glycine elutions containing eluted peptide phages were neutralized, pooled 
and amplified to serve as input into the next iterative panning round. A 
total of four panning rounds were completed.
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Streptavidin ^  Biotin Q  Caveolin Scaffolding
Domain
1). P re-adsorb  phage
library on Strepravidin M A G N E T  
coated m agn esp heres  
to delete  Streptavidin  
binders.
(C)
2). Pellet m agn esp here-p h ag e complex 
w ith  a m a g n e t  (b )  a n d  t r a n s fe r  
supernatan t to CSD-biotin  solution (c). 
Add s tre p ta v id in  m a g n e s p h e re s  to 
com plex biotin (d).
3 ). Pellet m ag n esp h ere - 
b i o t i n - C S D - p h a g e  
com plexes and discard  
*ion-b ind ing  p hage (e)
4 ). E lute bound phage using low pH (2 .2 ) glycine 
elutions coupled with sonication (f). Amplify eluted  
p h ag e  in bacterial host (g). Amplified phage serve  
as input into subsequent iterative panning rounds 
(h ). O n com pletion of panning individual phage  
clones w ere analysed by ELISA  against C S D .
Figure 6.3 Schematic of phage panning procedure to isolate peptides that bind caveolin-1 
scaffolding domain.
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6.3.3 ELISA 
6.3.3.1 Coating of streptavidin plates with CSD-biotin or biotin
Streptavidin coated 96 well plates were washed 3x w ith PBS-Tween-0.05% 
before each well was exposed to 300 pmoles of CSD-biotin in 60 pi TBS; the 
plates used comprised 30 pmoles o f streptavidin covalently bound to the 
bottom of the well. After 15 minutes, excess CSD-biotin was removed with 
3x 200pi PBS washes; coated plates were used immediately.
6.3.3.2 Plaque based amplification EUSA
In order to screen peptide phage clones w ith  medium to high throughput, a 
plaque based ELISA was developed. Individual, well separated phage 
plaques were cored from a Petri dish using a sterile 1ml pipette tip (a 
separate tip  was used for each plaque to avoid cross-contamination). 
These individual plaques were added to separate wells of a m icrotiter plate 
to which was also added a 250 pi aliquot of log-phase (OD600 ~  0.6) E. coli 
culture. This m icrotiter plate was covered and incubated for 4 hours at 
37°C on an orbital shaker (100 rpm). After centrifuging the plate at 1500g 
for 10 mins to pellet the E. coli, 100 pi samples of phage-containing 
supernatant were transferred from each well into a corresponding well of a 
96 well m icrotiter plate that had been coated w ith CSD-biotin and which 
serves as the plate for ELISA; the remaining supernatant was stored at 4 -  
8°C to serve as a stock for future experiments. After 1 hour the supernatant 
was aspirated from the CSD-coated wells and the wells were then washed 
6x w ith  TBS-T(0.5%). Thereafter, the ELISA protocol detailed in Chapter 2
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was followed. Negative control was insertless phage (n = 4 per plate) and a 
positive control was peptide-phage with sequence AC-GSYWHPQ-CGGGS 
(streptavidin binding; n = 4 per plate) binding to uncoated streptavidin 
wells. A further sequence, AC-PPTHGRH-CGGGS, isolated from glycine 
elution 3 of round 3 of the panning studies was included as an inter-plate 
control (n = 4 per plate). A total of 1008 clones were analysed using this 
plaque based assay (12 microtiter plates in total). Phage clones resulting in 
absorbance signal at least six-fold greater than insertless phages were 
deemed to be strong binders (moderate binders were classed as a ratio of
3-6 fold greater than insertless and < 3 fold were classed as weak binders).
6333 Sequencing
A random selection of 58 phage clones designated as strong binders based 
on ELISA data (6-fold greater absorbance than insertless phages) were 
gene sequenced to identify the displayed peptide. The preparation of DNA 
samples from phage clones and the subsequent gene sequencing protocol 
has previously been described in chapter 2.
6.4 Results
6.4.1 Stability of CSD-biotin
To assess the stability of a stock of CSD-biotin (1 mg-ml1 in 50:50 
acetonitrile:H20; 0.1% TFA), MALDI-TOF mass spectra were generated 
following 1 month storage in the dark at 4°C. The expected mass of CSD- 
biotin was 2990 Da and the observed mass was 2991.8 Da (Figure 6.4). 
These data indicated stability under the tested conditions and therefore
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panning experiments were undertaken w ith stocks prepared and stored in 
this way. After 1 month, any unused stock was discarded.
Figure 6.4 MALDI-TOF spectrograph of CSD-biotin stock stored for 1 month at 4°C. Predicted 
mass is 2990 Da, observed mass was 2991.8 Da.
6.4.2 Identification of peptide ligands for the caveolin-1 scaffolding domain 
using phage display
Phage panning studies were undertaken using the Ph.D.™-C7C cyclic 7-mer 
constrained library to identify novel peptides that bind CSD. The panning 
methodology used was based on sim ilar studies detailed in chapter 2 to 
identify peptides that bind streptavidin. Essentially, CSD-biotin was 
exposed to phage library in a solution phase before capture of the phage- 
CSD-biotin complex on streptavidin coated paramagnetic beads. In total, 
four rounds of panning were undertaken. The number of phages recovered 
from glycine elutions 1-3 in panning rounds 1-4 are shown in Figure 6.5. 
Of note, for the same initial input, the number of phages recovered in each
5(XH
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glycine elution increases from round 1 through 3 indicating enrichment for 
a binding population. In round 4, the number of phages recovered in glycine 
elutions 2 and 3 decreased compared to the previous round (glycine 
elutions 2 and 3 are assumed to contain the highest affinity binders) which 
indicates the selection process plateaus in round 3, and as a result round 4 
phages were discarded.
Figure 6.5 Number of phage recovered in glycine elution 1-3 in panning rounds 1 through 4 
against CSD-biotin as target In rounds 1 through 3, the number of phages recovered in each 
glycine elution increased indicating enrichment for CSD binding peptide phages. In round 4, a 
decrease in recovery in glycine elutions 2 and 3 was observed indicating enrichment had 
reached a plateau.
|  Glycine elution 1 ^  Glycine elution 2 Q  Glycine elution 3
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O)
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6.4.3 ELISA analysis
The data presented in Figure 6.5 is indicative of enrichment for a 
population of CSD-binding peptides. In previous chapters where phage 
display has been undertaken, a large random sample of phages from the 
final panning round were gene sequenced to identify conserved peptides or 
peptide motifs. Those conserved motifs were then taken forward to assess 
whether they were 'functional'; the assumption is that w ith the emergence 
of common motif(s) the panning procedure has been successful. To avoid 
false positives that result from sequencing data, in this chapter, functional 
assessment was made of an extensive number of phage clones isolated from 
the cyclic library in glycine elution 3 of round 3 before gene sequencing to 
identify the displayed peptide.
A mid to high-throughput ELISA assay was developed in which individual 
colonies o f phages were cored from agar plates and deposited into a culture 
o f £  coli in a well of a 96-well m icrotiter plate. The phages were amplified 
and then served as input into a standard phage ELISA experiment w ith CSD 
as target In previous ELISA studies detailed in this thesis, phages were 
amplified, purified and titered before a known amount of phages were 
inputted into the ELISA. This takes significant time and whilst in the high- 
throughput screen that was developed, the exact number of input phages 
was not known, a sample of 6 wells collected from 6 different plates 
revealed remarkable consistency w ith the number of phages present in the 
order of 1 x 106 ± 10%. On each microtiter plate three controls were
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included (n = 4 for each), an insertless phage, a streptavidin binding phage 
(sequence AC-GSYWHPQ-CGGGS) and a randomly selected phage from 
glycine elution 3 of round 3 (AC-PPTHGRH-CGGGS) to serve as a measure 
of plate to plate variability. In total, 1008 clones were assessed using this 
high-throughput ELISA screening. Figure 6.6 is a photograph of a 
representative plate that results from the ELISA. Of note insertless-M13 do 
not yield any signal (B2, E6, BIO, G12) whilst for the library phages there 
are a range of absorbances from weak e.g. D4, D7, F8 through to intense e.g. 
F2, B6, B12.
1 2  3 4 5  6 7  8 9  10 11 12
A  
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H
Figure 6.6 Representative high-throughput ELISA screening plate to discriminate peptide- 
phages that bind CSD with high affinity from those that only moderately bind. Note the 
intense signal in certain wells e.g. F2, B6, B12 etc which indicates high affinity binding. Plate 
controls were insertless phages (B2, E6, BIO, G12), streptavidin binding phage (C2, F6, CIO, 
H12J and a peptide-phage from glycine elution 3, round 3 (D2, G6, DIO, F12J.
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After completing ELISA studies, the ratio of peptide-phage ELISA signal to 
insertless phage ELISA signal was calculated for each of the individual 
colonies analysed (1008 in total). This data was then plotted against the 
observed frequency of a range of ratios (Figure 6.7); in the main a gaussian 
distribution was observed.
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Since intra- and inter- plate variability was low, as determined by positive 
and negative controls (see Table 6.2), absorbance readings across and 
between plates could be compared. As a consequence, high affinity binders 
were categorised as those clones having a 6-fold or greater ELISA signal 
compared to insertless phages; this accounts for approximately 20% of the 
colonies analysed (200 colonies).
Table 6.2 Inter- and intra- plate variability of ELISA assays. Interplate assays are the mean 
absorbance readings (± SD) of control wells (n = 4 per plate) for 12 plates. Intraplate 
variability is the mean absorbance (± SD) of control wells (n = 4 per plate) of a representative 
ELISA assay.
ELISA signal
Phage sample Intraplate variability fn=4) Interplate variability fn=48)
AC-GSYWHPQ-CGGGS 0.209 ± 0.056 0.224 ± 0.068
AC-PPTHGRH-CGGGS 0.402 ± 0.058 0.301 ± 0.177
Insertless-M13 0.087 ± 0.013 0.094 ± 0.029
To date 58 of the — 200 samples deemed to be high affinity binders have 
been gene sequenced (sequencing of the remaining phages is underway). 
Table 6.3 shows the identity of the displayed peptides, the ratio of ELISA 
signal achieved and the ELISA plate number in which the colony was 
identified. Of note, there are a number of peptides that are present within 
the population in high copy number. In addition, these peptides were 
identified from different ELISA plates that were analysed on different days 
indicating the high frequency of the clones is not as a result of any cross 
contamination.
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Table 6.3 Peptide sequences isolated from a cyclic 7-mer library that bind CSD with high 
affinity.
Plate Sequence ELISA signal
(peptide- 
M13 :insertless-M 13)
Plate Sequence ELISA signal 
(peptlde- 
M13:insertless-M13)
12 EPTFSPY 11.916 11 SLPKPML 6.269
15 GNTPLNG 7.125 4 SLPKPML 6.007
2 HLAVETL 7.218 11 SLPKPML 6.179
11 HLAVETL 7.962 5 SLYEKWD 8.438
4 HLAVETL 8.898 5 SLYEKWD 7.219
2 IPSWWHL 6.540 1 SLYEKWD 7.490
6 LHSNSVT 7.1971 1 SLYEKWD 7.704
3 LMWPQSV 9.810 11 SLYEKWD 6.115
10 LPVDLYQ 8.801 5 SPNPNAL 7.145
4 MSTFWW 6.944 5 SPNPNAL 6.479
5 MTLNAQN 7.125 5 SPNPNAL 9.441
6 NAGKAPP 4.853 5 STIAWHH 8.889
5 NAGKAPP 6.707 5 SVTASLQ 7.434
5 PHTPTLT 6.626 10 SVTASLQ 9.828
2 PHTPTLT 6.368 5 SVTASLQ 6.667
5 PHTPTLT 6.069 5 SVTASLQ 6.316
10 PPFDLGH 10.071 10 TNHGLGL 6.532
4 PPFDLGH 7.591 10 TNHGLGL 8.165
1 PPFDLGH 6.061 10 VGPYDHR 6.674
4 PSVNLLT 6.812 10 VINSLHH 7.903
10 PSVNLLT 7.453 10 VINSLHH 6.577
5 PSVNLLT 8.539 10 VINSLHH 6.082
1 PSVNLLT 6.061 5 VINSLHH 7.556
10 PSVNLLT 6.494 6 VINSLHH 7.602
7 PSVNLLT 6.234 5 VINSLHH 6.633
6 QAAAHIW 9.442 12 VINSLHH 6.438
10 QAAAHIW 7.236 10 VINSLHH 7.693
5 RAPLPSF 6.343 1 VINSLHH 6.010
3 RAPLPSF 6.524 3 VNLLTWG 8.365
Table 6.4 shows the frequency of the recovered peptides, the mean ELISA 
signal ratio of peptide-M13 to insertless-M13 and the number of separate 
plates the clone was identified on. The most common peptide-phage, 
VINSLHH, was observed with a frequency of 15.5 % and a mean ELISA ratio 
of 7.1 ± 0.7. Whilst sequencing of a selection of phages that were deemed to 
be poor [ratio < 3) or moderate (ratio 3-6) binders of CSD remains to be 
completed, the small variability in ELISA signal between multiple copies of
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the same peptide (in most cases < 10%) suggests that these high frequency 
clones w ill not be present amongst the poor to moderate binding clones.
Table 6.4 Frequency and mean ELISA ratio for high affinity CSD binding phages.
Sequence Frequency 
within the 58 
sequenced
ELISA Mean ratio peptide- 
M13: insertless-M 13
Number of plates clone 
identified on
VINSLHH 9 (15.5%} 7.1 ± 0.7 5
PSVNLLT 6 (10.3%) 7.0 ± 1.0 5
SLYEKWD 5 (8.6%) 7.4 ± 0.8 3
SVTASLQ 4 (6.9%) 7.6 ± 1.6 2
HLAVETL 3 (5.2%) 8.0 ± 0.8 3
PHTPTLT 3 (5.2%) 6.4 ± 0.3 2
PPFDLGH 3 (5.2%) 7.9 ± 2.0 3
SLPKPML 3 (5.2%) 6.2 ±0.1 2
SPNPNAL 3 (5.2%) 7.7 ± 1.6 1
NAGKAPP 2 (3.4%) 6.8 ± 0.1 2
QAAAHIW 2 (3.4%) 8.3 ± 1.6 2
RAPLPSF 2 (3.4%) 6.4 ±0.1 2
TNHGLGL 2 (3.4%) 7.3 ± 1.2 1
EPTFSPY 1 (1.7%) 11.9 1
GNTPLNG 1 (1.7%) 7.1 1
IPSWWHL 1 (1.7%) 6.5 1
LHSNSVT 1 (1.7%) 7.2 1
LMWPQSV 1 (1.7%) 9.8 1
LPVDLYQ 1 (1.7%) 8.8 1
MSTFWW 1 (1.7%) 6.9 1
MTLNAQN 1 (1.7%) 7.1 1
STIAWHH 1 (1.7%) 8.9 1
VGPYDHR 1 (1.7%) 6.7 1
VNLLTWG 1 (1.7%) 8.4 1
6.5 Discussion
The experiments and results described in this chapter represent the 
foundation of a program of work to identify peptides that bind caveolin-1 
scaffolding domain with high affinity. The program has as its ultimate aim, 
the development of small molecule peptidomimetics that interact with CSD 
to interfere with the functioning of caveolin-1. As discussed within the 
introduction to this chapter, such molecules w ill represent a novel 
therapeutic approach in the treatment of disease states where over­
expression of caveolin-1 dysregulates signaling pathways resulting in
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pathobiological processes. The studies in this chapter represent the very 
early stages of this program of work and therefore this discussion w ill focus 
on future works needed to progress the program.
Cyclic 7mer libraries exposed to caveolin-1 CSD showed increasing affinity 
for target with progressive rounds of panning until this affinity plateaued in 
round 3. A cyclic library was chosen because, in comparison to linear 
peptides, cyclic peptides that have a more constrained secondary structure 
not only interact with target with higher affinity but are also potentially 
easier structures from which to design small molecule peptidomimetics.
High-throughput ELISA studies were able to discriminate between peptide- 
phage clones that bound CSD-biotin with poor, moderate or high affinity at 
least in comparison to insertless phages. In the panning studies, CSD was 
attached to biotin and so in the next stage of work those clones identified to 
bind CSD with high affinity will be examined to ensure that they do not bind 
biotin and that they bind to CSD in the absence of biotin. A preliminary 
study using an amplified pool of cyclic 7mer phages from glycine elution 3 
of panning round 3 gave an ELISA signal against CSD of 0.221 ± 0.040 
versus 0.149 ± 0.027 for insertless phages which indicates minimal binding 
within the population to biotin. In addition, the peptides so far identified do 
not match the generic sequence of peptides that bind biotin 
(CXWXPPF(K/R)XXC)[32]. Whilst this does not necessarily preclude 
certain clones within the library binding biotin the high affinity binders 
would be unexpected to do so. This is because biotin must fit some 9A
316
Chapter 6
inside the streptavidin molecule to access its binding site. In panning 
studies, any phages interacting with biotin would likely have been 
displaced when the streptavidin magnespheres were exposed to CSD-biotin 
(the binding affinity for biotin to streptavidin (kD ~ 1015M) w ill not be 
competed by phage peptides) and therefore subsequently removed during 
washing stages. In addition in the ELISA studies where CSD-biotin was pre- 
imobilised before exposure to phage, the biotin should be already 'hidden' 
and unavailable for interaction.
Once it has been definitively confirmed that the phages do not bind biotin, a 
series of cell free assays w ill be undertaken to determine if the peptide 
phages selected can prevent CSD mediated inhibition of PKC; Oka and co- 
workers[33] have shown that CSD from both caveolin-1 and -3 inhibit the 
kinase activity and autophosphorylation of PKCa in cell free assays. In 
addition, given the importance of caveolin-1 oligomerisation (through CSD) 
a series of studies will be undertaken to assess whether identified peptides 
can inhibit oligomerisation. The primary technique that w ill be used is 
circular dichroism spectroscopy[34], a technology for measuring 
differential absorption of left- and right- handed circularly polarized light, 
that gives information about protein secondary structure and 
oligomerisation state[35-37].
Subsequently, a measure of the affinity of the peptides for CSD w ill be made 
(without the phages on board) using techniques such as surface plasmon 
resonance[38] and quartz crystal microbalances[39]. Studies have shown
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that the affinities of peptides identified from phage display for target are 
typically in the order of 10 -  100 pM [40-42]. This can be improved by 
screening focused libraries i.e. phage libraries that contain homologs of the 
originally identified binding peptide[43]. However, construction of a 
focused library is time consuming and relatively inefficient. Given that the 
structure of CSD is known and can therefore be modeled in-silico, the next 
stage of the work will be to use computational design models to modulate 
the peptide-CSD interaction to improve affinity. There is already some in- 
house experience with in-silico molecular modeling of peptides which was 
used to explore the interaction of a 4-AAP binding peptide (identified in 
chapter 2) with 4-AAP[44]. Improvements in affinity in the in-silico 
environment will be translated to the laboratory bench following synthesis 
of designed peptides. These peptides will have utility in their own right but 
the complex issues that surround the in-vivo administration of peptides will 
predicate the design of small molecule mimics of the peptides; discussions 
with potential collaborators are already underway to explore the feasibility 
of such an approach.
In summary, the studies conducted in this chapter have provided some 
exciting and encouraging data that suggest a number of peptides have been 
identified which bind the caveolin scaffolding domain. Ongoing studies are 
seeking to characterize the capacity of these peptides to modulate the 
function of CSD. Such peptides and small molecular peptidomimetics 
designed from them may have utility as novel therapeutics in glioblastoma
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multiforme and other disease states where over-expression of the caveolins 
has a negative effect on human health.
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Chapter 7 General discussion
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The incidence of central nervous system disorders is steadily rising and 
now represents a major component of overall healthcare spend. This is 
largely a result of rapidly increasing life expectancies in industrialised 
countries that have resulted in ageing populations. For example it is 
estimated that by 2050 approximately 20% of the US population w ill be 65 
or over[l]. Given that age remains the most significant non-genetic risk 
factor contributing to CNS disorders, and that improvements in diagnostic 
techniques coupled with growing coverage within the media have resulted 
in greater awareness of CNS disorders amongst the public, there is a 
growing pressure to deliver new therapeutics to the market.
The pharmaceutical industry recognises the potential for market growth in 
the treatment of CNS disorders; in 2005 fifteen pharmaceutical companies 
generated CNS sales in excess of $1 billion and this is forecast to rise in the 
next five years[2]. However, the global market for CNS-related therapies is 
dominated by the development of ‘me too' small molecule drugs for the 
treatment of depression [30% market share) [2]. Whilst the development of 
new classes of anti-depressants is lucrative it does not address the pressing 
need to develop novel therapeutics for the treatment of complex CNS 
disorders such as neurodegenerative disorders, neuroAIDS and brain 
cancers. The slow adaptation of the pharmaceutical industry to the 
development of new therapeutics for such diseases is partly as a result of 
the failure rate for CNS drugs in development to reach the clinic. Whilst US 
statistics show that approximately 11% of drugs that enter clinical trials
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reach the market, for CNS therapeutics it is only 3-4% and therefore by 
extension CNS drugs are far more costly to develop[3].
The high failure rate in clinical trials of new therapies for CNS disorders is 
as a consequence of many factors but particularly the relative failure to 
forecast the extent of transport of drug across the BBB into the brain[4] as 
well as the paucity of predictive animal models for complex CNS disorders 
such as Alzheimer's disease, brain cancers or neuroAIDs where there is no 
single dominant mechanism for disease[5]. As such it is difficult to interpret 
the value of translational research from cell model to animal model to 
human. For example it may be some time before a consensus is reached as 
to whether therapies that reduce amyloid plaque formation outperform 
therapies that stimulate neurotransmitter function in Alzheimer's 
disease[6].
It is fair to assume that the treatment of complex CNS disorders will benefit 
from a shift in focus from small molecule therapies to biomacromolecules 
that include peptides, proteins, antibodies, enzymes and genes. It is 
unfortunate then that many biomacromolecules displaying promising 
therapeutic effects in-vitro all too often prove ineffective when 
administered to animals or humans. This is often due to the limiting nature 
of the blood-brain barrier, which effectively excludes any molecule that is 
not small and lipophilic, i.e. the very antithesis of a biomacromolecule.
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The development of new CNS therapies can essentially be simplified to 
three issues: (i) identifying a druggable target within a CNS disorder that 
drives disease; (ii) identifying biomacromolecules that functionally interact 
with the druggable target to elicit a therapeutic effect; and (iii) designing 
strategies to enhance the penetration of such biomacromolecules into the 
CNS.
Recent methodological advances in areas such as gene microarrays, 
immuno-histochemical analyses and transgenic animals have afforded the 
molecular dissection of various disease pathways leading to the 
identification of new druggable targets in a host of CNS disorders. In 
addition there has been a maturation in polypeptide display systems that 
afford rapid identification of peptides, proteins, antibodies and enzymes 
that interact with molecular targets. A range of strategies have also been 
proposed to enhance the delivery of novel biomacromolecules to the brain 
including peptidergic[7] and proteinergic[8] delivery vectors that mediate 
traversal of macromolecules across the blood brain barrier. Phage display 
is a powerful combinatorial technology that affords the selection of 
peptides that bind to a target of interest and may therefore have 
application in the discovery of novel peptidergic therapies and deliveiy 
vectors within the field of brain disorders. As a consequence, the research 
conducted in this thesis has been focused on exploiting phage display for 
the discovery of peptides that will have utility within experimental 
therapeutics of brain disorders.
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Having no in-house experience of phage display, Chapter 2 detailed the 
validation of a cyclic 7-mer library against two molecules, streptavidin and 
paracetamol (4-AAP); the selection of these molecules was carefully 
considered. Streptavidin, a large macromolecule (~ 53 KDa), has been 
extensively probed with peptide phage libraries and there is a clear 
consensus in the literature that peptides containing a HPQ tripeptide motif 
bind with high affinity within the biotin-binding pocket of the streptavidin 
molecule[9-ll]. In-house selection experiments against streptavidin coated 
on either magnetic beads or on a plastic surface yielded a series of peptide 
sequences that contained the HPQ motif. As evidenced by ELISA assay, 
these peptide phages bound with high affinity to Streptavidin. Separate 
experiments against streptavidin immobilised on different solid supports 
resulted in the selection of a common series of peptides and demonstrated 
robustness in the selection technique.
4-AAP, a low molecular weight entity, was selected for its simplicity and 
because it has two structural isomers that differ from the parent molecule 
only by the orientation of the hydroxyl group around the benzene ring. 4- 
AAP has a very limited number of functional groups and it was therefore 
used as a proof of principle to examine if a phage library could identify 
peptides that interact with such a simple molecule. Immobilisation of 4- 
AAP to a solid support through one of its limited functional groups would 
reduce the number of points for peptide interaction and therefore a 
strategy of selecting phages against insoluble complexes of the molecule
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was devised. Whilst such complexes will present a heterogeneous surface, 
all the functional groups should be on display and available for interaction.
A peptide phage displaying sequence AC-NPNNLSH-CGGGS was identified 
to bind 4-AAP. In a peptide sequence-dependant manner AC-NPNNLSH- 
CGGGS phages were able to prevent the in-vitro hepatotoxicity of 4-AAP but 
not its isomer 3-AAP. In addition, the peptide phage reduced by ~ 20% the 
permeability of 4-AAP across a semi-permeable membrane. Since the 
publication of this work[12], the methodology of selecting against insoluble 
complexes has been repeated by Yu and co-workers to identify peptides 
that bind dexamethasone[13]. Whilst this strategy of selecting against 
insoluble complexes may not prove applicable to a wide range of molecules, 
peptides that bind low molecular weight entities should have utility in 
biological and environmental sensing applications and as therapeutics in 
their own right.
The increasing emphasis on early consideration of issues surrounding the 
delivery of candidate drug molecules to the brain within CNS drug 
discovery programs would benefit from the availability of robust in-vitro 
models of the in-situ blood brain barrier. This would complement 
investigations of in-vivo drug transport and predictions based on in-silico 
assessments of physico-chemical properties of candidate molecules[14-16]. 
Given the unique phenotype of BBB endothelia, it is somewhat of an 
anachronism then that the pharmaceutical industry rely on cell models that 
are neither cerebral in origin nor are endothelial in nature. It is true that
329
Chapter 7
considerable experience has been obtained in translating data garnered 
from epithelial cell lines (e.g. MDCK) to predict in-vivo brain uptake, but 
epithelial cell lines of non-cerebral origin cannot account for the unique 
cellular architecture, transport-, metabolic- and receptor- systems on brain 
endothelia. A better model would more closely resemble the in-vivo 
phenotype and would therefore provide a system in which to study 
quantitative permeation as well as mechanistic aspects of BBB transport 
and pathobiological processes.
A number of immortalised brain capillary endothelial cells lines have been 
developed both commercially and within academic laboratories (recently 
reviewed in [4, 16]) but so far these models have failed to generate a 
sufficiently restrictive paracellular architecture and therefore their value in 
high-throughput permeability screens of candidate molecules is limited. In 
contrast, primary or 1st passage cultures of freshly isolated brain 
microvasculature appear to retain many of the morphological and 
biochemical properties of the in-vivo phenotype. In chapter 3 the 
development and characterisation of a primary porcine brain 
microvascular capillary endothelia cell model was described. A porcine 
model was developed because of the limited availability and ethical 
constraints associated with using human brain tissue and regulatory 
restrictions on the use of bovine material that has accompanied the 
emergence of BSE. Attempts to establish a restrictive primary rat model 
were complicated by issues surrounding low cell yield and culture purity.
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In common with studies cited in the literature[17-19], introduction of 
puromycin into culture medium increased purity for rat endothelial cells 
however, monolayers failed to present a paracellular barrier that was 
significantly more restrictive than immortalised rat models. Nevertheless 
the primary rat model presented may still be of value in mechanistic uptake 
studies at the BBB.
The development of the porcine model, based on the methods of Galla[20], 
was more successful. Micrographs of confluent monolayers of PBMVECs 
revealed the cells adopt a spindle-like, squamous and attenuated phenotype 
that is consistent with endothelial microvasculature. Ultrastructural 
examination using T.E.M. revealed the presence of tight-junctional 
complexes at cell margins and vesicular structures consistent with caveolae 
and clathrin coated pits; on a subjective basis caveolae were more 
abundant. Primary cultures of PBMVECs were responsive to astrocyte 
factors as demonstrated by up-regulation in alkaline phosphatase activity 
when monolayers were co-cultured with the astroglioma cell line C6. Whilst 
C6 are commonly used in co-culture systems to improve paracellular 
restrictiveness it would be interesting to explore the effect of primary 
porcine astrocytes on the model. This would provide an isogenic model that 
may better represent the in-vivo BBB.
Monolayers of PBMVECs generated a restrictive barrier to solute 
permeability and discriminated between the permeability of transcellular 
and paracellular probes. In common with reports in the literature[21-27],
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the restrictiveness of the model was significantly improved by exposure to 
astrocytic factors either in the form of astrocyte conditioned medium or 
astrocyte co-culture, with the co-culture resulting in the greatest 
restrictiveness. Paracellular restrictiveness was improved by a 'switch' 
procedure that involved withdrawal of serum from the cultures for a period 
of 24 hours prior to the permeability study and supplementation with 
physiological concentrations of hydrocortisone[28] and cAMP 
modulators[29, 30]. The final model which comprised astrocyte co-culture 
and the 'switch' procedure resulted in a sucrose paracellular permeability 
co-efficient of ~ 7.5 x 10*6 cm.s*1. This is significantly more restrictive than 
immortalised brain microvascular models.
Expression of mRNA transcripts was confirmed for a number of key tight 
junctional elements (ZO-1, occludin, claudin-1 and claudin 5) and a series of 
transporters known to be expressed at the BBB including the multi-drug 
efflux transporter P-glycoprotein (P-gp) that presents a significant obstacle 
to the treatment of many CNS disorders[31-33]. Following confirmation of 
P-gp expression at the protein level using Western analysis, functional 
expression was determined. In accumulation-retention assays, the P-gp 
substrate rhodamine-123 was retained by PBMVECs around 7-fold greater 
in the presence of the P-gp inhibitor verapamil.
Issues that have prevented adoption of primary BBB models within 
industry include the time and technical resources required for model 
development, batch to batch variability and material wastage when only
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limited amounts of the isolated material are required for planned studies. 
Characterisation of the PBMVEC model has demonstrated that batch-to- 
batch variability is negligible and efforts to cryopreserve the cells were 
successful with little loss in paracellular restrictiveness when cells were 
recovered from frozen after 1 year.
At the end of chapter 3, the PBMVEC model along with immortalised mouse 
(bEnd3) and rat (RBE4] BBB models were used in phage selection studies 
for the identification of peptides that bind brain microvasculature. A series 
of studies was undertaken with the phage library exposed to confluent 
monolayers of BBB cultures maintained at 4°C throughout the experiment 
to prevent internalisation of the phages; the intent of the studies was to 
identify a series of peptides that increase residency time at the BBB. 
Discovering a peptide vector that specifically effects transcytosis at the BBB 
is a major and unmet challenge and it was hypothesised that it may prove 
easier to increase the local concentration of a drug at the brain by 
identifying a peptide that essentially ‘sticks' to brain microvasculature. This 
was corroborated by the significant transmigration of insertless phages 
across confluent BBB monolayers within 5 minutes of phage exposure 
suggesting that in-vitro monolayers are less than ideal for identifying 
peptides that mediate transvascular transport of cargo across the BBB, an 
aim probably best accomplished through the use of in-vivo phage panning 
experiments against brain tissue. Nevertheless, peptides that increase the 
exposure of brain microvasculature to a cargo through binding to the
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luminal surface of brain microvasculature should be effective in increasing 
the brain concentrations of the respective cargo even when BBB 
permeability to the cargo is relatively poor. However, the in-vitro phage 
studies did not result in the occurrence of a common peptide or conserved 
motif within any of the panning results from the brain microvascular cell 
lines examined and ELISA studies, used to monitor the binding of the 
selected phages to cell monolayers suggested a failure to identify 'true' 
binders to the luminal surface of the brain microvascular cells. However, a 
peptide was identified in the panning studies against the bEND3 
monolayers with sequence of AC-NTSVSKW-CGGGS. This sequence shares 
significant homology with a region of the V3 loop of HIV GP120 
glycoprotein (NISVSKW). Deletion and mutational analyses have yet to be 
undertaken to elucidate the exact region of GP120 that interacts with the 
brain microvascular surface but William Banks has shown that the uptake 
of free HIV virus at the BBB is mediated by GP120 probably by stimulating 
adsorptive endocytosis[34-37]. Of note this uptake is not CD4-dependant 
and ignores species barriers. The isoelectric point (pi = 10.1) of the peptide 
identified in panning experiments against bEnd3, AC-NTSVSKW-CGGGS, 
indicates the peptide to be cationic and would therefore be expected to 
interact with cell surfaces. However, an in-vivo single clone 
pharmacokinetic study to assess the brain uptake of phages displaying AC- 
NTSVSKW-CGGGS revealed that it does not enhance brain uptake to any 
greater extent beyond insertless phage.
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Chapter 4 describes experiments to select peptides that mediate traversal 
of phages across the in-vivo BBB. The BBB has been shown to effectively 
exclude phages from the brain and therefore any phages recovered from 
brain parenchyma would be assumed to arrive there as a result of the 
displayed peptide. In two separate strategies rats were intravenously 
administered phage library followed by a series of perfusions to remove 
circulating phages and phages bound to the vasculature. In the first strategy 
only phages from the brain were recovered for iterative panning rounds. In 
the second strategy phages were recovered from all the major organs and 
pooled to serve as input in subsequent panning rounds. After sequencing an 
extensive selection of phages associated with brain grey matter from the 
final round of each of the above described strategies, a number of peptides 
were identified in the population in high copy number, notably AC- 
PDVPHPA-CGGGS from strategy 1 and AC-SYTSSTM-CGGS and AC- 
SNTSSTT-CGGGS from strategy 2. Of note both AC-PDVPHPA-CGGGS and 
AC-SYTSSTM-CGGS were also associated with brain capillary fractions. 
Analysis of the amino acid distributions amongst all the peptides sequenced 
600 peptides sequenced) suggested that serine at positions 1, 4 and 5 
may be important for brain penetration. Extensive single phage clone in- 
vivo distribution studies revealed that the peptide sequence AC-SYTSSTM- 
CGGS enhanced the partitioning of phages into the brain by approximately
4-fold (as evidenced by measures of total brain AUC). An absence of basic 
residues and an isoelectric point of 5.9 indicates AC-SYTSSTM-CGGS would 
not be expected to stimulate adsorptive endocytosis like the cell
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penetrating peptides. In a departure from other studies that have looked at 
peptide uptake into the brain the studies detailed in this chapter only 
assessed phages associated with grey matter and not whole brain. This is 
important since estimates suggest only a small fraction of material that 
reaches the brain is associated with brain parenchyma 5 -  10%)[38]. 
Significant work remains to be undertaken to elucidate the nature of the 
interaction of this peptide with the BBB.
To contextualise the extent of brain uptake of AC-SYTSSTM-CGGGS a series 
of physiologically based pharmacokinetic simulations were undertaken. 
The simulations highlighted some of the errors that can occur when 
comparing treatments with respect to concentrations in a single tissue at 
one particular timepoint. Currently it is more common to report the 
difference in tissue concentration at some arbitrary time-point. Whilst this 
can give the impression that a significant enhancement in uptake has 
occurred, researchers need to make comparisons with respect to total AUC 
in the tissue of interest.
Chapter 5 examined the role of caveolin-1 in glioblastoma and hence the 
validity of targeting caveolin-1 for treatment of this aggressive brain 
tumour type. These studies served as a forerunner to the use of phage- 
based strategies for the discovery and development of novel peptides that 
interact with caveolin-1 scaffolding domain, the main functional component 
of the caveolin-1 protein, and ultimately serve to inhibit function. To date 
the exact role of caveolin-1 in glioma is uncertain since several independent
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clinical studies correlate positive caveolin-1 expression with aggressive 
disease whilst the limited in-vitro studies conducted in glioma cell lines are 
equivocal on a role for caveolin-1. In chapter 5 caveolin-1 siRNA was used 
to downregulate caveolin-1 and led to reduced glioma cell growth and 
invasion. For the first time caveolin-1 was shown to serve as a tumour 
promoter in in-vitro models of glioma driving two fundamentally important 
parameters of tumorigenesis, that of cellular proliferation and invasion.
Therefore caveolin-1 was identified as a novel drug target for gliomas and 
whose inhibition may serve to invoke treatment responses or at the very 
least limit disease progression. Such achievements would significantly 
increase the poor median survival rates that currently are under 1 year 
from the point of diagnosis[39]. Gliomas are traditionally highly resistant to 
chemo- and radio- therapies, especially upon recurrence after surgical 
resection. Hence an anti-caveolin-1 peptide or small molecule peptide 
mimetic would represent a novel addition to traditional treatments. 
Further, for reasons of pathobiology it is envisaged that an anti-caveolin 
molecule may actually serve to restore sensitivity to the standard chemo- 
and radio- therapies. For example, in A549 and FuDu cells, a non-small cell 
lung carcinoma cell line and a squamous head/neck cancer cell line 
respectively, ionizing radiation is shown to invoke src kinase stabilisation, 
activation and phosphorylation of caveolin-1. This results in the caveolin-1- 
mediated nuclear transport of EGF-R, DNA-PK activation and subsequent 
repair of DNA damage [40]. Additional lines of evidence that support a role
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for caveolin-1 in DNA repair in glioma following chemo- or radio- therapy 
include (i) the critical function of EGFRvIII and DNA-PK in glioma cell 
lines [41] and (ii) caveolin-1 knockout mice are less resistant to whole body 
gamma radiation than their caveolin-1 positive wild type counterparts [42] 
and (iii) caveolin-1 has very recently been shown to mediate radio­
resistance of pancreatic cancer cells in 3D cell models with increases in 
double stranded DNA breaks reported in cancer cells following caveolin-1 
knockdown [43]. Further, glioma is one of the most highly vascularised 
forms of solid tumours and as such has been the subject of intense focus for 
anti-angiogenic therapies [39, 44, 45]. Considerable evidence exits for the 
role of caveolin-1 in mediating tumour blood vessel formation. Correlative 
evidence from clinical samples indicate that caveolin-1 mediates 
angiogenesis in RCC[46], prostate cancer[47] and meningiomas [48]. 
Therefore it is highly likely that an anti-caveolin-1 molecule would exhibit 
anti-angiogenic properties in glioblastoma. In summary this chapter 
presents caveolin-1 as a novel drug target in glioblastoma and suggests that 
an anti-caveolin-1 molecule could inhibit multiple processes of glioma 
pathology, namely (i) proliferation [ii] invasion [iii) angiogenesis and (iv) 
Qhemo- and radio- resistance.
Having identified caveolin-1 as a potential therapeutic target in 
glioblastoma, chapter 6 details phage display selections to identify peptides 
that interact with the caveolin scaffolding domain. Phage libraries were 
exposed to caveolin-scaffolding domain that had a biotin tag attached.
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Subsequently, phage-CSD-biotin complexes were captured on streptavidin 
coated magnetic beads that were washed and the phages recovered using 
low pH washes. Increasing phage titers in iterative panning rounds 
indicated enrichment of a CSD binding population. Examination of the 
binding of over 1000 individual phage clones to CSD using ELISA indicated 
around 20% of the population bound with high affinity (> 6-fold ratio of 
peptide phage ELISA signal compared to insertless phage ELISA signal). 
Sequencing of a subset of these phages revealed a number of common 
peptides notably AC-VINSLHH-CGGS (15% of the high affinity population), 
AC-SLYEKWD-CGGGS and AC-PSVNLLT-CGGGS (both 9% of the high 
affinity population). These peptides are currently undergoing further 
analysis in cell free assays to determine if they can prevent the caveolin-1 
mediated inhibition of PKCa phosphorylation. It is hoped that these 
peptides will serve as a starting point for the rational design of small 
molecule anti-caveolin-1 therapies. This strategy is not without precedent. 
In many cancers, over-expression of MDM2 blocks p53 tumour suppressor 
activity by binding p53 at its transactivation domain[49]. X-ray 
crystallography of the MDM2-p53 complex revealed MDM2 interacts with a 
hydrophobic cleft on p53 through just three side chains of the helical region 
of p53 (Phel9, Leu26, and Trp23). Following high throughput chemical 
library screening and rational design, a series of c/s-imidazoline analogues 
were developed called Nutilins that bind MDM2[50]. X-ray crystallography 
studies revealed that the Nutilins bind MDM2 by mimicking the helical 
region of the hydrophobic cleft of p53. Displacement of p53 from MDM2
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increase p53 activity resulting in reduced proliferation and enhanced 
apoptosis in a range of cancers[50, 51].
In conclusion the results described in this thesis have explored issues 
surrounding the characterisation of druggable targets within brain 
disorders and the discovery of peptides that either interact with a 
druggable target or have utility as delivery vectors to mediate the traversal 
of biologies across the BBB. The work presented had ambitious aims and 
was intellectually stimulating. It has made a contribution towards a greater 
understanding of how over-expression of caveolin-1 increases the 
proliferation and invasiveness of gliomas. The in-vitro BBB cell model 
developed has been successfully commercialised and hopefully will find 
utility in the hands of other researchers in addressing health issues 
surrounding the brain. A peptide was identified that modestly increases the 
uptake of phages into the brain in a sequence specific manner and provides 
a foundation for further mechanistic studies to address how it enhances 
uptake. Such a peptide may find utility in the delivery of therapeutic cargos 
to the brain. Finally, a series of peptides were identified that appear to bind 
caveolin-1 scaffolding domain with high affinity. These peptides are 
currently being further characterised and there is significant expectation 
that they will be useful in developing anti-caveolin-1 therapeutics.
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Methods
Hep3B growth curve
A growth curve study of Hep3B cultures was undertaken to assess growth 
characteristics and to determine the optimal time to conduct toxicity 
studies with 4-AAP and its isomers. Hep3B cells were seeded onto a 24 well 
culture plate at a seeding density of 3x104 cells.cm-2. The plate was 
incubated at 37°C for 24 hours to allow cells to adhere. Subsequently, at 24 
hour intervals for 5 days, four wells were washed 2x with pre-warmed PBS 
and cell detachment affected by the addition of pre-warmed trypsin/EDTA 
(200 pi); cell detachment was monitored under an inverted light 
microscope. When the cells were completely detached, 300 pi of complete 
media was added to each well to neutralize the trypsin/EDTA. Two 20 pi 
aliquots from each well were counted using a Reichert Brightline 
haemocytometer (Hausser Scientific, USA). The mean counts ± SD from 
each day were used to construct a growth curve. The cell population 
doubling time was determined using linear regression of the exponential 
phase of growth and the time to 80% confluency calculated from the point 
of plateau in growth.
Micrographs
Hep3B cells were seeded on 24 well culture plates at a seeding density of 
3xl04 cells.cm-2 and grown to 80% confluency before exposure to 1, 5, 10 
or 20 mM 4-AAP for 6, 24,48 or 96 hours. Gross morphology was observed 
using a Leica DM IRB inverted light microscope (Leica Microsystems Ltd, 
Milton Keynes, UK) at lOx magnification. Micrographs were captured using
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Openlab™ (Improvision Limited, Coventry, UK). Contrast and brightness 
adjustments were made in Adobe Photoshop CS4.
Reactive oxygen species
The production of reactive oxygen species (ROS) was evaluated using 2',7'- 
dichlorofluorescein diacetate (DCF-DA) and flow cytometry. DCF-DA 
diffuses into the intracellular environment where it is hydrolysed by 
intracellular esterases and oxidised by ROS to dichlorofluorescein (DCF), a 
highly fluorescent compound. Following 4-AAP treatment (1, 5, 10 and 20 
mM) ± NAC (10 mM), medium was aspirated and cells were incubated with 
5 pm DCF-DA in DMEM:F12 (DCF-DA diluted from a 10 mM stock solution 
in DMSO) for 30 minutes at 37°C; final DMSO concentrations were always 
1%. Following incubation, the supernatant was aspirated and the cells 
detached with trypsin/EDTA as described previously. Cells were recovered 
in 300 pi of fresh complete media and then washed 3x with PBS. Cellular 
fluorescence intensity was measured using a FacsCalibur flow cytometer 
(Becton Dickinson, New Jersey, USA) set to collect fluorescent events in the 
FL-1 channel and with forward scatter (FSC) and side scatter (SSC) 
optimized to afford sampling from a single uniform cell population. A total 
of 10,000 events were recorded for each sample. Flowjo (Tree Star Inc, 
Oregon, USA) was used to analyse the data which were expressed as 
median fluorescence and percentage of respective controls ± NAC.
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LDH leakage
LDH is a stable cytosolic enzyme released from the cytoplasm when the 
integrity of the cellular membrane is lost. LDH released to culture 
supernatant was measured using a CytoTox 96® (Promega, Madison, USA) 
30 minute coupled enzyme assay which results in the conversion of a 
tetrazolium salt into a red formazan product in the presence of LDH. The 
manufacturers protocol was followed but with minor modifications. Briefly, 
after incubation with 4-AAP (1, 5,10 and 20 mM) ± NAC (10 mM) for 24 or 
48 hours, the culture supernatant was collected and centrifuged for 5 
minutes (4°C; 150g) to pellet any cellular debris. Supernatants were stored 
at -20°C for no longer than 7 days before being assayed. The maximum LDH 
activity in Hep3B cells was determined by extracting LDH from untreated 
cells by freeze-thaw lysis in a known volume of fresh culture medium. A 50 
pi aliquot of Substrate Mix was added to each sample and incubated for 30 
minutes at room temperature. A stop solution was added and the 
absorbance recorded at 490 nm. Background LDH in fresh culture medium 
was also measured and subtracted from sample results. LDH leakage was 
expressed as percentage of untreated cells i.e. cells not exposed to 4-AAP or 
NAC.
Results
Hep3B growth curve
Hep3B cell growth studies were undertaken to determine when cell 
monolayers of Hep3B reached 80% confluency, the point at which cell
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cultures would be exposed to 4-AAP. Supplementary Figure 1 shows the 
growth characteristics of Hep3B over a five day period.
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Supplementary figure 1. Five day growth curve 0/ the Hep3B cell line. Using linear regression 
of the exponential phase of growth cell doubling time was determined to be 14.76 hours and 
80% confluency was reached at 56 hours. Data are mean ± SD (n = 3).
The cell doubling time, calculated using linear regression of the exponential
growth phase, was 14.76 hours and the time at which the cells were 80%
confluent was 56 hours 2.3 days). Therefore, in all in-vitro toxicity
assays that follow, Hep3B cultures were exposed to 4-AAP or its isomers
after 2 days in-vitro.
•
Micrographs
The effects of 4-AAP toxicity on the in-vitro viability of the hepatocyte cell 
line HEP3B were observed microscopically and micrographs recorded. 
Supplementary figure 2 shows a series of time lapsed micrographs of 
confluent Hep3B monolayers exposed to different concentrations of 4-AAP.
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After a 5 hour exposure, a reduction in cell number was observed at 
concentrations greater than and including 5 mM 4-AAP. Further, in cells 
exposed to 20 mM 4-AAP for 5 hours, gross changes in cell morphology 
were evident with the cells becoming 'rounder' in shape. After a 24 hour 
exposure loss of monolayer confluency was overtly visible in cells exposed 
to 4-AAP concentrations 5 -  20mM and at 48 and 96 hour time-points, 
nearly all cells exposed to these concentrations were lost from the culture 
surface. A 4-AAP concentration of 1 mM did not appear visibly toxic to 
Hep3B cells at any time-point investigated.
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Supplementary figure 2. Light micrographs showing time and concentration dependent effects of 4-AAP on Hep3B cells.
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Reactive oxygen species
The effect of 4-AAP on the levels of reactive oxygen species in Hep3B cells is 
shown in Supplementary figure 3. Preliminary studies revealed 4-AAP at 
a concentration of 20 mM leads to greater ROS production as assessed by 
increases in hepatocyte fluorescence intensity using the fluorogenic marker 
DCFDA (Supplementary figure 3a). In contrast co-incubation with NAC 
totally abolished ROS generation (Supplementary figure 3b). The 
concentration dependent effects of 5 hour exposure to 4-AAP on ROS 
production were then assessed (Supplementary figure 3c). The maximal 
increase in levels of ROS occurred after exposure to 20 mM 4-AAP with a 
measured intensity of DCF fluorescence 183.71 ± 10.45 % of control (p <
0.05). Exposure to 4-AAP concentrations of 5 and 10 mM for 5 hours also 
increased ROS levels by 132 ± 17.41 and 135 ± 18.17% respectively (p 
<0.05). The production of ROS was abrogated at all concentrations 
following co-incubation with 20 mM NAC. The time dependent effects of 4- 
AAP exposure revealed that in the main, longer exposure to 4-AAP leads to 
reduced levels of ROS compared to control cells as ROS precursors are 
depleted as cell viability reduces (Supplementary figure 3d) which is in 
agreement with results observed by other research groups [1]
352
Appendix 1
B
100 - 100 -
80 - 80  -
2  6 0 - 60  -
o 40 ' 4 0  -
2 0 - 2 0 -
10° 10°
■S 20 mM 4-AAP  
■ Q  No boatment
■  Q  20 mM 4-AAP ♦ NAC 
H Q  No t/walment b
D
*  150-
1 5 10 20
4-AAP Concentration (mM)
1 5 10
4-AAP Concenbabon (mM)
Supplementary figure 3. Effects of 4-AAP exposure on intracellular production of reactive 
oxygen species (ROS). (A) After 5 hours exposure to 4-AAP an increase in DCF-DA 
fluorescence (blue line) is observed compared to non-treated cells (red line) signifying 
increased levels of intracellular ROS in the presence of 4-AAP. (B) After 5 hours co-incubation 
of 4-AAP with NAC (10 mM; blue line) the levels of cellular associated DCF-DA fluorescence 
are no different to non-treated cells (red) indicating no difference in intracellular ROS. (C) 
Concentration dependent elevation in intracellular ROS levels was observed in Hep3B cells 
exposed to 4-AAP; co-incubation with NAC prevented production of ROS. Results are 
presented as mean ± SD where n =4. * Signifies statistically significant difference (p <0.05) 
compared to no treatment cells. (D) Time dependent effects of 4-AAP on intracellular levels of 
ROS. Continuing exposure to 4-AAP (24 and 48 hours) generally led to reductions in 
intracellular concentrations of ROS compared to non-treated cells and is as a result of 
depletion of ROS precursors as cell viability continues to decline. Results are presented as 
mean ± SD (n=4). * signifies statistically significant increases in ROS concentrations (p <0.05)
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compared to no treatment cells, f  signifies statistically significant decreases in ROS 
concentrations (p <0.05) compared to no treatment cells.
LDH Leakage
To further assess the effects of 4-AAP on cell viability, the leakage of lactate 
dehydrogenase from Hep3B cells was determined. Supplementary figure 
4 shows the percentage cytotoxicity of 4-AAP, as a function of membrane 
integrity, with increasing concentration and exposure time.
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Supplementary figure 4. LDH leakage from 4-AAP treated Hep3B cells. LDH levels were 
measured in supernatant and expressed as percentage cytotoxicity i.e. the ratio of LDH in 
supernatant to the total cellular LDH content The data at 24 hours showing little toxicity 
indicates that loss in cellular membrane integrity is a late event in 4-AAP induced 
cytotoxicity. The results are presented as mean ± SD (n=4). * signifies statistically significant 
difference (p < 0.05) compared to no treatment cells.
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The cytotoxicity is calculated as a ratio of LDH leakage from sample to the 
maximum LDH released when a population of untreated Hep3B cells is 
lysed. Whilst this data reinforces previous results that 4-AAP toxicity is 
both time and concentration dependent, the loss in cell membrane 
integrity, the cause of LDH leakage, appears to be a late event in the 
toxicological cascade with 24 hour exposures to 4-AAP only resulting in 
significant toxicity at 4-AAP concentrations of 20 mM. This contrasts with 
MTT studies where as low as 5 mM concentrations result in significant 
toxicity (Chapter 2) at 24 hours. After 48 hours, LDH leakage parallels the 
MTT assay where all concentrations of 4-AAP result in considerable 
toxicity.
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Figure A2: Model of the structure and function of caveolin-1 in the pathogenesis of 
glioblastoma multiforme. In astrocytomas, upregulation of caveolin-1 combined with 
post-translational modifications (caveolin-1 phosphorylation) result in altered 
subcellular compartmentalisation and loss of caveolin-1 mediated tumour 
suppressive activity that together subvert normal tissue homeostasis.
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J Drug Target 2006 May; 14(4): 191-214.
Endocytosis at the blood-brain barrier: from basic 
understanding to drug delivery strategies.
Smith MW, Gumbleton M.
Pharmaceutical Cell Biology, Welsh School of Pharmacy, Cardiff University, 
Redwood Building, Cardiff CF10 3XF, UK.
The blood-brain barrier (BBB) protects the central nervous system (CNS) 
from potentially harmful xenobiotics and endogenous molecules. 
Anatomically, it comprises the brain microvasculature whose functionality 
is nevertheless influenced by associated astrocyte, pericyte and neuronal 
cells. The highly restrictive paracellular pathway within brain 
microvasculature restricts significant CNS penetration to only those drugs 
whose physicochemical properties afford ready penetration into 
hydrophobic cell membranes or are capable of exploiting endogenous 
active transport processes such as solute carriers or endocytosis pathways. 
Endocytosis at the BBB is an essential pathway by which the brain obtains 
its nutrients and affords communication with the periphery. The 
development of strategies to exploit these endocytic pathways for the 
purposes of drug delivery to the CNS is still an immature field although 
some impressive results have been documented with the targeting of 
particular receptors. This current article initially provides an overview of 
general endocytosis processes and pathways showing evidence of their 
functional existence within the BBB. Subsequent sections provide, in an 
entity-specific manner, comprehensive reviews on BBB transport 
investigations of endocytosis involving: transferrin and the targeting of the 
transferrin receptor; hormones; cytokines; cell penetrating peptides; 
microorganisms and toxins, and nanoparticles aimed at more effectively 
delivering drugs to the CNS.
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Phage display identification of functional binding 
peptides against 4-acetamidophenoI (Paracetamol): 
an exemplified approach to target low molecular 
weight organic molecules.
Smith MW, Smith JW, Harris C, Brancale A, Allender CJ, Gumbleton M.
Biomaterials and Biological Interfaces, Welsh School of Pharmacy, Redwood 
Building, Cardiff University, Cardiff CF10 3XF, UK.
Peptide-phage display has been widely used to explore protein-protein 
interactions, however, despite the potential range of applications the use of 
this technology to identify peptides that bind low molecular weight organic 
molecules has not been explored. In this current study, we identified a 
phage clone (PARA-061] displaying the cyclic 7-mer peptide sequence N' 
AC-NPNNLSH-CGGGS C' that binds the low molecular weight organic 
molecule 4-acetamidophenol (4-AAP; paracetamol]. To avoid occupancy of 
key functional groups on the target 4-AAP molecule our panning strategy 
was directed against insoluble complexes of 4-AAP rather than against the 
target linked to a stationary support or bearing an affinity tag. To augment 
the panning procedure we deleted phage that also bound the 4-AAP 
isomers, 2-AAP and 3-AAP. The identified PARA-061 peptide-phage clone 
displayed functional binding properties against 4-AAP in solution, able in a 
peptide sequence-dependant manner to prevent the in vitro hepatotoxicity 
of 4-AAP and reduce (approximately 20%) the permeability of 4-AAP 
across a semi-permeable membrane. Molecular dynamic simulations 
generated a stable binding conformation between the PARA-061 peptide 
sequence and 4-AAP. In conclusion, we show that a phage display library 
can be used to identify peptide sequence-specific clones able to modulate 
the functional binding of a low molecular weight organic molecule. Such 
peptides may be expected to find utility in the next generation of hybrid 
polymer-based biosensing devices.
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Primary porcine brain microvascuiar endothelial 
ceils: biochemical and functional characterisation as 
a model for drug transport and targeting.
Smith M, Omidi Y, Gumbleton M.
Pharmaceutical Cell Biology, Welsh School of Pharmacy, Cardiff University, Cardiff, 
UK.
The blood-brain barrier (BBB) remains a significant obstacle to the delivery 
of therapeutic agents into the central nervous system (CNS). Primary cell 
cultures of brain capillary endothelial cells represent the closest possible 
phenotype to the in vivo BBB cell providing a convenient model for the 
study of transport systems and events that mediate solute delivery to the 
CNS. In this investigation we have characterized an in vitro primary BBB 
model from porcine brain microvascuiar endothelial capillary (PBMVEC) 
cells after recovery from cryopreservation of upto 12 months and studied 
their modulation by astrocytes. Co-cultures of PBMVECs with astrocytes 
(C6 astroglioma) resulted in trans-endothelial electrical resistance of up to 
approximately 9000mega cm2 and marked discrimination between the 
para- and trans- cellular markers sucrose and propranolol. Micrographs of 
confluent monolayers of PBMVECs showed the presence of tight junction 
complexes and vesicles with the morphological characteristics of either 
caveolae or clathrin coated pits. Extensive RT-PCR evaluation highlighted 
the expression of tight junction transcripts, ABC transporters, leptin 
receptor and select nutrient transporters. Functional studies examined the 
kinetics of transport of glucose, large neutral amino acids and p- 
glycoprotein (P-gp). Our findings indicate primary PBMVECs retain many 
barrier characteristics and transport pathways of the in vivo BBB. Further, 
primary cells can be stored as frozen stocks which can be thawed and 
cultured without phenotypic drift many months after isolation. Frozen 
PBMVECs therefore serve as a robust and convenient in vitro cell culture 
tool for research programs involving CNS drug delivery and targeting and 
in studies addressing blood-brain barrier transport mechanisms.
